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1. Introduction 
1.1. Lentiviral vectors 
Lentiviruses (Lentiviridae) are a genus of the retrovirus family (Retroviridae), a family which 
comprises a multiplicity of enveloped viruses characterized by the eponymous reverse transcription of 
their RNA genome into DNA. This DNA intermediate is then integrated into the host genome as 
provirus and subsequently transcribed and translated by the host cell machinery. Among the 
Retroviridae, lentiviruses possess the remarkable ability to infect not only dividing but also non-
dividing cells (Weinberg et al., 1991; Lewis et al., 1992). They are not depending on the mitotic 
dissolution of the nuclear membrane as the viral pre-integration complex can rather be imported into 
the nucleus passing through the nuclear pore complex (Bukrinsky, 2004). Lentiviral vectors (LV) are 
derived from lentiviruses such as the Human Immunodeficiency Virus-1 (HIV-1) or -2 (HIV-2), 
Simian Immunodeficiency Virus (SIV) or Equine Infectious Anemia Virus (EIAV). In contrast to the 
viruses they originate from, vectors are not replication competent, since the genetic information 
indispensable for the assembly of progeny is not packaged within the particles. Hence, each LV is only 
able to transfer its genetic information into one single target cell, a process called transduction, which 
is distinguished from infection by replication-competent viruses. 
1.1.1. Structure 
Lentiviruses are enveloped viruses of approximately 100 nm in diameter. Their pseudodiploid, 
positive sense, single stranded RNA genome of 7 - 12 kbp (per single RNA strand) comprises three 
major genes named gag, pol, and env (5’-gag-pol-env-3’, see Figure 1C). Gag codes for matrix (MA, 
p17), capsid (CA, p24), nucleocapsid (NC, p7), and p6 protein. Since MA, CA, and NC organize the 
structure of mature particles, with membrane-associated matrix proteins surrounding the core shell-
forming capsid proteins, which in turn inclose viral RNA-bound nucleocapsid proteins (Figure 1B), 
these proteins are termed structural proteins. In contrast, p6 has no structural role, but is required for 
budding and release of particles. The pol gene includes the information for the viral enzymes protease 
(PR), reverse transcriptase (RT, reverse transcription of viral RNA into cDNA), and integrase (IN, 
integration of proviral sequences into host chromosomes). Both Gag and Gag/Pol are synthesized as 
polyproteins with cleavage sites of the viral protease separating all functional domains. Thereby, Pol is 
translated upon a programmed -1 ribosomal frameshift changing the open reading frame from gag to 
pol (Jacks et al., 1988), which occurs in about 5% - 10%, of translational events. The single 
polyprotein components are subsequently released by the action of the viral protease starting with an 
autocatalytic cleavage of the enzyme itself from the precursor (Louis et al., 2000). Processing of Gag 
and Gag/Pol takes place concomitant with or after budding. It is indispensable for particle maturation 
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which is accompanied by the reorganization of the spherically arranged Gag layer into a cone-shaped 
core and infectivity (Figure 1A) (Peng et al., 1989). However, proteolysis is not necessary for particle 
formation or budding of immature viral particles, which only requires Gag polyprotein assembly at the 
plasma membrane. Each immature virion contains approximately 5,000 Gag molecules (Briggs et al., 
2004) which are membrane-anchored via the myristylated, N-terminally located matrix protein 
(Hearps and Jans, 2007). Interaction of matrix with the env encoded envelope proteins, embedded 
within the plasma membrane, ensures selective incorporation of the envelope proteins in the particle 
(Yu et al., 1992). The envelope proteins mediate the specific interaction with the cellular receptor(s) 
and are responsible for the subsequent pH-independent membrane fusion. Thus, they determine the 
host cell spectrum of the virus. In addition to the three named major genes, lentiviruses possess 
different accessory genes, which influence stages of the viral life cycle and pathogenesis. In HIV-1, 
the auxillary genes are tat, rev, nef, vif, vpu, and vpr (Li et al., 2005) (Figure 1C).  
The entire lentiviral genome, including major and accessory genes, is flanked by two identical long 
terminal repeats (LTRs), containing the viral promoter, enhancer elements, a transcription termination 
sequence, a polyaldenylation signal and at their ends the attachment sites for viral integration into the 
host chromosome. Initiation of viral RNA genome dimerization and its encapsidation in infective 
particles, the so-called virions, depend on the cis-acting RNA packaging sequence Ѱ, which is located 
between 5’ LTR and the start codon of the gag reading frame (Lever et al., 1989; Clever and Parslow, 
1997).  
 
In contrast to lentiviruses, thereof derived lentiviral vectors are replication-incompetent and thus only 
able to transfer their genetic information, commonly therapeutic or marker genes, into a single 
transduced target cell. LVs are generated by transfecting so-called packaging cells with the genetic 
information indispensable for vector particle production (Figure 1C). The required genes are usually 
provided by three to four different plasmids (split genome approach), encoding Gag/Pol (packaging 
plasmid), Env (Env protein expression plasmid) and the transgene of interest (transfer vector). The 
packaging plasmid may additionally encode Tat and Rev, which are essential for viral transcription 
and nuclear export of unspliced transcripts, respectively, and are therefore indispensable for vector 
production (Zufferey et al., 1997). Alternatively, these proteins are provided by another expression 
plasmid. All other accessory genes besides tat and rev are deleted. Gag/pol and env expression is 
under control of strong heterologous promoters such as CMV (derived from the cytomegalovirus) or 
SFFV promoter (derived from the spleen focus-forming virus) whereas the transfer vector still harbors 
lentiviral LTRs. Thereby, safety of current lentiviral vectors is improved by deleting parts of the 3’ 
LTR abolishing promoter activity of the resulting self-inactivating (SIN)-LTR without affecting vector 
titers or transgene expression (Miyoshi et al., 1998; Zufferey et al., 1998). As only the transfer vector 
still harbors the packaging signal Ѱ, just the transgene RNA is encapsidated into the vector particle 
Introduction 
3 
 
and transferred into transduced target cells. Ѱ is deleted from packaging plasmid and Env protein 
expression construct(s), hampering the formation of viral progeny.  
 
 
Figure 1: HIV-1 particle structure and release. (A) HIV-1 particle assembly and release. HIV-1 Gag/Pol is 
produced in the cytoplasm of HIV-1 infected cells, where it already starts to oligomerize and associates with 
genomic RNA. N-myristylation of matrix (purple) anchors Gag-RNA complexes at the plasma membrane, where 
Gag/Pol further multimerizes and the budding process is initialized. The interaction of matrix and envelope 
glycoproteins (Env) ensures incorporation of envelope proteins in the virion. Activation of the viral protease and 
subsequent cleavage of Gag and Gag/Pol polyproteins leads to particle maturation and gives rise to the infectious 
virion. (B) Structure of a HIV-1 virion. The viral genome, comprised of two single stranded RNAs, is bound to 
nucleocapsid proteins and associated with the viral enzymes integrase and reverse transcriptase. A core, 
composed of capsid proteins, surrounds these RNA-protein complexes. It is itself enclosed in matrix proteins, 
which are membrane-anchored and connected with the envelope proteins. HIV-1 envelope proteins consist of 
gp120, the surface unit, and transmembrane unit gp41. (C) Genome structure of HIV-1 and thereof derived 
second generation lentiviral vectors. Top: The HIV-1 genome is flanked by long terminal repeats (LTRs) and is 
composed of three main genes (gag, pol, and env) and six accessory genes (vif, vpr, tat, rev, vpu and nef). Gag 
encodes for matrix (MA), capsid (CA), nucleocapsid (NC), and p6. Pol comprises the information for the viral 
enzymes protease (PR), reverse transcriptase (RT) and integrase (IN). The envelope glycoproteins of HIV-1 are 
encoded by env. Env is cleaved into a surface unit (SU) and transmembrane domain (TM) by the host cell 
protease furin. Tat and Rev are involved in regulation of viral transcription and bind to the 5’ LTR (Tat) or the 
Rev responsible element (RRE). Bottom: Second generation lentiviral vectors are produced by transfection of 
packaging cells with three different plasmids (split genome approach). The packaging plasmid encodes for Gag, 
Pol, Tat and Rev. Env is expressed by the Env expression plasmid. In both, packaging plasmid and Env 
expression plasmid, LTRs are replaced by a strong heterologous promoter (Prom) and a polyadenylation signal 
(pA). Only the transfer vector, harboring the transgene, contains Ѱ and is thus packaged into vector particles. Vif, 
vpr, vpu, and nef are deleted. Panels A and B modified after Martin-Serrano and Neil, 2011, panel C modified 
after Sakuma et al., 2012.  
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However, the described split genome approach does not only lead to increased safety of the vectors 
due to the avoidance of recombination events, which may cause production of fully replicative 
lentiviruses. It also facilitates the manipulation of viral vectors, e.g. the exchange of the vector’s own 
envelope proteins against heterologous ones (pseudotyping, see 1.2.1). Moreover, as only Gag is 
required for spontaneous self-assembly of particles (Lingappa et al., 2014), particles with different 
characteristics can be produced by leaving out single components of the vector. Omitting the Env 
encoding plasmid(s) for instance, leads to the production of “bald” particles where no envelope 
glycoproteins are incorporated into the membrane. Particles without a transgene are called “virus-like 
particles” as they closely resemble infectious viruses. They may or may not be equipped with envelope 
proteins.  
1.1.2. Lentiviral vectors as vehicles for gene and protein transfer 
Lentiviral vectors are frequently used in gene therapy or basic research for the genetic manipulation of 
cells. Their broad application is justified by several beneficial features, some of which are unique to 
LVs: (1) Stable integration of the transgene into the host chromosome guarantees a sustained gene 
expression (Blömer et al., 1997; Kafri et al., 1997), which is of special interest in the clinical setting 
aiming for long-term correction of genetic defects. LVs were shown to preferentially integrate into 
transcriptionally active genes (Mitchell et al., 2004), but no particular enrichment in proto-oncogenes, 
cancer-associated common integration sites, or growth-controlling genes was observed (Cattoglio et 
al., 2007), accounting for the low genotoxicity and low oncogenic potential of LVs (Montini et al., 
2006). (2) Moreover, as they are able to transduce not only dividing but also non-dividing cells 
(Naldini et al., 1996), LVs are applicable for gene transfer into a variety of cell types, which are not 
accessible with other vectors. Nevertheless, a few cell types, particularly resting lymphocytes 
(Maurice et al., 2002; Frecha et al., 2009) or monocytes (Neil et al., 2001), proved to be rather 
resistant to genetic modification by conventionally used HIV-1 derived vectors like VSV-G 
pseudotyped LVs (VSV-LV). Commonly, productive transduction of T cells required minimal 
stimulation to induce entry of cells into the G1b phase of cell cycle (Cavalieri et al., 2003) as already 
shown for the parental HIV-1 virus (Korin and Zack, 1998). (3) Another advantage of LVs is their 
high packaging capacity. An analysis systematically determining the packaging capacity of HIV-1 
derived LVs revealed that there seems to be no absolute packaging limit although titers 
semilogarithmically decrease with the transfer vector length (Kumar et al., 2001). Generally, 
packaging of 8 – 10 kb heterologous DNA is considered feasible (Kumar et al., 2001; Sinn et al., 
2005). Due to their high packaging capacities, LVs can transfer more than only one gene. Successful 
transfer of tricistronic expression cassettes has been described (Mitta et al., 2002; Ibrahimi et al., 
2009). Thereby, insertion of internal ribosomal entry sites (IRES) or 2A sequences between the single 
open reading frames allows for the co-expression of individual proteins encoded by a single RNA. An 
IRES is a RNA element, which promotes internal initiation of RNA translation as it enables ribosome 
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binding in the absence of the 5’ cap (Ngoi et al., 2004). In contrast, the small viral 2A sequences, e.g. 
derived from thosea asigna virus (T2A) or foot-and-mouth disease virus (F2A), mediate co-
translational “cleavage” of polyproteins at their own C-termini by a ribosomal skip mechanism 
(Donnelly et al., 2001). (4) Last but not least, there is generally no pre-existing immunity against LVs 
to be expected which is important for in vivo applications. Moreover, LVs themselves are 
characterized by low immunogenicity (Abordo-Adesida et al., 2005). However, as true for all gene 
delivery systems, the transgene can potentially provide antigenic epitopes and therefore induce 
immunity (Follenzi et al., 2004).  
 
Besides efficient transfer of foreign genes, retro- and lentiviral particles are also capable to transfer 
cargo proteins into transduced cells when the cargo is genetically fused to the structural proteins of the 
vector (Voelkel et al., 2010; Aoki et al., 2011). Thereby, these particles also enable immediate (no 
delay caused by de novo protein synthesis) and completely transient cell modification (protein 
degradation). Initially, HIV-1 Gag was tagged with the marker protein GFP in order to study its 
cellular localization (Perrin-Tricaud et al., 1999; Hermida-Matsumoto and Resh, 2000). As no adverse 
effects of a GFP-fusion were observed for cellular routing and localization (Perrin-Tricaud et al., 
1999), fluorescently labeled Gag (MA-GFP) was later on also used to track HIV-1 particles (Müller et 
al., 2004; Hübner et al., 2007; Lampe et al., 2007). Recently, the approach has been shown to be 
highly promising also for the transfer of heterologous proteins exerting enzymatic functions, e.g. Flp 
recombinase or β-lactamase, by retro- and lentiviral particles (Voelkel et al., 2010; Aoki et al., 2011). 
Quite commonly, the cargo protein encoding sequences are inserted 3’ of matrix (Müller et al., 2004; 
Voelkel et al., 2012) although fusion to the N-terminus of Gag has also been described (Aoki et al., 
2011). Fusion to the N-terminally myristylated matrix results in membrane-association of the cargo 
protein and might be exploited, if membrane-proximity is of interest. Alternatively, engineered 
recognition sites for the viral protease can be introduced between cargo and structural protein to ensure 
free release of the heterologous protein from Gag and Gag/Pol precursors into the target cells’ cytosol 
(Voelkel et al., 2010). A particularity for the generation of functional protein-transferring particles is 
the potential requirement of wild-type Gag/Pol co-assembly which is likely due to steric requirements 
of the cargo proteins. However, both assembly of mixed particles composed of cargo-fused and wild-
type Gag/Pol (Larson et al., 2005; Voelkel et al., 2010) as well as particles made up of cargo-tagged 
Gag/Pol alone (Aoki et al., 2011; Voelkel et al., 2012) have been reported. 
 
Concluding, lentiviral particles can be used as efficient vehicles for gene transfer, combined gene and 
protein transfer, or protein transfer alone (as virus-like particles), rendering them highly flexible tools 
for stable and/or transient cell modification.  
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1.2. Altering the vector tropism 
Efforts have been made to improve safety and efficacy of LVs by restricting the vector tropism to the 
cell or tissue type of interest. Confining transgene expression to target cells can amongst others be 
achieved by the use of cell- or tissue-specific promoters (transcriptional targeting), or by introduction 
of microRNA target sites into vector genomes abolishing transgene expression in off-target cells or 
tissues (“detargeting”) (Frecha et al., 2008b). However, these methods have several drawbacks, e.g. 
limited availability of truly cell-specific promoters and microRNAs or potential leakiness of promoters, 
which might cause anti-transgene immunity, if the transgene is unwantedly expressed in antigen 
presenting cells (Frecha et al., 2008b). Moreover, there is a need for threshold microRNA-expression 
levels ensuring RNA silencing, and, most importantly, broad transduction and transgene insertion in 
both target and non-target cells, which may be associated with a higher risk of insertional mutagenesis 
due to genetic alterations of more cells than required for therapy (Frecha et al., 2008b). A promising 
alternative is transductional targeting. This strategy is based on surface modified vectors, either 
incorporating heterologous glycoproteins with natural restricted tropism (pseudotyping, see 1.2.1) or 
engineered, ligand-displaying glycoproteins which determine the vector’s specificity (see 1.2.3). Here, 
the modification of cells is already restricted at the stage of cell entry, thus preserving non-target cells 
from transduction and thereby unwanted side-effects. More details on entry targeting, used in this 
thesis to generate SLAM- and CD4-specific lentiviral vectors, are provided in the following sections. 
1.2.1. Pseudotyping of lentiviral vectors 
Cell entry of enveloped viruses and viral vectors is dependent on the interaction of viral surface 
proteins with the complementary cellular receptors. This interaction determines the host cell range 
(tropism) of the virus or vector particle. Most lentiviral vectors are derived from HIV-1. Its envelope 
protein complex, consisting of gp120 and gp41, interacts with CD4 (Dalgleish et al., 1984; Klatzmann 
et al., 1984) and commonly either one or both of the main co-receptors CXCR4 (Feng et al., 1996) or 
CCR5 (Alkhatib et al., 1996; Deng et al., 1996; Dragic et al., 1996). These surface proteins are found 
on T helper cells, dendritic cells, monocytes, macrophages, and microglia (Shieh et al., 1998; Lee et al., 
1999) and thus enable HIV-1 infection of the named cell types.  
In order to change the vector tropism, HIV-1 envelope proteins can be substituted by envelope 
glycoproteins of other viruses as first shown in 1990 by Page et al. using amphotropic murine 
leukemia virus (MLV) glycoproteins (Page et al., 1990). The process of equipping vectors with 
heterologous envelope glycoproteins, which then determine the vector’s specificity, is called 
pseudotyping. Commonly used for this purpose is the G protein of the vesicular stomatitis virus 
(VSV-G), resulting in stable particles which can be concentrated by ultracentrifugation to high titer 
vector stocks (Burns et al., 1993). VSV-G binds to the widespread expressed low-density lipoprotein 
receptor (LDL-R) and its family members (Finkelshtein et al., 2013), accounting for the broad tropism 
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of VSV-G pseudotyped vectors. Due to their stability and target cell spectrum, VSV-G pseudotyped 
vectors are currently used as gold standard to evaluate the performance of other pseudotypes. Besides 
VSV-G, also a wide variety of glycoproteins derived from other enveloped viruses have been 
functionally incorporated into lentiviral particles (Cronin et al., 2005). Examples are the envelope 
proteins of ebola virus (Kobinger et al., 2001), lymphocytic choriomeningitis virus (Beyer et al., 2002), 
and measles virus (Frecha et al., 2008a). As expected, also here the resulting particles possessed the 
tissue specificity of the virus the glycoproteins originated from, e.g. a tropism for airway epithelia in 
case of ebola virus pseudotypes (Kobinger et al., 2001). However, pseudotyping with heterologous 
glycoproteins does only allow targeting of tissues or cells, if viral envelope proteins with the tropism 
of interest do exist, at all. Moreover, the expression of the used cellular receptor might not be 
restricted to the target tissue or target cell type, but also cover other tissues or cell populations, whose 
alteration might be not desirable. To allow highly selective transduction of distinct target cell 
populations, attempts have been made lately to genetically modify viral Env proteins to incorporate 
peptide ligands, growth factors or single-chain antibodies targeting a protein of choice (Froelich et al., 
2010). Among these strategies, a targeting system based on engineered measles virus glycoproteins 
proved to be extraordinary promising (Funke et al., 2008) which is presented in detail in section 1.2.3. 
1.2.2. Measles virus glycoproteins and their receptors  
Measles virus (MV), the causative agent for the highly contagious measles disease, is a representative 
of the genus Morbillivirus within the family Paramyxoviridae. As all other enveloped viruses, it enters 
its target cells by binding to its cellular receptors followed by fusion of viral and target cell membrane. 
For several enveloped viruses, for instance the family Rhabdoviridae exemplified by the well-known 
vesicular stomatitis virus, one glycoprotein mediates receptor binding and membrane fusion. In 
contrast, receptor attachment and fusion function are separated onto two proteins in the family of 
Paramyxoviridae (Iorio et al., 2009). As its name implies, the Fusion protein F initiates the fusion of 
viral and cellular membranes. Receptor binding of Paramyxoviridae is mediated by hemagglutinin-
neuraminidase (HN), hemagglutinin (H) or glycoprotein (G), which also exert fusion-helper functions 
(Ader et al., 2012).  
H protein is a type II transmembrane glycoprotein with a molecular weight of approximately 75 kDa. 
It exists as tetramer formed of two disulfide-linked dimers. Each H protein possesses an amino-
terminal cytoplasmic tail, a transmembrane segment, and a long, extracellular stalk region which is 
connected to a cuboidal head with six-blade β-propeller structure (Navaratnarajah et al., 2011) (Figure 
2). The well-characterized binding sites for the MV receptors are located at one site of the β-propeller 
(Vongpunsawad et al., 2004; Santiago et al., 2010; Hashiguchi et al., 2011b). The second MV 
envelope protein, the 55 kDa F protein, is a type I glycoprotein, which assembles into trimers (Figure 
2). It is synthesized as nonfusogenic F0 precursor protein, which is activated by furin-mediated 
proteolytic cleavage into the disulfide-bond-linked subunits F1 and F2 in the Golgi apparatus (Bolt and 
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Pedersen, 1998). H tetramers are associated with F trimers in hetero-oligomeric complexes, which 
already form in the endoplasmatic reticulum (ER) (Plemper et al., 2001). The stalk region of H 
interacts with the globular head of the F glycoprotein (Paal et al., 2009) (Figure 2). Receptor binding 
of H therefore locates F at an appropriate distance to reach the target cell membrane (Buchholz et al., 
1996). Moreover, receptor attachment of H leads to rearrangements in its stalk region, which in turn 
initiate conformational changes in F (Plemper et al., 2011; Ader et al., 2012), exposing a hydrophobic 
fusion peptide. Subsequent insertion of the fusion peptide into the host cell membrane and refolding of 
F into a highly stable six-helix-bundle drives membrane fusion. Fusion of viral and cellular membrane 
is pH-independent (Plemper, 2011).  
 
 
Figure 2: Schematic depiction of MV envelope 
proteins. Space-filling representation of the crystal 
structure of a MV H dimer and parainfluenza virus 5 
(PIV5) F trimer. PIV5 is a paramyxovirus closely related 
to MV. Stalk, transmembrane domain, and cytoplasmic 
tail of H are depicted as vertical lines, disulfide-bonds 
stabilizing H dimers are indicated as red horizontal lines. 
Each H or F monomer, respectively, is depicted in a 
different color. Membrane-associated matrix proteins 
(M) interact with the cytoplasmic tails of H and F. 
Figure modified after Griffin and Oldstone, 2008. 
 
MV can be divided into wild-type strains and vaccine strains with distinct receptor usage. Wild-type 
strains, like IC-B, the strain molecular clone MVwt323 is derived from (Takeda et al., 2000), use 
CD150/ Signaling Lymphocyte Activation Molecule (SLAM) as cell entry receptor (Tatsuo et al., 
2000). In humans, SLAM is expressed on activated B and T cells, thymocytes, mature dendritic cells, 
monocytes, macrophages, and platelets (Sidorenko and Clark, 1993; Cocks et al., 1995; Kruse et al., 
2001; Farina et al., 2004). Its predominant expression on immune cells explains the immune cell 
tropism and concomitant immunosuppressive properties of measles viruses. The extracellular domain 
of SLAM is composed of two immunoglobulin-like domains, V and C2 (Figure 3A). The binding site 
of H was mapped to the V domain (Ono et al., 2001b; Hashiguchi et al., 2011b). 
Many vaccine strains are derived from an isolate from a measles patient with family name Edmonston. 
The blood and throat washings of the boy were used to infect primary human kidney cells and the live-
attenuated MV Edmonston strain was developed by several passages in chicken eggs and chicken 
embryo cells (Enders and Peebles, 1954; Enders et al., 1960). In addition to SLAM, these vaccine 
strains and also the laboratory strains derived thereof use CD46 as cell entry receptor (Dörig et al., 
1993; Naniche et al., 1993). CD46 is a type I transmembrane protein with four extracellular short 
consensus repeats (SCR 1-4), which is expressed on all nucleated, human cells (Hashiguchi et al., 
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2011a). The protein exhibits co-factor activity for the degradation of the complement components C3b 
and C4b by Factor I and is thus involved in prevention of complement-mediated lysis of self-tissue. 
The binding site of MV H was shown to be located on SCR1 and SRC2 (Figure 3B) (Buchholz et al., 
1997; Hsu et al., 1997; Casasnovas et al., 1999).  
Besides SLAM and CD46, the existence of a third, epithelial cell receptor (EpR) for MV has been 
proposed. Epithelial cells do not express SLAM but have been shown repeatedly to be infectable by 
MVwt in vitro and in vivo (Sakaguchi et al., 1986; Takeuchi et al., 2003; Takeda et al., 2007). Since 
MV infects only epithelial cell connected by the apical adhesion complex, involvement of the EpR in 
the formation of epithelial intracellular junctions has been assumed (Leonard, V.H.J. et al., 2008). 
 
 
Figure 3: Measles virus receptors. (A) Schematic structure of SLAM. The ectodomain of SLAM is composed 
of two immunoglobulin-like domains, termed V (variable) and C2 (constant). Binding of MV wild-type, vaccine 
or laboratory strains has been mapped to the V domain. SAP, SLAM-associated protein; MHC, Major 
histocompartibility complex; TCR, T cell receptor. (B) Schematic structure of CD46. The N-terminal 
extracellular domain of CD46 consists of four short consensus repeats (SCR). MV vaccine and laboratory strains 
bind to SCR1 and SCR2 whereas an interaction of SCR3 and SCR4 with the complement proteins C3b and C4b 
is described. Figure modified after Sato et al., 2012. 
 
1.2.3. Engineering of measles virus glycoproteins 
As already mentioned, targeting approaches based on pseudotyping are restricted by the availability of 
viral glycoproteins with the tropism of interest and their capacity to effectively pseudotype the 
respective particles. This constraint prompted the development of glycoprotein engineering strategies 
in order to enable specific targeting of any receptor of choice. These efforts included insertion of 
single-chain antibodies (scFv), i.e. antigen-binding variable heavy (VH) and light (VL) chains of an 
IgG antibody, which are stably connected via a polypeptide linker (Figure 4), or growth factors in viral 
glycoproteins. Albeit specific binding of most ligand-displaying envelope glycoproteins to the 
corresponding receptors was reported, no or only inefficient transduction of target cells has been 
observed (Verhoeyen and Cosset, 2004). These data indicated the inability of retargeted envelope 
proteins to induce fusion activity upon receptor binding via the added targeting domain (Sandrin et al., 
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2003) and initiated attempts to use membrane fusion protein complexes in which receptor attachment 
and membrane fusion functions are separated onto two glycoproteins, as for example found in MV. 
Indeed, in 2005 Nakamura et al. reported successful rescue and propagation of fully retargeted 
measles viruses (Nakamura et al., 2005). Here, four point mutations in the hemagglutinin gene, 
defined before to be critical for interaction with the respective receptors (Vongpunsawad et al., 2004), 
ablated fusion induction via the natural receptors SLAM (mutation R533A) and CD46 (mutations 
Y481A, S548L, and F549S). The coding sequences of one of the single-chain antibodies binding to 
CD38, EGFR, or EGFRvIII, respectively, were genetically fused to the C-terminus of mutated H and 
cloned into the MV genome. The resulting viruses were shown to specifically and efficiently interact 
with cells expressing the corresponding target antigens in vitro and in vivo, mediating receptor-
dependent anti-tumor activity, whilst being blind for SLAM and CD46.  
In 2008, Funke et al. successfully translated this targeting approach based on engineered MV 
glycoproteins (MV-GPs) into a flexible pseudotyping system for HIV-1 derived lentiviral particles 
(Funke et al., 2008). In addition to the mutations described by Nakamura et al. (Nakamura et al., 2005), 
efficient incorporation of genetically modified MV-GPs into LV particles required cytoplasmic 
truncation of H and F proteins by 18 or 30 amino acid residues, respectively. Blinded hemagglutinin 
was fused to a scFv binding CD20. The specificity of the resulting CD20-LV vector was demonstrated 
in mixed cell populations and primary human lymphocytes (Funke et al., 2008). Since this proof of 
principle the system has demonstrated its applicability for a broad variety of target receptors of human 
and murine origin, including GluR (Anliker et al., 2010), CD105 (Anliker et al., 2010; Abel et al., 
2013), CD133 (Anliker et al., 2010), MHC II (Ageichik et al., 2011), CD8 (Zhou et al., 2012) and 
CD19 (Kneissl et al., 2013). As an alternative to scFv, also DARPins can be used as binding moieties 
(Münch et al., 2011).  
 
 
Figure 4: Schematic depiction of an antibody and a 
thereof derived single-chain antibody. Each IgG 
antibody consists of two heavy chains (H) and two light 
chains (L) which are connected via disulfide bonds. The 
variable domains of heavy and light chains (VH and VL, 
respectively) form the antigen binding site. The constant 
regions (CH1-3 and CL) are responsible for the effector 
functions of the antibody. A single-chain variable 
fragment (scFv) or single-chain antibody consists of the 
variable regions of heavy and light chain, connected via 
a linker. 
 
 
DARPins, acronym for Designed Ankyrin Repeat Proteins, are synthetic proteins derived from natural 
ankyrin repeat (AR) proteins. AR proteins are found in bacteria, archaea, eukarya, as well as in certain 
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viruses, and are commonly involved in protein-protein interactions (Mosavi et al., 2004). Indeed, 
besides immunoglobulins they are the most abundant protein class involved in binding (Wetzel et al., 
2008). They are characterized by the eponymous ankyrin repeats, which stack together to form protein 
domains of variable length with a continuous target-binding surface typically established by several 
adjacent repeats (Binz et al., 2003). Each of these repeat modules is commonly composed of 33 amino 
acids, which form two antiparallel helices, linked by a loop, and is connected with the following repeat 
unit via a β-turn (Binz et al., 2003) (Figure 5A). The resulting domains resemble a cupped hand with 
β-hairpin-fingers and a palm made up of α-helices (Sedgwick and Smerdon, 1999) (Figure 5B). Amino 
acids involved in binding are located in the ankyrin groove (Figure 5B). 
 
 
Figure 5: Schematic depiction of secondary structure elements of an ankyrin repeat domain and DARPin. 
(A) Top view of an ankyrin repeat domain. An ankyrin repeat domain is formed by several ankyrin repeats, 
which are composed of two α-helices (cylinders) and a β-turn (arrow), respectively. A single repeat is indicated 
in red. (B) Side view of an ankyrin repeat domain. The dotted arc indicates the ankyrin groove where residues 
involved in binding are located. (C) Three dimentional representation of a N3C DARPin. Designed ankyrin 
repeat proteins (DARPins) consist of an N-capping repeat, internal repeats of a freely selectable number (here 
three), and a C-capping repeat. Randomized residues, mediating binding to the target protein of choice, are 
depicted in blue. Panels A and B derived from Sedgwick and Smerdon, 1999; panel C modified after Stumpp et 
al., 2008. 
 
By an in silico consensus design approach considering approximately 2,500 different natural AR 
sequences, Binz et al. identified a consensus sequence of an AR domain (Binz et al., 2003). 26 of the 
33 amino acids building an ankyrin repeat were characterized as conserved framework residues while 
the remaining seven surface-exposed residues (Figure 5C) were non-conserved ones which might 
potentially mediate interaction with a given binding partner (Binz et al., 2003). Based on the identified 
consensus sequence, combinatorial DARPin libraries with defined repeat numbers were generated 
where non-conserved positions were randomized (Plückthun, 2015). Using these libraries, high 
affinity binders to a target structure of choice can be selected in vitro by phage display (Smith and 
Petrenko, 1997) or ribosome display (Hanes and Plückthun, 1997). Similar to the parental AR proteins, 
the resulting DARPins are composed of stacked repeat units, usually up to six, forming a hydrophobic 
core. This hydrophobic core is shielded by N- and C- capping ankyrin repeats (Figure 5C), which 
increase folding yield and prevent aggregation of DARPins (Forrer et al., 2003). Due to their structure, 
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DARPins show low tendency to aggregate, even when highly concentrated, and are characterized by 
tremendous thermodynamic stability against denaturation induced by heat or chemicals which 
increases with the number of repeats (from Tm = 60°C for N1C, i.e. a DARPin consisting of one full-
consensus repeat and N- and C-capping repeats, to Tm > 100°C for N3C) (Wetzel et al., 2008). 
Moreover, they are small, e.g. 14 kDa for a N3C DARPin, which equals approximately one tenth the 
size of a conventional IgG antibody (Stumpp et al., 2008), bind with affinities in low nanomolar or 
even picomolar range (Binz et al., 2003; Steiner et al., 2008) and are cost-efficiently producible 
(Stumpp et al., 2008). The named features render them attractive as an alternative binding motive to 
single-chain antibodies. 
Of particular interest for this thesis is DARPin D29.2 which interacts specifically with domain D1 of 
human CD4 (Schweizer et al., 2008). With a dissociation constant in the subnanomolar range (KD = 
1.49 x 10
-9
 M), D29.2 is a high affinity binder (Schweizer et al., 2008). It showed no effects on cell 
viability or activation, CD4
+
 memory cell function, or CD4 receptor surface density (Schweizer et al., 
2008).  
1.3. Immune cells as targets for gene and immunotherapy 
Bacteria, viruses, and other microorganisms are constantly dispersed in the environment. In view of 
this, catching an infection is rather a rare event. This is due to the presence of the immune system, 
which defends the body from invading pathogens. Thus, immune dysfunctions can have profound 
consequences for the health of respective patients, exemplified by inherited diseases such as X-SCID 
(X-linked severe combined immunodeficiency). X-SCID is caused by mutation of the gene encoding 
the interleukin (IL)-receptor common γ chain, which ablates the development of functional natural 
killer (NK) and T cells, the latter also entailing defects in humoral immunity (Noguchi et al., 1993). 
Affected persons are easily infected by microorganisms and without treatment rapidly succumb to 
disease. Besides inherited diseases, also pathogens targeting immune cells themselves can account for 
serious immune disorders. The most prominent example here is HIV-1 infection of CD4
+
 immune 
cells, i.e. T cells, dendritic cells (DCs), monocytes, and macrophages, which finally results in the 
acquired immune deficiency syndrome (AIDS). Due to the vital function of the immune system, 
immune cells represent important targets for gene and immunotherapy. Thereby, specific modification 
of distinct immune cell subpopulations is highly desirable, e.g. genetic alteration of CD4
+
 cells in 
HIV-1 infected patients. Moreover, also stimulating the immune system by prophylactic or therapeutic 
vaccination to recognize and destroy particular microorganisms or altered (cancerous) body cells is of 
great interest.  
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1.3.1. The adaptive immune system 
In vertebrates, the immune system is comprised of two arms, namely the innate and the adaptive 
immunity. Innate immunity is also referred to as non-specific immunity and is the first line of defense 
as it detects and suppresses pathogens instantly (Medzhitov and Janeway, 2000). However, it does not 
confer long-term memory against invading microorganisms. In contrast, the adaptive immune system 
has a gradual onset over a few days but is highly specific for single pathogens and additionally 
provides a memory (Janeway et al., 2008). Adaptive immunity can be further divided into humoral 
immunity, i.e. antibody-mediated immunity, which involves B cells, and cellular immunity, dependent 
on (effector) T cells. Essential for the induction of adaptive immune responses are antigen presenting 
cells (APCs), which serve as a link between innate and adaptive immune response.  
The most potent APCs known are myeloid dendritic cells (mDCs) (Gaspari and Tyring, 2008). As 
such, the main function of DCs is uptake, processing and presentation of antigens to T cells and their 
subsequent activation. Immature dendritic cells, residing in the tissues, take up extracellular antigens 
via receptor-mediated endocytosis, phagocytosis or macropinocytosis (Caux and Dubois, 2001). 
Moreover, also cytosolic pathogens, such as viruses, are processed by DCs after becoming infected, 
and respective antigens are presented. While taking up pathogens, DCs are activated by their pathogen 
recognition receptors (PRRs), such as Toll like receptors, as a response to pathogen-associated 
molecular patterns (PAMPs), like lipopolysaccharides (LPS) (Dearman et al., 2009), or so-called 
danger-associated molecular patterns (DAMPs), like cytokines released in the context of infection or 
extracellularly dislocated heat shock proteins (Shurin and Salter, 2009). During their subsequent 
maturation, DCs upregulate different surface molecules including the chemokine receptor CCR7, the 
dendritic-cell-specific adhesion molecule DC-SIGN, high levels of major histocompatibility complex 
(MHC) class II molecules as well as co-stimulatory molecules like B7.1/CD80 and B7.2/CD86 
(Janeway et al., 2008). Mature dendritic cells are no longer phagocytic, but are characterized by 
enhanced antigen processing and presentation (Banchereau et al., 2000). These activated dendritic 
cells migrate into the peripheral lymphoid organs (lymph nodes, spleen, and mucosa-associated 
lymphoid tissues, like the Peyer’s patches in the gut), where they trigger T cell responses.  
Naïve T cells, i.e. T cells that have not yet encountered the antigen their T cell receptor (TCR) is 
specific for, roam through the lymphoid tissues, transiently bind to DCs, and test the peptides 
presented on the DC’s surface by MHC complexes. Thereby, peptide presentation on MHC molecules 
is indispensable for recognition by the TCR-complexes of respective T lymphocytes (Alberts, 2002). 
There are two different MHC classes, namely MHC I and MHC II. MHC I molecules are expressed by 
all nucleated cells of the body, whereas MHC II expression is restricted to APCs. Accordingly, 
peptides bound to MHC I molecules are usually derived from proteasomally degraded cytosolic 
proteins (Rock et al., 2002) (Figure 6A). In contrast, MHC II associated peptides originate from 
endocytic protein uptake, i.e. from internalized extracellular proteins, or from pathogens residing 
intracellularly within the vesicular system (Janeway et al., 2008). Here, proteins are degraded in 
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acidified late endosomes by proteases, such as cathepsin S, prior loading onto MHC II molecules 
(Villadangos and Ploegh, 2000) (Figure 6A). However, also exogenous antigens can be presented on 
MHC I molecules, a process called cross-presentation or cross-priming (Bevan, 1976). Loaded MHC I 
complexes interact with specific TCRs and the co-receptor CD8 on CD8
+
 T cells, while CD4
+
 T 
lymphocytes specifically recognize MHC II-peptide complexes via TCR and CD4 (Coico and 
Sunshine, 2009) (Figure 6B). The presence of either the co-receptor CD8 or CD4 characterizes two 
main T cell subsets, which can be further divided into naïve, effector, and memory cells. 
However, priming, i.e. initial activation and differentiation of naïve T cells into effector T cells does 
not only require the interaction of TCR/CD3-complex and CD4 or CD8 with the peptide-MHC 
complex (Figure 6B). Instead, an activated APC simultaneously needs to provide so-called “co-
stimulation” to T cells, achieved by binding of co-stimulatory molecules, upregulated on activated 
APCs, to their respective receptors on T cells, e.g. interaction of the B7 family members CD80 or 
CD86 (on APCs) with CD28 (on T cells) (Janeway et al., 2008). This engagement provides a critical 
co-stimulus necessary for clonal expansion of T cells. Moreover, the differentiation of particularly 
CD4
+
 T cells (into the subsets discussed below) is commonly influenced by cytokines, which may be 
seen as a third signal indispensable for development of distinct effector cell subsets (Janeway et al., 
2008). Significance of co-stimulation is illustrated by functional inactivation, so-called anergy, of 
naïve T cells recognizing “their” antigen without receiving the appropriate co-stimulation (Schwartz, 
2003).  
Upon encounter of their antigen and appropriate co-stimulation, naïve T cells differentiate into effector 
T cells. T cells expressing the co-receptor CD8 kill degenerated or pathogen-infected cells (Barry and 
Bleackley, 2002) and therefore counteract tumor formation and growth or eliminate sources of new 
viruses or intracellular bacteria (Figure 6B). Hence, they are also termed cytotoxic T lymphocytes 
(CTLs). In contrast, CD4
+
 T cells either provide additional signals for the activation or dampening of 
other immune cells by cell-cell contact or cytokine secretion (Beverley, 2002). CD4
+
 T cells can be 
further divided into subsets with distinct functions, amongst others in T helper type 1 cells (Th1), T 
helper type 2 cells (Th2), T helper type 17 cells (Th17) or regulatory T cells (Treg) (Figure 6B). Th1 
cells are involved in the elimination of intracellular infections, as they activate the microbiocidal 
functions of infected macrophages, stimulate the proliferation of CD8
+
 cytotoxic T cells and the 
generation of CD8
+
 memory cells and activate B cells to produce strongly opsonizing antibodies, i.e. 
antibodies that bind to the surface of pathogens to stimulate Fc receptor-mediated ingestion by 
phagocytes (Janeway et al., 2008; Luckheeram et al., 2012). In contrast, Th2 lymphocytes provide 
essential help for antibody production by B cells and activation of eosinophils and therefore the fight 
against extracellular pathogens (Geginat et al., 2013). Th17 cells stimulate the production of 
chemokines by fibroblasts, epithelial cells, and keratinocytes, leading to the recruitment of neutrophils 
and macrophages, which then ingest and destroy microorganisms at the site of infection (Nijkamp and 
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Parnham, 2011), whereas Treg cells suppress the activity of other lymphocytes and thus limit immune 
responses and prevent autoimmunity (Vignali et al., 2008).  
 
 
Figure 6: Antigen processing and presentation by APCs and activation of naïve T cells. (A) Antigen 
processing and presentation by APCs. The arrow pointing from the exogenous to the endogenous pathway 
indicates cross-presentation, i.e. presentation of extracellular antigen-derived peptides on MHC I molecules. ER, 
endoplasmatic reticulum. Panel A is modified after Beverley, P C L, 2002. (B) Activation of naïve T cells by 
mature APCs to become effector cells. Activation of naïve T cells requires three kinds of signals provided by 
activated APCs: (1) Interaction of antigen peptide-MHC complexes on APCs with the TCR/CD3-complex and 
the respective co-receptor (CD4 or CD8) on T cells. (2) Simultaneous co-stimulation of the naïve T cell by the 
APC, e.g. by interaction of a B7 family molecule (on APC) with CD28 (on T cell), leading to augmented 
proliferation and survival of the respective T cell. (3) Signal three, commonly cytokines, influences the 
differentiation of the naïve T cell, especially of CD4
+
 T cells. Only T cells which have received all three signals 
develop into effector cells. CD8
+
 T cells kill pathogen-infected cells or tumor cells, whereas CD4
+
 T cells 
regulate the activity of other immune cells like macrophages (M), CD8
+
 cytotoxic T cells (CTL), B cells (B) or 
eosinophils (E). The figure depicts only a selection of CD4
+
 effector T cell subsets.  
 
When the respective pathogen is cleared, long-lived, antigen-specific lymphocytes persist, so-called 
memory cells. They are antigen-experienced and able to quickly initiate an immune response upon re-
encounter of the respective antigens. Memory T cells are characterized by the expression of several 
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surface molecules, which are not found in the naïve T cell population, e.g. CD45RO (Dutton et al., 
1998). They can be classified into effector memory T cells (TEM) with high immunomodulatory or 
cytotoxic potential, and central memory T cells (TCM) with low immunomodulatory or cytotoxic but 
high proliferative potential (Sallusto et al., 1999). TEM patrol through non-lymphoid organs and 
immediately fulfill effector functions, whereas TCM roam through secondary lymphoid organs and 
undergo massive proliferation upon encounter of their antigens presented by activated DCs, yielding 
large amounts of effector cells after this amplification loop. 
 
Besides their essential role in the activation of naïve T cells, DCs are also crucial to orchestrate the 
humoral immune response. As aforementioned, DCs indirectly trigger T cell-dependent B cell 
responses via activation of CD4
+
 T helper cells, which provide essential stimuli for B cells to become 
antibody-secreting plasma cells. Furthermore, T cell help is crucial for class switching, i.e. change of 
antibody heavy chains, which determine the effector functions of the antibody species. Moreover, DCs 
can directly induce specific antibody responses by transferring unprocessed antigens to naïve B cells 
and additionally provide cell-bound signals to B cells for survival and class switching (Wykes et al., 
1998; Wykes and MacPherson, 2000). Antibodies or immunoglobulins (Ig) are soluble forms of B cell 
receptors (BCRs) with the same specificity, released into extracellular space and fluids such as blood. 
They play a crucial role in opsonization of pathogens, complement activation (resulting in the lysis of 
marked pathogens) and antibody-dependent cellular cytotoxicity (i.e. killing of antibody-coated cells 
by cytotoxic effector cells) (Janeway et al., 2008). Besides, they are involved in neutralization of 
toxins and of pathogens by binding to critical areas on the pathogens’ surface, thereby e.g. sterically 
blocking receptor binding domains necessary for viral cell entry (Janeway et al., 2008).  
Similar to TEM and TCM, also long-lived plasma cells and B memory cells persist after the primary 
infection has resolved. Plasma cells, residing in bone marrow niches, produce antibodies in an antigen-
independent manner, leading to constant levels of specific antibodies in blood and therefore ensure 
imminent protection (Radbruch et al., 2006). In contrast, B memory cells do not secrete antibodies 
until antigen re-encounter by their antigen-specific BCR complex. This induces their rapid 
differentiation into plasma cells, which subsequently produce large amounts of high-affinity antibodies, 
enabling strong and accelerated immune responses upon a secondary infection with the same pathogen 
(Plotkin et al., 2012).  
Taken together, lymphocytes efficiently combat pathogens in the extracellular space by the production 
of antibodies and intracellularly by killing of infected cells, after initiation of antigen-specific 
responses by activated antigen presenting cells.  
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1.3.2. Immunology of vaccination 
The term vaccination describes the administration of single or multiple immunogenic antigens (the so-
called vaccine) into individuals to artificially induce antigen-specific adaptive immunity. Vaccination 
can either serve prophylactic or therapeutic purposes, i.e. aiming at disease prevention or treatment, 
respectively. As already described in chapter 1.3.1, adaptive immune responses are triggered by APCs, 
which have been activated by PRR signaling in response to PAMPs and/or DAMPs and present a 
processed form of the antigen on MHC complexes. Without danger signals, APCs like DCs undergo 
no maturation and interaction of immature DCs with naïve T cells will either induce apoptosis of T 
cells, T cell anergy or development of regulatory CD4
+
 T cells (Mahnke et al., 2002). Thus, it is of 
utmost importance that a vaccine is composed of an antigen and, in order to induce immunity rather 
than tolerance, an activation signal for APCs (Kreutz et al., 2013).  
 
Based on their ability to replicate, vaccines can be categorized into two major groups (Plotkin et al., 
2012). The first group comprises live-attenuated, replicating vaccines, whereas the second group 
includes non-replicating vaccines, like inactivated vaccines, subunit vaccines, DNA vaccines, or 
recombinant vector vaccines (Clem, 2011). Live-attenuated vaccines, such as the measles vaccine 
(Hilleman et al., 1968), are attenuated strains of the respective pathogens, eliciting comparable cellular 
and humoral immune responses like the wild-type microorganism (Pulendran and Ahmed, 2011), but 
causing no disease, any longer. Thus, live-attenuated vaccines trigger strong, broad, and long-lasting 
immune responses, presumably by efficient activation of APCs following engagement of their PRRs 
with the vaccine’s PAMPs and activation of APCs at multiple sites due to the vaccine’s replication and 
dissemination (Plotkin et al., 2012). However, as exemplified for the Sabin polio vaccine strain (Cann 
et al., 1984), live-attenuated microorganisms may revert back to their pathogenic wild-type form in 
immunized patients. Besides, live-attenuated vaccines may still cause disease in immunocompromised 
individuals (Centers for Disease Control and Prevention, 1996). 
There are no such safety concerns for vaccines devoid of living organisms. These vaccines are 
significantly less efficient in inducing immunity though they may still contain PAMPs. This is due to 
the lack of replication and spread in the organism, which restricts the activation of immune responses 
to the limited time frame of antigen persistence and the site of vaccine injection (Plotkin et al., 2012). 
Therefore, most dead vaccines contain adjuvants, which are defined as any substances that potentiate 
immunogenicity of antigens in vivo, by either activating APCs (immunomodulators, e.g. PAMPs), or 
enhancing antigen presentation (depot formulation and delivery systems, e.g. antigen-targeting to 
APCs) (Pashine et al., 2005; Plotkin et al., 2012). In humans, the most frequently used adjuvants are 
aluminum salts, such as aluminium potassium sulphate (alum). Alum, thought to act via depot 
formation (Petrovsky and Aguilar, 2004), preferentially induces Th2 responses. In contrast, the 
adjuvant AS04, composed of the considerably detoxified LPS-derivate monophosphoryl lipid A 
formulated on alum, favors Th1 responses (Coffman et al., 2010). Thus, different adjuvants can be 
Introduction 
18 
 
used to tailor the relevant immune reaction. Also packaging of antigen-encoding sequences or antigens 
into/onto liposomes or cationic polylactide co-glycolide (PLG) microparticles (O'Hagan et al., 2004; 
Fan et al., 2015), or presentation of antigens on the surface of virus-like particles (McBurney et al., 
2007) have been shown to elicit beneficial effects on immunogenicity (adjuvanted delivery system).  
However, although adjuvants improve immunogenicity of dead vaccines, these vaccines are 
commonly not capable to confer life-long immunity (Pulendran and Ahmed, 2011) and therefore 
require booster immunizations to reactivate immune memory. A prime-boost scheme of vaccination 
can be either homologous (readminsitration of the same vaccine) or heterologous (administration of 
the same antigen by different delivery systems). Thereby, it has been shown that multiple 
administrations of an identical vaccine can efficiently boost humoral, but hardly any cellular immunity, 
whereas heterologous prime-boost regimes have been demonstrated to be highly promising at boosting 
the latter (Woodland, 2004).  
Which kind of adaptive immune responses are mainly required for success of a given vaccine depends 
on the respective pathogen (e.g. extracellular versus intracellular localization, etc.) and the type of 
intended vaccine use (prophylactic or therapeutic vaccine). Most classical vaccines are assumed to act 
primarily by induction of antigen-specific antibodies (Plotkin et al., 2012). However, triggering of 
strong CD4
+
 T cell and CD8
+
 CTL responses is favorable for the development of therapeutic vaccines 
applied to treat chronic infections and cancer (Bachmann and Jennings, 2010). DCs are the most 
potent inducers of T cell responses. Thus, the efficiency of a vaccine can be enhanced by targeting it to 
DCs (Kastenmüller et al., 2014), thereby not only inducing CTL, but also B cell responses, as both 
require adequate CD4
+
 T cell help. For this purpose, DC-targeted recombinant vaccine vectors are 
attractive vaccine candidates. Here, an attenuated vector, e.g. a lentiviral vector (see 1.1), transfers 
antigen-encoding sequences of a pathogen of choice into DCs, while simultaneously stimulating DCs 
which recognize the PAMPs of the vector backbone. The antigen is subsequently expressed by the 
transduced DCs, processed, and antigenic peptides are presented on MHC I or MHC II molecules. 
Thereby, antigen-specific CD4
+
 and CD8
+
 T cells are activated and antibody production is induced. 
Lentiviral vectors pseudotyped with, e.g. Sindbis virus Env (targeting DC-SIGN) (Yang et al., 2008; 
Dai et al., 2009), measles virus Env (targeting SLAM) (Humbert et al., 2012) or engineered MV-GPs 
displaying a single chain antibody fragment directed against MHC II (Ageichik et al., 2011; Ciré et al., 
2014) have been successfully used for DC-targeting in vitro and in animal models in vivo.  
In general, the antigen delivery system accounts for the route of antigen cell entry and thus for 
presentation on MHC I or MHC II molecules, resulting in activation of CD8
+
 and CD4
+
 T cells, 
respectively. Cytosolic delivery results in predominant MHC I presentation, whereas endocytotic 
uptake favors loading onto MHC II molecules, although some antigens can also gain access to MHC I 
presentation by cross-presentation (Figure 6A).  
However, not only vaccine type, adjuvant, vaccination schedule or route of antigen uptake, but also 
amount, persistence, and chemical nature of the antigen influence vaccination success. A hallmark of 
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vaccine-induced immunity is long-term protection, achieved by the generation of memory cells. 
Memory B cells are exclusively generated during T cell-dependent B cell responses, triggered by 
proteinaceous antigens, and not during T cell-independent responses to lipopolysaccharides, 
polysaccharides or polymeric proteins (Janeway et al., 2008). Moreover, whereas the linear T cell 
epitopes can be generated from basically any region of an antigen and their recognition by antigen 
peptide-specific TCRs is only further limited by MHC restriction, B cells do exclusively recognize 
linear or conformational epitopes located at the surface of antigens (Janeway et al., 2008). 
Additionally, also the antigen dose has an impact on the triggered immune responses. In general, 
higher doses of priming-antigen preferably induce plasma cells, whereas lower doses predominantly 
induce B memory cells (Plotkin et al., 2012). Similarly, also the development of Th1 (essentially 
induced by low antigen doses) or Th2 (essentially induced by high antigen doses) CD4
+
 T cells is 
biased by antigen dose (Plotkin et al., 2012).  
 
Concluding, vaccination is an efficient method to induce protective immunity against pathogens. 
However, its success and the nature of elicited immune responses are influenced by multiple 
parameters, including (1) the type of vaccine, (2) adjuvants, (3) vaccination schedule, (4) antigen 
uptake route, (5) chemical nature of the antigen and (6) antigen dose (Plotkin et al., 2012), making 
vaccine development a challenging endeavor. 
1.4. Objectives 
The aim of this thesis was the generation and characterization of entry-targeted lentiviral vectors for 
specific and efficient protein or gene transfer into SLAM- or CD4-positive immune cells, respectively. 
Both targeting approaches should be realized by pseudotyping LVs with measles virus glycoproteins, 
either exploiting the natural tropism of MVwt-GPs or using engineered MV-GPs.  
 
In the first part of this thesis, MVwt-GP pseudotyped, SLAM-targeted lentiviral vectors should be 
generated to mediate protein transfer into SLAM-expressing APCs, such as DCs, and their potential to 
induce antigen-specific vaccination responses should be assessed. In order to define the entirety of 
MVwt-LV target cells, the postulated but hitherto unknown epithelial MV receptor had to be initially 
identified. Since myeloid cells like DCs are described as somewhat resistant to genetic modification 
by LVs (Pion et al., 2006), it was hypothesized that antigen protein transfer might be an attractive 
alternative to circumvent post-entry blocks to gene transfer, furthermore avoiding its potentially 
genotoxic effects. Protein transfer should be achieved by fusion of cargo protein encoding sequences 
to matrix as already described for HIV-1-derived or retroviral vectors (Müller et al., 2004; Voelkel et 
al., 2010). For that purpose, an optimal protocol to generate protein transfer vectors (PTVs) had to be 
established. Next, the suitability of MVwt-GPs pseudotyped PVTs to mediate SLAM-specific 
cytoplasmic protein transfer should be analyzed by GFP, Cre, and Ova protein transfer into receptor 
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transgenic (indicator) or naturally SLAM-expressing cell lines. The potential of PTVs to induce model 
antigen (Ova)-specific cellular immune responses should be determined in co-cultures of ex vivo 
transduced myeloid dendritic cells and Ova-specific primary T cells before in vivo applicability of 
Ova-PTVs as vaccines should be assessed in huSLAM-knock in mice. 
 
In the second part of the present thesis, a CD4-specific lentiviral vector should be generated based on 
the highly flexible targeting system introduced by Funke et al. (Funke et al., 2008). Here, the CD4-
specific DARPin 29.2 served as binding domain fused to mutated H. First of all, the specificity of 
CD4-LV should be determined on receptor-positive and -negative cell lines and primary peripheral 
blood mononuclear cells (PBMC). Special focus was given to the potential of CD4-LV to transduce 
also resting CD4
+
 T lymphocytes, which are described to be particularly resistant to gene transfer by 
commonly used VSV-LV (Maurice et al., 2002; Frecha et al., 2009). Moreover, it should be 
determined whether transduction success is restricted to CD4
+
 lymphoid immune cells or also extends 
to CD4-expressing cells of the myeloid lineage. This question was tackled for macrophages.  
Finally, in case of highly CD4-specific and efficient transduction, the potential of CD4-LV to mediate 
in vivo gene transfer upon systemic administration should be evaluated. Therefore, a humanized mouse 
model had to be established in our working group. Biodistribution of CD4-LV should be assessed by 
in vivo imaging, whereas cell-specificity had to be confirmed by flow cytometry.  
 
Both SLAM-targeted PTVs and CD4-LV generated in this thesis will be powerful tools for various 
applications in basic research and gene and immunotherapy, relying on the specific modification of 
SLAM- and CD4-positive immune cell subtypes, respectively. 
 
  
Material and Methods 
21 
 
2. Material and Methods 
2.1. Material 
2.1.1. Chemicals 
Table 1: List of used chemicals. 
Name Source of supply 
 
2-Log DNA Ladder New England Biolabs 
2-Mercaptoethanol Sigma-Aldrich 
Acetic acid Carl Roth 
Acrylamide/ Bis-Acrylamide solution (Rotiphorese
®
 Gel 30) Carl Roth  
Agarose (electrophoresis grade) Biozym 
Ammonium persulfate (APS) Carl Roth  
Ampicillin Serva 
Bovine serum albumin fraction V (BSA) AppliChem 
Bromophenol blue Sigma-Aldrich 
Citric acid Fluka 
Deoxyribonucleotide Mix (10 mM each) 5Prime 
Dimethylsulfoxide (DMSO)  Calbiochem, Merck Millipore 
Dithiothreitol (DTT) Sigma-Aldrich 
D-Luciferin Potassium Salt Caliper 
D(+)-Saccharose Carl Roth  
Ethidium bromide (10 mg/ml) Sigma-Aldrich 
Ethylenediaminetetraacetic acid (EDTA, 1 M) Paul-Ehrlich-Institut 
Fetal calf serum (FCS) 
 
PAA and Biochrome (standard cell culture) 
Sigma (dendritic cell culture) 
 
Geneticin (G418) Gibco, Life Technologies 
Glutaraldehyde Sigma-Aldrich 
Glycerin AppliChem 
Glycine Merck 
HCl Carl Roth 
HEPES (1 M, pH 7.4) Paul-Ehrlich-Institut 
Histopaque
®
 -1077 Sigma-Aldrich 
Horse serum Gibco, Life Technologies 
L-Glutamine  Biochrom, Merck Millipore 
Lipofectamine
®
 2000  Invitrogen, Life Technologies 
Lipopolysaccaride Sigma 
Lysing Buffer (BD Pharm Lyse™) BD Biosciences 
Milk powder Carl Roth 
NaOH Carl Roth 
N,N,N',N'-Tetramethylethylendiamin (TEMED) Carl Roth 
Non-essential amino acids (NEA) Biochrom, Merck Millipore 
NP-40 Biochemika  
Paraformaldehyde Merck 
Penicillin-streptomycin solution Paul-Ehrlich-Institut 
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Name Source of supply 
 
Polyethyleneimine (PEI), branched, 25 kDa Sigma-Aldrich 
Potassium chloride Carl Roth 
Precision Plus Protein™ Kaleidoscope™ Standard Bio-Rad 
Protamine sulfate Sigma-Aldrich 
Protease Inhibitor Cocktail complete Roche 
Restore™ PLUS Western Blot Stripping Buffer  Thermo Scientific 
Sodium azide Merck 
Sodium carbonate Merck 
Sodium chloride Carl Roth 
Sodium dodecyl sulfate (SDS), 10% solution Paul-Ehrlich-Institut 
Sodium hydrogen carbonate Biochrom (cell culture) or Merck 
Sodium pyruvate Sigma-Aldrich 
TMB ELISA Substrate BD Biosciences or eBioscience 
Tris(hydroxymethyl)aminomethane (Tris) Carl Roth 
Triton
®
 X-100 Serva 
Trypan Blue Solution Sigma-Aldrich 
Tween
®
 20 Carl Roth 
Ultrapure Water Paul-Ehrlich-Institut 
Urea Carl Roth 
Western Blotting Substrate (Pierce
®
 ECL 2) Thermo Scientific 
Western Blotting Substrate (Amersham™ ECL™ Prime) GE Healthcare 
 
2.1.2. Consumables  
Table 2: List of used consumables. 
Name Source of supply 
 
Amersham Hybond™-P PVDF Membrane GE Healthcare 
Blood collection tubes (Microtainer lithium-heparin tubes) Becton Dickinson 
Blood collection tubes (Coagulation 9NC/10ml Monovette
®
, citrate) Sarstedt 
C-Chip Hemocytometer Digital Bio 
Cell culture dishes (15 cm) TPP 
Cell culture multidish plates (96-well, 48-well, 24-well, 12-well, 6-well) Nunc 
Cell scraper TPP 
Cell star
®
 cell culture flasks (T25, T75, T175) Greiner Bio-One 
Cell star
®
 tubes (15 ml, 50 ml) Greiner Bio-One 
Cell strainer (70 µm) BD Biosciences 
Centrifuge tubes (225 ml) Corning Life Sciences 
Chemiluminescence detection film (Amersham Hyperfilm™) GE Healthcare 
Combitips (10 ml) Eppendorf  
Cryo-tubes (Cryo.s ™, 2 ml) Greiner Bio-One 
ELISpot Foil (Eli.Foil)  A.EL.VIS 
ELISpot MultiScreen
®
-IP Filtration Plate Merck Millipore 
Flow cytometry round-bottom tubes (5 ml) BD Biosciences 
Flow cytometry U-bottom tubes (1.4 ml) Micronic 
Insulin syringe (30 G) B. Braun 
LS Columns for MACS Separation Miltenyi Biotec 
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Name Source of supply 
 
Microtubes (low binding, 1.5 ml) Axygen 
Minisart
®
 syringe filter (0.45 µm, 0.2 µm) Sartorius 
Omnifix
®
 disposable syringe (1 ml, 2 ml, 5 ml) B. Braun 
Pasteur pipette glass (150 mm) VWR International 
Pipette tips (10 µl) Eppendorf 
Pipette tips (100 µl, 1000 µl) Sarstedt 
Pipette filter tips (10 µl, 100 µl, 1000 µl) 4titude 
Reaction tube (1.5 ml, 2 ml) Sarstedt 
Reagent reservoir (50 ml) Corning Life Sciences 
Serological pipettes, sterile (2 ml, 5 ml, 10 ml, 25 ml) Greiner Bio-One 
Sterican 
®
 disposable cannulas (20 G, 25 G, 30 G) B. Braun 
Stericup 
®
 & Steritop ™ vacuum-driven filtration systems (0.45 µm, 0.2 µm) Millipore 
Tissue  Tork 
Ultracentrifuge tubes (36 ml) Beckmann Coulter 
Western Blotting Filter Paper Bio-Rad 
 
2.1.3. Instruments and software 
Table 3: List of used instruments. 
Name Type Manufacturer 
Cell separator AutoMACS Pro Miltenyi Biotec 
Centrifuge 
Heraeus Pico 17 Centrifuge 
Heraeus Multifuge 3SR
+
  
Avanti
®
 J-26 XP Centrifuge 
Thermo Scientific 
Thermo Scientific 
Beckman Coulter 
Cryo freezing container Qualifreeze Qualilab
®
 
Ear punch pliers KN 293  Bioscape 
ELISpot Punching Tool Eli.Punch A.EL.VIS 
ELISpot Scanner Eli.Scan A.EL.VIS 
Exposure cassette BioMax Kodak 
Film processor Curix 60 Agfa  
Flow cytometer LSRII Becton Dickinson 
Fluorescence microscope and 
camera 
Axiovert 200 with AxioCam Carl Zeiss 
Gel documentation station  UVstar Biometra 
Gel-electrophoresis chamber 
 Agarose gels 
 SDS-PAGE 
 
DNA Sub Cell™  
Mini-Protean
®
 Tetra System 
 
Bio-Rad 
Bio-Rad 
Incubator BBD 6220  Heraeus  
Incubator Shaker Innova 4000/ 4200/ 4230 New Brunswick Scientific 
In vivo bioluminescence detection 
and gas anesthesia system 
Ivis Spectrum 
XGI-8 Gas Anesthesia System  
Caliper, Perkin Elmer 
Isoflurane anesthesia unit 
Vaporizer 
Matrx™ VMR  
VIP 3000  
Midmark 
Laminar Flow Cabinet 
 Cell culture 
 Bacteria culture 
 
SterilGARD
®
 III Advance 
HLB 2448 BS 
 
The Baker Company 
Heraeus 
Laser Scanning Microscope LSM 7 Live Carl Zeiss 
Magnetic stirrer RCT basic IKA  
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Name Type Manufacturer 
Microplate reader SpectraMax 340PC Molecular Devices 
Microplate washer ELx405 Bio-Tek 
Microscope Axiovert 25 Carl Zeiss 
pH electrode inoLAb WTW 
Pipettes Reference Eppendorf 
Pipetting Aid Accu-jet
®
  Brand 
Platform Shaker Polymax 2040 Heidolph 
Power supply unit 
Power Pac 200 
Standard Power Pack P25 
Bio-Rad 
Biometra 
Roller mixer SRT6 Stuart
®
 
Scales LP 4200 S Sartorius 
Semi-dry blotter 
Trans-Blot
®
 SD Semi-Dry Transfer 
Cell 
Bio-Rad 
Stepper Multipette
®
 plus Eppendorf 
Thermocycler 
DNA Engine
®
  
PTC 200 
Bio-Rad 
MJ Research 
Thermomixer ThermoStat plus Eppendorf 
Transmission electron microscope  EM109  Carl Zeiss 
Ultracentrifuge and rotor 
Optima™ L-70K Ultracentrifuge 
and rotor SW28 
Beckman Coulter 
UV-VIS spectrophotometer NanoDrop 2000c peQlab Biotechnologie GmbH 
Vacuum pump VacuSafe comfort IBS Integra Biosciences 
Vortex mixer Vortex Genie2™ Bender & Hobein  
 
Table 4: List of used software. 
Name Version Manufacturer 
 
Axio Vision 4.8 Carl Zeiss 
BD FACSDiva 6.1.3 Becton Dickinson 
Citavi 4.4.0.28 Swiss Academic Software 
Eli.Analyse 5.0 A.EL.VIS 
FCS Express 4 De Novo Software 
GraphPad Prism 5.4 Graph Pad Software 
Living Image 4.2 Caliper, Perkin Elmer 
Microsoft Office 2010 Microsoft
®
 
Vector NTI  9 InforMax 
ZEN microscope software (LSM) ZEN black 2012 Carl Zeiss 
 
2.1.4. Buffers, solutions and media 
Table 5: List of used buffers and solutions. 
Name Composition 
Ammonim chloride buffer 
0.86% (w/v) NH4Cl 
H20 
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Name Composition 
Citric acid buffer 
40 mM citcic acid 
135 mM NaCl 
10 mM KCl 
H20 
adjust pH of 3.0 with NaOH 
DNA Loading buffer (6x) 
10% (v/v) Glycerin 
20% (v/v) 6x Gel Loading Dye, blue (by NEB) 
H20 
ELISA Blocking Buffer 
10% (v/v) Fetal Calf Serum  
PBS w/o Ca
2+
/Mg
2+
 
ELISA/ ELISpot Wash Buffer 
0.05% (v/v) Tween 20 
PBS w/o Ca
2+
/Mg
2+
 
FACS-wash 
2 % (v/v) Fetal Calf Serum 
0.1% (v/v) NaN3  
PBS w/o Ca
2+
/Mg
2+
 
FACS-fix 
1% (w/v) paraformaldehyde  
PBS w/o Ca
2+
/Mg
2+
 
MACS Buffer 
2 mM EDTA 
0.5% (w/v) BSA 
PBS w/o Ca
2+
/Mg
2+ 
pH 7.2 
Phosphate buffered saline (PBS) 
w/o Ca
2+
/Mg
2+
 
137 mM NaCl 
2.7 mM KCl 
8.1 mM Na2HPO4 
1.47 mM KH2PO4 
adjust pH of 7.1 with HCl 
Red Blood Cell Lysis Buffer 
155 mM NH4Cl 
10 mM Tris 
H20 
adjust pH of 7.5 with HCl 
RIPA buffer 
50 mM Tris-HCl pH 8.0  
150 mM NaCl  
1% (w/v) NP-40  
0.5% (w/v) Sodium Desoxycholate 
0.1% SDS  
H20 
Supplemented with Roche Protease Inhibitor Cocktail 
Complete before usage  
SDS running buffer 
25 mM Tris 
200 mM Glycine 
1% (w/v) SDS 
H2O  
Sucrose 20%  
20% (w/v) Sucrose  
PBS w/o Ca
2+
/Mg
2+
 
TAE buffer 
40 mM Tris  
20 mM Acetic acid  
1 mM EDTA  
H20  
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Name Composition 
TBS-T buffer 
50 mM Tris 
150 mM NaCl  
H20 
adjust pH of 7.4 with HCl  
0.1% (v/v) Tween 20  
Triton
®
 X-100 lysis buffer (10x) 
5% (v/v) Triton
®
 X-100 
PBS w/o Ca
2+
/Mg
2+
 
Urea sample buffer (2x) 
200 mM Tris-HCL pH 6.8 
8 M Urea  
5% (w/v) SDS  
0.1 mM EDTA  
0.03% (w/v) Bromophenol blue  
1.5% (w/v) DTT 
Western Blot Blocking Buffer 
5% milk powder (w/v) or horse serum (v/v) 
TBS-T 
Western Blot Blotting buffer 
60 mM Tris 
40 mM Glycerin 
20% (v/v) Methanol 
H2O 
 
Table 6: List of used media. 
Name Composition 
Dendritic cell culture medium 
RPMI-1640  
10% (v/v) Fetal Calf Serum 
2 mM L-Glutamine 
1% (v/v) Penicillin-streptomycin stock solution 
10 mM HEPES 
1 mM Sodium Pyruvate 
0.1 mM 2-Mercaptoethanol 
Dulbecco’s Modified Eagle Medium (DMEM) 
obtained from Lonza, 
supplemented with 10% FCS and 2 mM L-Glutamine 
before use 
Eagle’s Minimum Essential Medium (EMEM) 
obtained from Invitrogen, Life technologies 
supplemented with 10% FCS and 2 mM L-Glutamine 
before use 
Freezing Medium 
90% (v/v) FCS 
10% (v/v) DMSO 
Lysogeny broth (LB)-ampicillin Agar  
4% (w/v) LB-Agar 
100 µg/ml ampicillin 
H2O 
Lysogeny broth (LB)-ampicillin X-gal Agar 
4% (w/v) LB-Agar 
100 µg/ml ampicillin 
0.009% (w/v) X-Gal  
2 mM IPTG 
H2O 
Lysogeny broth (LB) Medium 
1% (w/v) Tryptone 
0.5% (w/v) Yeast extract 
1% (w/v) NaCl 
H2O 
pH 7.0 
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Name Composition 
Opti-MEM
®
 (1x) + GlutaMAX™ Gibco, Life Technologies 
Macrophage medium 
RPMI-1640 
10% (v/v) Fetal Calf Serum 
2 mM L-Glutamine 
1% (v/v) Penicillin-streptomycin stock solution 
10 mM HEPES 
0.25 mM 2-Mercaptoethanol 
McCoy’s 5A modified medium 
obtained from Biochrom, Merck Millipore 
supplemented with 10% FCS and 2 mM L-Glutamine 
before use 
MEM-α 
obtained from Life technologies, supplemented with 
20% (v/v) Fetal Calf Serum, 2 mM L-Glutamine, 
1 mM Sodium Pyruvate and 5 ng/ml GM-CSF before 
use 
Roswell Park Memorial Institute (RPMI) 1640 
Medium 
obtained from Biowest, 
supplemented with 10% FCS and 2 mM L-Glutamine 
before use 
S.O.C.-Medium  
2% (w/v) Tryptone 
0.5% (w/v) Yeast extract 
8.6 mM NaCl 
2.5 mM KCl 
10 mM MgCl2 
20 mM Glucose 
H2O 
pH 7.0 
T cell culture medium 
RPMI-1640  
10% (v/v) Fetal Calf Serum 
2 mM L-Glutamine 
0.4% (v/v) Penicillin-streptomycin stock solution 
25 mM HEPES (pH 7.4) 
freshly supplemented with 100 IU/ml IL-2 for 
activated T cells (but not for resting PBMC) 
 
2.1.5. Antibodies 
Table 7: List of used antibodies.  
Name Clone Application 
Dilution/ 
Concentration
a 
 
Source of supply 
FcR Blocking Reagent 
(human FcR Block) 
 Flow cytometry 1:100 Miltenyi Biotec 
Purified rat anti-mouse 
CD16/CD32 (mouse FcR 
Block) 
2.4G2 Flow cytometry 1:100 BD Biosciences 
Purified NA/LE mouse 
anti-human CD3 
UCT1 Coating 
1 µg/ml or 
3 µg/ml 
BD Biosciences 
Purified NA/LE mouse 
anti-human CD28 
CD28.2 Coating 
1 µg/ml or 
3 µg/ml 
BD Biosciences 
mouse IgG1, κ Isotype 
Control/pure 
X40 Flow cytometry 1:50 BD Biosciences 
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Name Clone Application 
Dilution/ 
Concentration
a 
 
Source of supply 
mouse IgG1, κ Isotype 
Control/ APC/ Pacific 
Blue™/ PE 
MOPC-21 Flow cytometry 1:100 BD Biosciences 
mouse IgG2a, κ Isotype 
Control/ Pacific Blue ™ 
G155-178 Flow cytometry 1:100 BD Biosciences 
rat anti-mouse IgG1/ APC A85-1 Flow cytometry 1:100 BD Biosciences 
rat IgG2b, κ Isotype 
Control/ FITC 
A95-1 Flow cytometry 1:100 BD Biosciences 
mouse anti-human CD3/ 
APC/ Pacific Blue ™ 
UCHT1 Flow cytometry 1:100 BD Biosciences 
mouse anti-human CD4/ 
APC/ PE 
RPA-T4 Flow cytometry 1:100 BD Biosciences 
mouse anti-human CD8/ 
APC/ Pacific Blue ™ 
RPA-T8 Flow cytometry 1:100 BD Biosciences 
mouse anti-human CD14/ 
Pacific Blue ™ 
M5E2 Flow cytometry 1:100 BD Biosciences 
mouse anti-human CD25/ 
PE 
M-A251 Flow cytometry 1:100 BD Biosciences 
mouse anti-human CD45/ 
PE 
HI30 Flow cytometry 1:100 BD Biosciences 
mouse anti-human Nectin-
1/pure 
R1.302 Flow cytometry 1:32 
M. Lopez (Cocchi 
et al., 1998) 
mouse anti-human Nectin-
2/pure 
R2.477 Flow cytometry 1:67 
M. Lopez (Lopez et 
al., 1998) 
mouse anti-human 
PVR/pure 
PV.404 Flow cytometry 1:220 
M. Lopez (Lopez et 
al., 1998) 
mouse anti-human Nectin-
4/pure 
N.4.40 Flow cytometry 1:200 
M. Lopez (Fabre et 
al., 2002) 
mouse anti-human PVR4 - Flow cytometry 1:1,000 
LifeSpan 
BioSciences 
armenian hamster anti-
mouse CD11c/ APC 
HL3 Flow cytometry 1:500 BD Biosciences 
rat anti-mouse CD45/ 
FITC 
30-F11 Flow cytometry 1:100 BD Biosciences 
armenian hamster anti-
mouse CD69/ PE-Cy7 
H1.2F3 Flow cytometry 1:100 BioLegend 
rat anti-mouse CD86/ 
Pacific Blue ™ 
GL-1 Flow cytometry 1:100 BioLegend 
anti-His/ PE 
GG11-
8F3.5.1  
Flow cytometry 1:11 Miltenyi Biotec 
rabbit anti human 
Ron/MST1R/pure 
EP1132Y Flow cytometry 1:20 Abcam 
goat anti-mouse Ig/PE polyclonal Flow cytometry 1:50 BD Biosciences 
rabbit anti-Cre polyclonal Western Blot 1:20,000 Novagen 
rabbit anti-chicken 
ovalbumin 
polyclonal Western Blot 1:40,000 Novus Biologicals 
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Name Clone Application 
Dilution/ 
Concentration
a 
 
Source of supply 
rabbit anti-GFP polyclonal Western Blot 1:2,000 Life technologies 
rabbit anti-H [H606] polyclonal Western Blot 1:2,000 Eurogentec 
mouse anti-HIV-1 p24 38/8.7.47 Western Blot 1:1,000 ZeptoMetrix 
rabbit anti-F [F1034] polyclonal Western Blot 1:4,000 Eurogentec 
mouse anti-α Tubulin B-5-1-2 Western Blot 1:50,000 Sigma-Aldrich 
donkey anti-rabbit IgG 
(H&L)/HRP 
polyclonal Western Blot 1:10,000 Rockland 
rabbit anti-mouse 
IgG+A+M (H&L)/HRP 
polyclonal Western Blot 1:10,000 
Invitrogen, Life 
technologies 
a
 Isotype controls were applied in the same concentration as the respective antibody. 
 
2.1.6. Recombinant proteins and peptides  
Table 8: List of used recombinant proteins and peptides. 
Name Source of supply 
Antigens 
Concanavalin A Sigma-Aldrich 
Ovalbumin S. Schülke, Paul-Ehrlich-Institut (Schülke et al., 2010) 
Ova257-264 (SIINFEKL) InvivoGen 
Ova323-339 (ISQAVHAAHAEINEAGR) InvivoGen 
Cytokines 
human Interleukin-2 Roche or R&D 
Mouse GM-CSF R&D 
Enzymes 
KOD Hot Start Polymerase  Merck Millipore 
Restriction endonucleases  New England Biolabs 
Taq DNA polymerase  5Prime 
T4-Ligase (Rapid ligation Kit) Roche 
Trypsin 2.5% (Sigma) Paul-Ehrlich-Institut 
Inhibitors 
Fusion Inhibiting Peptide (FIP, 2-D-Phe-Phe-Gly-OH) Bachem 
 
2.1.7. Plasmids 
Table 9: List of used plasmids. 
Name Characterization Origin 
pcDNA3.gpGFP.4xCTE HIV-1 MA-GFP packaging plasmid  A. Schambach, MH Hannover  
pCG-1 empty eukaryotic expression plasmid 
R. Cattaneo, Mayo Clinic 
(Cathomen et al., 1995)  
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Name Characterization Origin 
pCG-FcΔ30 
encodes MVNSe F with a truncated 
cytoplasmic tail of 30 amino acids under 
control of the CMV promoter 
A. Maisner, Phillips-
Universität Marburg 
(Moll et al., 2002) 
pCG-Fwt323Δ30 
encodes MVwt F with a truncated 
cytoplasmic tail of 30 amino acids under 
control of the CMV promoter 
S. Kneissl, Paul-Ehrlich-
Institut 
(Funke et al., 2009) 
pCG-H-αCD4 
encodes MVNSe H with the four point 
mutations Y481A, R533A, S548L and 
F549S, a truncated cytoplasmic tail of 18 
amino acids and the CD4-specific DARPin 
29.2 fused to its C-terminus 
C. Osterburg, Paul-Ehrlich-
Institut 
pCG-Hwt323Δ18 
encodes MVwt H with a truncated 
cytoplasmic tail of 18 amino acids under 
control of the CMV promoter 
S. Kneissl, Paul-Ehrlich-
Institut 
(Funke et al., 2009) 
pcHIV1_MA_P_Cre 
HIV-1 MA-Cre packaging plasmid, with 
HIV-1 protease recognition site between 
MA and Cre 
J. Reusch, Paul-Ehrlich-
Institut 
(Reusch, 2013) 
pcHIV1_MA_P_GFP 
HIV-1 MA-GFP packaging plasmid, with 
HIV-1 protease recognition site between 
MA and GFP  
generated within this thesis 
pcHIV1_MA_P_Ova 
HIV-1 MA-Ova packaging plasmid, with 
HIV-1 protease recognition site between 
MA and Ova 
generated within this thesis 
pCMVΔR8.9 HIV-1 packaging plasmid 
U. Blömer, University 
Hospital Kiel  
(Zufferey et al., 1997) 
pET15b-Ova expression plasmid coding for ovalbumin 
S. Schülke, Paul-Ehrlich-
Institut 
(Schülke et al., 2010) 
pS-luc2-GFP-W 
HIV-1 packagable vector encoding firefly 
luciferase and sfGFP under control of the 
SFFV promoter 
T. Abel, Paul-Ehrlich-Institut 
(Abel et al., 2013) 
pSEW 
HIV-1 packagable vector encoding 
GFP under control of the SFFV promoter 
M. Gretz, Georg-Speyer-Haus 
(Demaison et al., 2002)  
pSEW-Cre 
HIV-1 packagable vector encoding Cre 
recombinase under control of the SFFV 
promoter 
J. Bryzna, Paul-Ehrlich-Institut 
(Anliker et al., 2010) 
pSEW-TurboFP635 
HIV-1 packagable vector encoding the red-
fluorescing Katushka protein under control 
of the SFFV promoter 
T. Abel, Paul-Ehrlich-Institut 
(Bach et al., 2013) 
pMD.G2 encodes VSV-G 
D. Trono, École Polytechnique 
Fédérale De Lausanne 
 
2.1.8. Oligonucleotides 
Table 10: List of used oligonucleotides.  
Name Sequence 5’ 3’a 
CA-Prot-Ova(-) GCACTATAGGGTAATTTTGGCTGACGCCCCCAGGGGAAACACATCTGCCAAA
GAAGAG 
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HIVgag-BaeI(-) 
 
GCTGAAAACATGGGTATCACTTCTGG 
HIVgag-ClaI(+) CGGGGGAGAATTAGATCGATGGG 
MA-Prot(-) ATTCTGGACGATGGGGTAGTTCTGGGACACCTGATTGCTGTGTCCTGTGTCAG
CTGC 
MA-Prot-GFP(+) CAGGACACAGCAATCAGGTGTCCCAGAACTACCCCATCGTCCAGAATGGCGG
GATGGTGAGCAAGGGCGAGG 
MA-Prot-Ova(+) CAGGACACAGCAATCAGGTGTCCCAGAACTACCCCATCGTCCAGAATGGCGG
GATGGGCTCCATCGGCGCAG 
Prot-CA(+) GGGGGCGTCAGCCAAAATTACCCTATAGTGC 
a
 Nucleotides encoding the HIV-1 protease motif (amino-acid sequence VSQNY↓PIVQN) are underlined. 
 
2.1.9. Kits 
Table 11: List of used kits. 
Name Source of supply 
BD OptEIA™ Set Mouse IL-2 BD Biosciences 
BD OptEIA™ Set Mouse IFN-γ BD Biosciences 
Chicken Egg Ovalbumin ELISA Kit Alpha Diagnostic International 
CD4 MicroBeads, human Miltenyi Biotec 
CD4
+
 T Cell Isolation Kit II, mouse Miltenyi Biotec 
CD8a
+
 T Cell Isolation Kit, mouse Miltenyi Biotec 
EndoFree
®
 Plasmid Maxi Kit Qiagen 
Expand High Fidelity
PLUS
 PCR System  Roche 
Geneclean 
® 
Turbo Kit MP Biomedicals 
HIV-1 p24 Antigen ELISA Gentaur 
Jetstar 2.0 Endotoxin-free Plasmid Giga Kit Genomed 
Mouse IFN gamma ELISPOT Ready-Set-Go!
®
 eBioscience 
Pan T Cell Isolation Kit II, mouse Miltenyi Biotec 
QIAprep 
®
 Spin Miniprep Kit  Qiagen 
QIAquick 
®
 PCR Purification Kit  Qiagen 
Rapid DNA Ligation Kit  Roche 
Topo
®
 TA Cloning
®
 Kit Invitrogen, Life technologies 
 
2.1.10. Cell lines and bacteria 
Table 12: List of used cell lines. 
Name Characterisation Medium Split ratio Origin 
B95a 
Marmoset lymphoblastoid cell 
line transformed with Epstein-
Barr-Virus 
DMEM 1:7 (Kobune et al., 1990) 
CHO-CD46 
Chinese hamster ovary cell 
line genetically engineered to 
express human CD46 
DMEM + 
1.2 mg/ml G418 
1:20 
(Nakamura et al., 
2004) 
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Name Characterisation Medium Split ratio Origin 
CHO-hSLAM 
Chinese hamster ovary cell 
line genetically engineered to 
express human SLAM  
RPMI +  
0.5 mg/ml G418 
1:20 
Y. Yanagi, Kyushu 
University (Tatsuo et 
al., 2000) 
CHO-hSLAM-blue 
Chinese hamster ovary cell 
line genetically engineered to 
express human SLAM with 
integrated expression cassette 
for floxed cerulean 
RPMI +  
0.5 mg/ml G418 
1:20 
S. Kugelmann, Paul-
Ehrlich-Institut 
(Kugelmann, 2013) 
CHO-K1 
Chinese hamster ovary cell 
line 
DMEM 1:20 ATCC, CCL-61 
CHO-K1-blue 
Chinese hamster ovary cell 
line with integrated expression 
cassette for floxed cerulean 
DMEM 1:20 
S. Kugelmann, Paul-
Ehrlich-Institut 
(Kugelmann, 2013) 
CHO-Nectin-1 
Chinese hamster ovary cell 
line genetically engineered to 
express human Nectin-1 
DMEM + 
0.5 mg/ml G418 
1:12 
M. Lopez, INSERM 
(Reymond et al., 
2004) 
CHO-Nectin-2 
Chinese hamster ovary cell 
line genetically engineered to 
express human Nectin-2 
DMEM + 
0.5 mg/ml G418 
1:12 
M. Lopez, INSERM 
(Reymond et al., 
2004) 
CHO-Nectin-4 
Chinese hamster ovary cell 
line genetically engineered to 
express human Nectin-4 
DMEM + 
0.5 mg/ml G418 
1:12 
M. Lopez, INSERM 
(Fabre-Lafay et al., 
2005) 
CHO-PVR 
Chinese hamster ovary cell 
line genetically engineered to 
express human PVR 
DMEM + 
0.5 mg/ml G418 
1:12 
M. Lopez, INSERM 
(Reymond et al., 
2004) 
H23 Human lung cell line RPMI 1:3 ATCC, CRL-5800 
H358 Human lung cell line RPMI 1:3 ATCC, CRL-5807 
H441 Human lung cell line RPMI 1:3 ATCC, HTB-174 
H522 Human lung cell line RPMI 1:3 ATCC, CRL-5810 
HEK-293T 
Human embryonic kidney cell 
line genetically engineered to 
express the large T antigen  
DMEM 1:12 ATCC, CRL-11268 
HT1080 Human fibrosarcoma cell line DMEM 1:12 ATCC, CCL-121 
HT1080-Cre 
Human fibrosarcoma cell line 
with integrated loxP gene 
cassette (loxP-RFP-loxP-
eGFP) 
DMEM 1:12 (Galla et al., 2004) 
HT-1376 Human bladder cell line EMEM 1:3 ATCC, CRL-1472 
JAWSII 
Murine, immature dendritic 
cell line from C57BL/6 mice 
MEM-α 
1:10 
(weekly) 
ATCC, CRL-11904 
JAWSII-Ova 
Murine, immature dendritic 
cell line from C57BL/6 mice, 
genetically engineered to 
express Ovalbumin 
MEM-α 
1:10 
(weekly) 
B. Bodmer, Paul-
Ehrlich-Institut 
(Bodmer, 2015) 
Molt4.8 
Human T cell leukemia cell 
line 
RPMI 1:10 
I. Schneider, Paul-
Ehrlich-Institut 
Raji 
Human Burkitt’s lymphoma 
cell line 
RPMI 1:20 ATCC, CCL-86 
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Name Characterisation Medium Split ratio Origin 
Raji-blue 
Human Burkitt’s lymphoma 
cell line with integrated 
expression cassette for floxed 
cerulean 
RPMI 1:20 
S. Kugelmann, Paul-
Ehrlich-Institut 
(Kugelmann, 2013) 
SCaBER Human bladder cell line 
EMEM + 1.5 g/l 
NaHCO3 + 
0.1 mM NEA + 
1 mM sodium 
pyruvate 
1:3 ATCC, HTB-3 
T24 Human bladder cell line McCoy’s 5A  1:3 ATCC, HTB-4 
Vero-hSLAM 
African green monkey kidney 
cell line genetically 
engineered to express human 
SLAM 
DMEM + 
0.5 mg/ml G418 
1:10 
Y. Yanagi, Kyushu 
University (Ono et 
al., 2001a) 
 
Table 13: List of used bacterial strains. 
Strain Genotype Origin 
E. coli GM2163 
F
-
, ara-14, leuB6, fhuA31, lacY1, tsx78, supE44, galK2, 
galT22, hisG4, rpsL136(Str
R
), xylA5, mtl-1, thi-1, 
dam13::Tn9(Cam
R
), dcm-6, hsdR2, mcrA, mcrB1, rfbD1) 
New England 
Biolabs 
E. coli Top10 
F
-
, mcrA, Δ(mrr-hsdRMSmcrBC), Φ80lacZΔM15, lac224, 
deoR, recA1, araD139, Δ(ara-leu)7697, galU, galK, rpsL 
(Str
R
), endA1, nupG 
Invitrogen, Life 
Technologies 
 
2.1.11. Mice 
Table 14: List of mouse strains used in this thesis.  
Strain Characterization
a
 Origin 
C57BL/6 Widely used inbred strain (Murray and Little, 1935)  
IFNAR
-/-
 N20 C57BL/6 Interferon Type I Receptor knockout (Gerlach et al., 2006) 
IFNAR
-/-
 SLAM
ki
 
C57BL/6 
Interferon Type I Receptor knockout and SLAM 
knock in (replacement of V domain of mouse 
SLAM by that of human SLAM) 
(Ohno et al., 2007) 
NOD-scid IL2Rγ-/-  
Immunodeficient, lack of B cells, T cells and NK 
cells 
(Shultz et al., 2005) 
OT-I C57BL/6 
MHC I-restricted, ovalbumin257-264 -specific CD8
+
 
T cells 
(Hogquist et al., 1994) 
OT-II C57BL/6 
MHC II-restricted, ovalbumin323-339-specific CD4
+
 
T cells 
(Barnden et al., 1998) 
a
 All animals were bred in-house. 
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2.2. Methods 
2.2.1. Methods of molecular biology  
2.2.1.1. Transformation of plasmids in competent E. coli 
An aliquot of chemically competent E. coli Top 10 (highly transformable E. coli strain) or E. coli 
GM2163 (E. coli strain lacking dam methylation) was thawed on ice and 1 µl of DNA (re-
transformation) or 2 µl of newly ligated plasmid was added. After 20 minutes incubation on ice, 
bacteria were heat-shocked for 30 seconds at 42°C. Then, E. coli were placed on ice for further 
2 minutes before addition of 250 µl S.O.C. medium without any antibiotics. The bacteria were 
subsequently shaken at 650 rpm at 25°C or 37°C for 1 hour to allow the expression of plasmid-
encoded resistance genes. Finally, 10 µl – 100 µl of the suspension were plated on LB-agar plates with 
a selection antibiotic, here ampicillin (50 µg/ml), and incubated at 25°C for 48 to 72 hours or 37°C 
overnight until single colonies could be detected. In general, the incubation temperature depended on 
the size and kind of plasmid: for large plasmids, low-copy-number plasmids, and for lentiviral transfer 
vectors containing LTRs 25°C was recommended, in the last case to avoid unwanted recombination of 
the LTRs. Bacteria containing other plasmids could be grown at 37°C.  
2.2.1.2. Amplification and preparation of plasmids 
To amplify plasmid-DNA, single colonies of the previously transformed and plated bacteria were 
picked and inoculated into 5 ml LB medium containing 50 µg/ml ampicillin (“Mini-prep” scale). 
Bacterial cultures were shaken at 25°C for 72 hours or 37°C overnight (see 2.2.1.1) at 180 rpm. Then, 
500 µl retained sample were taken off and stored in the fridge. The remaining culture was pelleted at 
3000 rpm for 10 min. The isolation of “Mini-prep” plasmid-DNA was performed using the QIAprep® 
Spin Miniprep kit following the manufacturer’s instructions. The DNA was subsequently subjected to 
a restriction digest (see 2.2.1.4) and electrophoretically separated on an agarose gel (see 2.2.1.7). 
Two positive clones were selected and the respective retained samples were inoculated into 200 ml 
LB-ampicillin medium for a “Maxi-prep”. Again, bacteria were grown at 25°C for 72 hours or at 37°C 
overnight at 180 rpm. For DNA-preparation, bacteria were pelleted for 15 min at 6000 rpm and 4°C 
and processed using the EndoFree
®
 Plasmid Maxi Kit (Qiagen) according to the protocol. However, 
the neutralized cell lysate was not directly added to the “QIAfilter Cartridge” but centrifuged for 
10 min at 3000 rpm to clear it from cell debris with less fluid loss maximizing DNA-yield. DNA was 
eluted from the column with an appropriate volume of elution buffer (50 µl – 200 µl, depending on the 
DNA pellet size and thus the expected amount of DNA). For Giga-prep scale plasmid isolation, a 
single colony was picked from a LB-ampicillin plate and inoculated into 5 ml LB-ampicillin medium. 
6-8 hours later, this starter culture was used to inoculate the 2.4 l main culture, which was grown as 
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aforementioned. To pre-analyze the DNA, 5 ml of the main culture were removed for a “Mini-prep” 
with subsequent restriction digest and agarose gel-electrophoresis. If the result was satisfying, plasmid 
isolation from the main culture was conducted with the Jetstar 2.0 Endotoxin-free Plasmid Giga Kit as 
described in the manual. Giga-DNA was resuspended in TE-buffer. After DNA isolation, the amount 
of DNA was quantified (see 2.2.1.3) and DNA was aliquoted and stored at -20°C. 
2.2.1.3. Quantification of DNA 
DNA was quantified measuring the absorbance at 260 nm (A260) by means of the UV-VIS 
spectrophotometer NanoDrop 2000c. The absorbance at 260 nm is caused by the π-electrons of the 
purine and pyrimidine rings of nucleotides and thus correlates with the DNA or RNA content of a 
given solution. Thereby, an A260 of one equals 50 µg/ml double-stranded DNA or 40 µg/ml RNA. For 
qualitative statements, also A280 was determined as aromatic amino acids have an absorbance 
maximum at 280 nm. Therefore, the ratio of the absorbance at 260 nm and 280 nm (A260/280) is an 
indicator for the purity of the sample and should optimally be 1.8 (pure DNA). A260/280 < 1.8 
corresponds to a protein contamination whereas A260/280 > 1.8 points at the presence of RNA.  
2.2.1.4. Restriction of plasmid DNA 
To confirm the identity of a certain plasmid or to isolate a desired subfragment, plasmid DNA was 
subjected to a restriction digest. Thereby, the DNA was cut by restriction enzymes in characteristic 
fragments, which were then electrophoretically separated (2.2.1.7) and extracted from the gel (2.2.1.8), 
if applicable. A restriction reaction composed the chemicals listed in Table 15. If a double digest was 
performed, the buffer ensuring the maximal activity for both enzymes was chosen. The applied 
volume of enzymes did never exceed 10% of the total reaction volume. For analytic purposes, the 
mixture was incubated for 1 hour at the temperature recommended by the manufacturer. Using time 
saver endonucleases, digestion time could be reduced to 30 minutes. Preparative digests took place at 
the temperature optimum of the restriction endonuclease(s) for at least 3 hours or overnight. For partial 
digests, 20 µg DNA were digested in a total volume of 100 µl. 1 min, 2 min, 5 min and 10 min after 
starting the digest, 25 µl were removed and the reaction was instantly stopped on ice with ice-cold 6x 
loading buffer.  
 
Table 15: Composition of analytic, preparative or partial digestion reactions. 
Chemical Analytic digest Preparative digest Partial digest 
DNA 1 µg or 5 µl Miniprep DNA 5 µg  20 µg  
10x buffer 2 µl 5 µl 10 µl 
10x BSA (if required)  2 µl 5 µl 10 µl 
Enzyme(s) 0.5 µl - 1 µl each  up to 5 µl 0.5 µl 
H2O ad 20 µl ad 50 µl ad 100 µl 
Material and Methods 
36 
 
2.2.1.5. Polymerase chain reaction (PCR) 
The polymerase chain reaction, short PCR, allows the amplification (and modification) of specific 
DNA sequences defined by the used primers. In the present thesis the Expand High Fidelity
PLUS
 PCR 
System by Roche was applied according to the manufacturer’s instructions. The composition of the 
reaction mix is given in Table 16, the used primers are listed in Table 10.  
 
Table 16: Composition of a PCR. 
Chemical Amount 
Template DNA 50 ng 
Forward primer (10 pM) 2 µl 
Reverse primer (10 pM) 2 µl 
Reaction buffer (5x) 10 µl 
dNTP-Mix (10 mM each) 1 µl 
Polymerase (5 U/ µl) 0.5 µl 
H2O ad 50 µl 
 
The thermal cycling is depicted in Table 17. A typical PCR cycle started with a denaturation step at 
94°C to separate the double stranded DNA. Then, a temperature reduction followed to allow the 
hybridization of primers and complementary single stranded DNA. The temperature was chosen 
depending on the melting temperature of the respective primers specified by the producer company 
Eurofins MWG Operon. During the last step, the elongation phase performed at 72°C, the 
thermostable blend of Taq DNA Polymerase amplified the DNA sequence flanked by forward and 
reverse primer using the provided dNTPs. The described cycle was repeated up to 20 times to amplify 
the desired DNA sequence exponentially.  
 
Table 17: Thermal cycles used for PCR. 
Step Temperature [°C] Time Cycles 
Initial denaturation 94 2 min 1x 
Denaturation 94 30 sec  
Annealing 52 - 68 (depending on Tm primers) 30 sec 20x 
Elongation 72 1 min/kb  
Final elongation 72 7 min 1x 
Cooling 4 ∞  
 
2.2.1.6. Dephosphorylation and ligation of DNA 
Dephosphorylation of DNA 
Plasmids harboring two compatible ends, e.g. after linearization with one enzyme or digest with blunt 
end cutters, tend to religate. To prevent this event, these backbones were dephosphorylated at their 
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5’ends using Antarctic phosphatase. For that purpose, 10x reaction buffer (1/10 of the total reaction 
volume) and 1 µl Antarctic phosphatase were added to the DNA and incubated for 15 min at 37°C 
before heat inactivation of the enzyme at 65°C (5 min) was performed. Afterwards, the 
dephosphorylated DNA was directly purified with the QIAquick
®
 PCR Purification Kit according to 
the provided protocol. 
 
Ligation of DNA with T4 DNA ligase 
To ligate previously digested DNA, the Rapid DNA Ligation Kit by Roche was employed as 
instructed by the manufacturer. The insert was added in a molar ratio of 3:1 to the backbone. Ligation 
was performed for 5 - 20 min at room temperature or, in more difficult cases, at 16°C overnight. To 
assess if religation of backbone occurred, a ligation reaction containing only the backbone but no 
insert was prepared in parallel. Finally, 2 µl of the ligation reaction or the religation control were used 
to transform chemically competent E. coli (2.2.1.1).  
 
TOPO-TA-Ligation 
PCR products which were previously amplified by Taq polymerase (2.2.1.5) can be directly inserted 
into the linearized plasmid backbone pCR2.1-TOPO provided in the TOPO
®
 TA Cloning
®
 Kit 
(Invitrogen, Life technologies) in a Topoisomerase I-dependent reaction. The reaction was conducted 
as instructed by the manufacturer using 4 µl gel-purified PCR product (2.2.1.7. and 2.2.1.8). 2 µl of 
the ligation were transformed into chemically competent E. coli (2.2.1.1). Successful transformation 
could be visualized by blue-white screening on LB-ampicillin-X-gal agar plates as pCR2.1-TOPO 
harbors a lacZ-operon, which is disrupted by inserted PCR products. The insertion site of the PCR 
product in pCR2.1-TOPO is flanked by a multiple cloning site and complementary sequences for 
standard primers like T7 or M13, facilitating sequencing of the PCR product.  
2.2.1.7. Agarose gel electrophoresis 
To separate DNA fragments according to their size, agarose gel electrophoresis was performed. 
Thereby, the agarose matrix functions as a sieve for the negatively charged DNA, which migrates 
through the gel when an electric current is applied. This migration is dependent on the size of the 
fragments: larger nucleic acids move more slowly than shorter ones resulting in a separation. 
Additionally, the migration of the fragments is affected by the agarose content which influences the 
density of the matrix. For the separation of large DNA pieces high percentage agarose gels were used 
whereas low percentage gels have a better resolution for small DNA fragments.  
To generate an agarose gel, an appropriate amount of agarose powder was solved in TAE buffer 
resulting in a 0.7% - 1.5% (w/v) solution. This agarose-TAE-solution was heated up in a microwave 
until the agarose was completely dissolved and then slightly cooled down before ethidium bromide 
solution was added to a final concentration of 50 µg/ml. The melted agarose was then poured into a 
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casting tray and a comb was inserted to create wells for sample-loading. After approximately 
20 minutes, when the gel was completely polymerized, it was transferred to an electrophoresis 
chamber filled with TAE buffer. Then, the samples were premixed with 6x DNA-loading buffer and 
subsequently loaded onto the agarose gel. Additionally, 10 µl 2-log-DNA ladder were pipetted into 
one well as a marker. For analytic gels, electrophoretic separation took place at 120 V for 
approximately 60 minutes. The DNA was afterwards visualized by fluorescence of DNA-intercalating 
ethidium bromide excited by UV light at the gel documentation station. For preparative purposes, only 
80 V were applied for several hours. DNA was isolated from the gel as described below (see 2.2.1.8). 
2.2.1.8. Isolation of DNA from agarose gels 
Ethidium bromide stained DNA was visualized under UV-light at the gel documentation station. 
Agarose, containing the desired DNA-fragment, was cut out of the gel by a scalpel. The piece of 
agarose was then transferred to a 1.5 ml reaction tube and DNA was subsequently isolated with the 
Geneclean
®
 Turbo Kit following the manufacturer’s instructions.  
2.2.1.9. Sequencing of DNA 
DNA sequencing was performed at Eurofins MWG Operon. For this purpose, 15 µl plasmid DNA 
with a concentration of 50-100 ng/µl was sent to the company. Suitable primers could be chosen from 
a catalog of available standard primers as done so for pCR2.1-TOPO plasmids sequenced with T7 
forward and M13 reverse primer. If no applicable primer was present at Eurofins MWG Operon, 15 µl 
primer with a concentration of 10 pmol/µl were posted. The obtained sequences were analyzed with 
the ContigExpress software and compared to an in silico reference sequence. 
 
2.2.2. Methods of protein biochemistry  
2.2.2.1. Preparation of cell lysates 
Cell lysates from transfected cells were prepared approximately 48 hours post transfection, as gene 
expression is at its maximum at that point of time. In contrast to that, cells were lysed 4 hours after 
transduction with Ova-PTV at MOI 1 to assess ovalbumin protein transfer. In order to inhibit protease 
activity when preparing cell lysates, all following described procedures took place on ice using ice-
cold buffers which were, in case of the lysis buffer, additionally supplemented with protease inhibitors. 
At the beginning, the culture medium was taken off and cells were briefly washed with PBS before 
being incubated with cold PBS for 5 min on ice. Then, ice-cold lysis buffer was added, e.g. 500 µl per 
cavity of a 6-well plate. After 10 min incubation a suspension was generated by pipetting up and down 
thoroughly. This suspension was subsequently transferred to a 1.5 ml reaction tube. To remove cell 
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debris, lysates were centrifuged at 13,000 rpm for 15 min at 4°C (Heraeus Pico 17 Centrifuge). The 
supernatants were transferred to a new reaction tube and either directly used or stored at -80°C.  
2.2.2.2. SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
The sodium dodecyl sulfate-polyacrylamide gel electrophoresis, short SDS-PAGE, is a technique to 
separate proteins in an electric field according to their molecular weight. The method was performed 
according to Laemmli, 1970. The anionic tenside SDS masks the intrinsic charge of the proteins and, 
together with the denaturation caused by boiling, leads to their linearization. Therefore, the evenly 
negatively charged polypeptide chains migrate to the anode independent of their original charge and 
conformation. As larger proteins are stronger retained within the gel than shorter ones, separation 
depending on the chain length is achieved which is proportional to the molecular mass of the protein.  
Previously prepared cell lysates (2.2.2.1) or vector particles (2.2.4.3) were mixed with 2x Urea Sample 
Buffer and denatured for 10 min at 95°C. For vector particles, 1 µl concentrated vector stock 
(undiluted or up to 1:10 pre-diluted) was added to 14 µl RIPA buffer before subjoining 15 µl 2x Urea 
Sample Buffer. Subsequently, samples and 10 μl Precision Plus ProteinTM KaleidoscopeTM Standard 
(Bio-Rad) were loaded on polyacrylamide gels in a gel-electrophoresis chamber filled with SDS 
running buffer. The 1.0 mm or 1.5 mm thick 10% SDS polyacrylamide gels were produced beforehand 
as specified in Table 18. If not all wells were loaded with sample, remaining slots were filled up with 
equal volumes of 1:1 mixed RIPA/2x Urea Buffer. Initially, electrophoresis was conducted at 80 V. As 
soon as the samples entered the resolving gel, 120 V were applied by means of the Bio-Rad Power Pac 
200. After the dye front had left the resolving gel, electrophoresis was terminated.  
 
Table 18: Composition of resolving and stacking gel. 
Chemical Resolving gel (10%) Stacking gel (5%) 
30% acrylamide solution (Rotiphorese
®
 Gel 30) 3.33 ml 825 µl 
1M Tris pH 6.8 - 625 µl 
1M Tris pH 8.8 3.9 ml - 
10% SDS  110 µl 25 µl 
50% glycerin  820 µl - 
TEMED 13 µl 10 µl 
20% APS  26 µl 20 µl 
H2O 1.84 ml 3.5 ml 
 
2.2.2.3. Western blot analysis and immunostaining 
Proteins separated by SDS-PAGE (2.2.2.2) can be transferred to a membrane (Western Blot) for 
antibody-based detection (immunostaining). Here, proteins were immobilized on a PVDF membrane 
using the Trans-Blot
®
 SD Semi-Dry Transfer Cell by Bio-Rad. For that purpose, the membrane was 
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briefly activated in methanol, rinsed in transfer buffer and then placed underneath the polyacrylamide 
gel between two layers of thick filter paper soaked with transfer buffer. Blotting was performed at 
180 mA per gel for 45 min and 25 V maximum. The successful transfer of proteins to the membrane 
was visualized by the colored protein marker. After blotting, unspecific protein binding sites on the 
membrane were blocked with 5% milk powder or 5% horse serum in TBS-T for 1 hour at room 
temperature. Then, the membrane was transferred in a 50 ml tube with 5 ml primary antibody in 
blocking buffer, recognizing the protein to be detected. The antibody incubation took place overnight 
at 4°C on a roller mixer. The next day, the membrane was washed three times for 10 min each in 
TBS-T at room temperature. 10 ml HRP (horseradish peroxidase)-conjugated secondary antibody in 
blocking buffer were subsequently added and incubated with the membrane for 1 hour at room 
temperature. All primary and secondary antibodies used in this thesis are listed in Table 7. The 
membrane was washed again three times for 10 min in TBS-T buffer at room temperature. Afterwards, 
Western Blotting Substrate (Pierce
®
 ECL 2 or Amersham™ ECL™ Prime) was prepared according to 
the manufacturer’s instructions and pipetted onto the membrane. While the horseradish peroxidase 
converted its substrate into a product, light was emitted which exposed a chemiluminescence detection 
film (Amersham Hyperfilm™) by GE Healthcare. Exposure times varied from 1 sec to 1 hour 
depending on the signal intensity. After development of the film, the molecular weight of the detected 
proteins could be determined in relation to the protein marker. To reprobe the membrane for other 
proteins, the bound antibody was removed with Restore™ PLUS Western Blot Stripping Buffer by 
Thermo Scientific for 20 min at room temperature. Subsequently, the membrane was washed three 
times for 10 min in TBS-T at room temperature and then blocked as described above before starting a 
new detection circle.  
2.2.2.4. Enzyme-linked immunosorbent assay (ELISA) 
The enzyme-linked immunosorbent assay, short ELISA, is an antibody-based immunological method 
to detect and quantify antigens or antibodies in a given sample. Thereby, antigens are captured by a 
specific antibody bound to the ELISA plate whereas antibodies can be enriched by antigen-coated 
well-plates. The immobilized proteins are then recognized by an enzyme-coupled (secondary) 
antibody. The addition of the substrate and the following enzymatic reaction finally lead to a 
measurable signal and visualize the presence of the protein of interest. The amount of the protein can 
be quantified in relation to a standard with known protein concentrations. In the present thesis, ELISA 
was used to characterize vector particles for the amount of HIV-1 p24 and chicken ovalbumin. 
Moreover, the activation of T cells co-cultured with transduced mDCs was analyzed by determining 
the levels of IL-2 and IFN-γ secreted in the culture supernatant.  
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Anti HIV-1 p24 ELISA 
HIV-1 p24 was quantified by the Gentauer HIV-1 p24 Antigen ELISA Kit following the provided 
protocol. The vectors were diluted in 1:5 steps from 1:50 to a 1: 97,656,250 dilution.  
 
Anti Ova-ELISA 
To determine the Ova content of Ova-PTV preparations, the Ova-concentration of PTV particles was 
estimated by a semi-quantitative Western Blot analysis prior performing the Chicken Egg Ovalbumin 
ELISA with the kit by Alpha Diagnostic International. Based on that estimation, all samples were pre-
diluted to an assumed final concentration of 0.5 ng/ml and 1.5 ng/ml as these values lie well within the 
measurement range of the assay. In a first step, 5 ng/ml or 15 ng/ml vector particles in PBS w/o 
Ca
2+
/Mg
2+
 were lysed with a final concentration of 0.5% Triton
®
 X-100 for 15 min at room 
temperature to ensure the accessibility of Ova in PTVs. Then, the particles were further 1:10 diluted in 
sample diluent to reduce the amount of Triton
®
 X-100 in the assay. Triton
®
 X-100 was also added to 
standards, positive control and blanks resulting in the same end concentration of the detergent. All 
measurements were performed in duplicates.  
 
Anti mouse IL-2 and IFN-γ ELISA 
Murine IL-2 and IFN-γ were quantified using the respective BD OptEIA™ Sets according to the 
manufacturer’s instructions. To measure the IL-2 concentration the supernatants were 1:8 prediluted, 
to determine the IFN-γ concentration supernatants were diluted in a 1:20 ratio.  
 
2.2.3. Cell culture methods 
2.2.3.1. Cultivation of cells 
Cells were cultivated in the appropriate medium (see Table 12) in an incubator (BBD 6220, Heraeus) 
at 37°C with 6% CO2 and 96% humidity. All media were supplemented with 10% decomplemented 
fetal calf serum (decomplementation for 30 min at 56°C) and 2 mM L-glutamine but did not contain 
penicillin/streptomycin to prevent masking of contaminations. The cells were regularly checked under 
the microscope for morphology and density as well as the absence of contaminations. When reaching a 
confluence of about 90%, cells were splitted twice a week in the indicated ratios (see Table 12) under 
sterile conditions. Therefore, adherent cells were washed with 10 ml PBS w/o Ca
2+
/Mg
2+
 and 
incubated with 2 ml trypsin/EDTA (T75 flask) or 5 ml trypsin/EDTA (T175 flask) until cells were 
detached. Then, new culture medium was added and the desired part of the suspension remained in the 
flask whereas the other portion was discarded. For T75 flasks, medium was filled up to 12.5 ml, for 
T175 flasks to 20 ml. Suspension cells were cultivated in 20 ml medium in upright standing T75 flasks. 
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All cells were passaged less than 30 times or three months after thawing. After that period of time, 
cells were replaced by newly thawed ones. 
Primary cells were cultured as described above with the respective media (Table 5) supplemented with 
penicillin/streptomycin and cytokines, if applicable. To enable long-term cultivation, T cells needed to 
be activated (see 2.2.3.4) and new TCM blended with 100 IU/ml IL-2 had to be added every three 
days. Human macrophage cultures were maintained with medium exchange every three days. 
However, these cells did not require regular splitting but could survive without singularization for at 
least 14 days without any problems.  
2.2.3.2. Freezing and thawing of cultured cells 
For freezing, cells were expanded to four T175 flasks and cultured until they reached a confluency of 
60% - 80%. At this point of time, cells are in a logarithmic growth phase and best suited for freezing. 
First, 250 µl culture medium was sampled from each T175, pooled and spun down for 1 min at 
2000 rpm (Heraeus Pico 17 Centrifuge). The supernatant was stored at -80°C until used for 
mycoplasma testing. Then, the remaining culture medium was taken off, the cells were washed with 
10 ml PBS w/o Ca
2+
/Mg
2+
 and were detached by addition of 5 ml trypsin/EDTA per flask. Trypsin was 
inactivated by subjoining of 7 ml fresh culture medium per T175 and the resulting suspension from all 
four flasks was combined. The cells were pelleted for 5 min at 1200 rpm, 4°C (Heraeus Multifuge 
3SR
+
) and solved in 20 ml cold freezing medium (Table 5). The suspension was subsequently 
aliquoted at 1 ml into pre-cooled cryo-tubes. The aliquots were placed into a 4°C cold isopropanol-
filled freezing container in a -80°C freezer. The employed freezing container guaranteed a defined 
cooling rate of 1°C per minute until reaching -80°C. After 24 hours the cryo-tubes were transferred 
from the freezing container to a liquid nitrogen tank where they were stored in the gas phase. To assess 
if the frozen cells can be successfully thawed and cultured again, one aliquot of the frozen cells was 
initially subjected to a test thawing.  
For thawing of cells, one cryo-tube of the desired cell line was taken out of the liquid nitrogen tank 
and thawed at room temperature until only a fraction of the cell-suspension remained frozen. Then, the 
cells were put into 25 ml pre-warmed, fresh culture medium without antibiotics. The suspension was 
centrifuged for 5 min at 1200 rpm, 4°C (Heraeus Multifuge 3SR
+
) and the DMSO-containing 
supernatant was discarded. The cell pellet was subsequently solved in 13 ml (adherent cells) or 20 ml 
(suspension cells) pre-warmed, fresh culture medium without antibiotics and transferred to a T75 cell 
culture flask. After cultivating the cells for 24 hours at 37°C, the medium was exchanged to remove 
residual DMSO and cell debris. The medium used now was normal culture medium also containing 
selection antibiotics, if necessary.  
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2.2.3.3. Transfection of adherent cells 
Plasmid DNA was introduced into adherent cells by Lipofectamine
®
 2000 or polyethylenimine. 
Lipofectamine
®
 2000 was used for transfection of up to 1 x 10
6
 cells in a 6-well format whereas the 
low-cost polyethylenimine-transfection was conducted for higher numbers of HEK-293T cells. 
Maximum gene expression was reached 48 – 72 hours after transfection. 
 
Transfection of cells using Lipofectamine 2000 
One day prior transfection, 7 x 10
5
 HEK-293T cells were seeded per cavity of a 6-well plate. The next 
day, when the cells were about 75% - 90% confluent, 5 µg plasmid DNA were diluted in 250 µl cold 
Opti-MEM
®
. In another reaction tube 10 µl Lipofectamine
®
 2000 were mixed with 250 µl cold Opti-
MEM
® 
and subsequently incubated for 5 min at room temperature. Then, the Lipofectamine
®
 2000 
solution was transferred to the DNA mix. After thorough vortexing, the mixture was incubated for 
another 20 min at room temperature to allow the formation of DNA-Lipofectamine
®
 2000 complexes. 
In the meantime, the culture medium of the cells was replaced by 1.5 ml pre-warmed Opti-MEM
®
. 
Finally, the transfection mix was gently dripped onto the cells. Medium exchange to 2 ml normal 
growth medium was performed after 4 hours incubation at 37°C. Transfection efficiency was assessed 
by transfecting a separate HEK-293T well with an expression plasmid encoding a fluorescing protein, 
e.g. pSEW-TurboFP635.  
 
Transfection of cells using polyethylenimine 
For large-scale vector productions in T175 flasks, HEK-293T cells were transfected with 
polyethylenimine (PEI, 18 mM stock). One day before transduction, 1.85 x 10
7
 cells were seeded per 
T175 flask. The flasks were placed carefully balanced into the incubator to ensure even distribution of 
the cells. The following day, the confluency of the cells was checked under the microscope. For 
transfection it should optimally be between 75% and 90%. In a first step, the culture medium of the 
cells was exchanged to 10 ml DMEM with 15% FCS and 2 mM L-glutamine. Then, 35 µg DNA were 
united with 2.3 ml DMEM (with 2 mM L-glutamine, w/o FCS). In another reaction tube, 140 µl PEI 
reagent (18 mM) were diluted in 2.2 ml DMEM (with 2 mM L-glutamine, w/o FCS) and both tubes 
were mixed thoroughly. The PEI-DMEM solution was then transferred to the DNA-mix and 
rigorously vortexed. The transfection mixture was incubated for 20 min at room temperature and 
subsequently added to the prepared cells resulting now in 10% FCS-containing medium. The next day, 
the medium was replaced by 16 ml new culture medium. Successful transfection was visualized by 
fluorescence of cells transfected with the transfer vector plasmid, which was usually encoding a 
fluorescing protein.  
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2.2.3.4. Isolation and activation of human peripheral blood mononuclear cells (PBMC) 
Human peripheral blood mononuclear cells (PBMC) were isolated from buffy coats obtained from the 
German Red Cross Blood Donor Service Frankfurt or fresh in-house donor blood by density 
centrifugation with Histopaque-1077
®
. First of all, the blood was mixed with the same volume of room 
temperature PBS w/o Ca
2+
/Mg
2+
. Subsequently, 15 ml cold Histopaque-1077
®
 were carefully overlain 
with 25 ml diluted blood in a 50 ml tube and centrifuged at 1800 rpm for 30 min at room temperature 
without break (Heraeus Multifuge 3SR
+
). The blood was separated into a top layer of plasma, the 
PBMC-containing “lymphocyte ring” (lymphocytes, monocytes, and macrophages) and pelleted 
erythrocytes and polymorphonuclear cells (granulocytes). The PBMC-fraction was aspirated 
cautiously and collected in a new 50 ml tube. The cells were washed twice with 45 ml room 
temperature PBS w/o Ca
2+
/Mg
2+
 per 5 ml PBMC and pelleted in the course thereof for 10 min at 
1500 rpm and then at 1200 rpm. All cells were subsequently combined and blended with PBS 
w/o Ca
2+
/Mg
2+
 once again. After centrifugation at 1200 rpm for 10 min (Heraeus Multifuge 3SR
+
), the 
pellet was resuspended in 10 ml 0.86% ammonium chloride buffer and incubated 20 min at 37°C to 
lyse remained erythrocytes. Following, PBMC were washed twice as previously described. The cells 
were counted and either directly used for further experiments or activated.  
Activation of PBMC was accomplished by addition of anti-CD3 and anti-CD28 antibodies, and IL-2. 
In a first step, cell culture plates were coated with the aforementioned antibodies. Thereby, 1 ml 
pre-warmed PBS w/o Ca
2+
/Mg
2+
 with 3 µg/µl of each antibody (6-well) or 500 µl PBS w/o Ca
2+
/Mg
2+
 
containing 1 µg/µl anti-CD3 and anti-CD28 antibody (24-well, 48-well) were added to a tissue 
culture-treated well-plate. The plate coated at 37°C for 2 hours or at 4°C overnight. Afterwards, the 
PBS-antibody solution was replaced by 2% BSA in water and the plate was incubated for at least 30 
min at 37°C. Then, the wells were washed twice with 3 ml PBS w/o Ca
2+
/Mg
2+
 (6-well) or 1 ml PBS 
w/o Ca
2+
/Mg
2+
 (24-well, 48-well) before the cells were added. Up to 1 x 10
7
 cells in 3 ml T cell culture 
medium (TCM) could be stimulated in a 6-well. A 24-well was suited for the activation of up to 
1 x 10
6
 PBMC in 1 ml TCM and a 48-well for 5 x 10
5
 PBMC in 1 ml TCM. The medium was 
supplemented with 100 IU/ml IL-2. The cells were cultivated in the antibody-coated stimulation plates 
for 3 days before being used for experiments.  
2.2.3.5. Magnetic cell sorting (MACS) 
Pan T cells, CD4
+
 or CD8
+
 cells were isolated from murine splenocytes (extracted from mouse spleen 
as described in 2.2.5.7) or human PBMC (2.2.3.4) using MACS cell separation kits from Miltenyi 
Biotech (see Table 11) according to the manufacturer’s instructions. This method allows the separation 
of cell populations depending on the expression of surface molecules. Antibodies directed against an 
antigen of interest are coupled to magnetic beads which retain the so-labeled cells within a column 
surrounded by a strong magnetic field. In contrast to that, unlabeled cells are washed away. After 
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removal of the magnetic field, the retained cells are eluted. The target cells can either be the beads-
conjugated fraction (positive selection) or found in the flow through (depletion of unwanted cells or 
untouched isolation). Positive selection was applied to remove human CD4
+
 cells from PBMC 
whereas murine CD4
+
 and CD8
+
 cells as well as pan T cells were isolated untouched. Separation took 
place using the AutoMACS Pro Separator (Miltenyi Biotech) or was performed manually.  
2.2.3.6. Generation and co-culture of transduced myeloid dendritic cells with T cells 
Myeloid dendritic cells (mDCs) were generated by cultivation of bone marrow cells in the presence of 
the cytokine GM-CSF (Schülke et al., 2010). Bone marrow cells were isolated from two IFNAR
-/-
 N20 
C57BL/6 and two IFNAR
-/-
 SLAM
ki
 C57BL/6 mice, respectively, as described in 2.2.5.7. Usually, 
3 - 5 x 10
7
 cells were obtained from of one animal. For differentiation of myeloid dendritic cells 
1.5 x 10
7
 cells were seeded in 15 ml dendritic cell medium supplemented with 100 ng/ml GM-CSF per 
T75 flask. The cells were cultivated for 8 days with partial medium exchange every 2 – 3 days. After 
that period of time, the bone marrow cells developed into a mixed population of macrophages and 
myeloid dendritic cells. mDCs could be detached by rinsing the cell culture flask with medium, 
whereas the strongly adherent macrophages sticked to the bottom of the T75. The so harvested mDCs 
of one donor were pooled, pelleted at 1200 rpm for 5 min (Heraeus Multifuge 3SR
+
) and resuspended 
in 10 ml DC medium. 3.2 x 10
5
 cells were seeded in 0.5 ml or 1 ml DC medium supplemented with 
100 ng/ml lipopolysaccharide (LPS) in a 24-well plate. LPS was added in order to upregulate SLAM, 
the main cell entry receptor for MVwt H, in mDCs generated from IFNAR
-/-
 SLAM
ki
 C57BL/6 mice 
(Ohno et al., 2007). mDCs derived from IFNAR
-/-
 N20 C57BL/6 animals were treated likewise. The 
next morning, mDCs were transduced with protein transfer vectors at MOI 1 or 3. For this purpose, a 
master mix was prepared: at first, PTVs were prediluted in the solvent Opti-MEM
®
 resulting in the 
same volume Opti-MEM
®
 per volume vector solution to be added to one well. Secondly, the required 
volume DC medium was subjoined. Then, the culture medium was removed from the cells and 
replaced by 250 µl of the prepared transduction mixture. If transduction in the presence of the fusion-
inhibitor FIP (Richardson et al., 1980) was contemplated, 200 µM FIP-containing medium was added 
at least 30 min before transduction with PTVs. Besides, inhibitor-supplemented medium was used for 
all further steps of the experimental procedure. After incubating mDCs with PTVs for 4 hours, PTV-
containing medium was replaced by 8 x 10
5
 primary T cells solved in 1 ml DC medium. These T cells 
had been previously isolated by untouched magnetic cell separation (see 2.2.3.5) from the spleens of 
OT-I C57BL/6 or OT-II C57BL/6 mice. OT-I C57BL/6 mice are characterized by CD8
+
 ovalbumin-
specific T cells whereas OT-II C57BL/6 possess CD4
+
 ovalbumin-specific T cells (Hogquist et al., 
1994; Barnden et al., 1998). 24 hours after addition of T cells, 100 µl co-culture supernatant were 
sampled for the quantification of secreted IL-2 by ELISA (2.2.2.4). The collected supernatant was 
incubated with 0.2% (v/v) Tween-20 for 10 min - 20 min at room temperature to inactivate vector 
particles. Then, the samples were stored at -20°C for further analysis. 72 hours after starting the co-
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culture, the remaining supernatant was harvested for IFN-γ ELISA (2.2.2.4). Vector particles were 
inactivated as aforementioned and samples were stored at -20°C.    
2.2.3.7. Enzyme-linked immuno spot assay (ELISpot) 
The enzyme-linked immuno spot assay (ELISpot) is a method to determine the number of single, 
stimulated immune cells. It is based on the detection of cytokines secreted upon activation, which then 
become immobilized to a membrane.  
In this thesis, the IFN-γ-secretion of splenocytes obtained from PTV-vaccinated mice upon addition of 
appropriate stimulants was analyzed using the Mouse IFN gamma ELISPOT Ready-Set-Go!
®
-Kit 
from eBioscience. One day prior to the assay, MultiScreen filter plates with hydrophobic Immobilon-P 
PVDF membrane were activated with 50 µl 70% ethanol per well. Immediately, 200 µl sterile water 
were added to the wells and the fluid was decanted. The plate was washed twice more with sterile 
water and then once with sterile PBS w/o Ca
2+
/Mg
2+
 before proceeding following the manufacturer’s 
instructions. Splenocytes were isolated as described (2.2.5.7). 5 x 10
5
 splenocytes solved in 100 µl 
RPMI-1640 (with 10% FCS, 2 mM L-glutamine, and 1% penicillin/streptomycin) were aliquoted per 
well of a 96-U-well plate. Then, 100 µl of stimulatory peptides, proteins or controls diluted in 
complete RPMI-1640 medium were added to each well. 10 µg/ml concanavalin A served as a positive 
control, plain medium as a negative control. Cells were specifically restimulated by addition of 
10 µg/ml recombinant Ova, 5 µg/ml Ova257-264 (MHC I-restricted immunodominant peptide epitope of 
ovalbumin) or 5 µg/ml Ova323-339 (MHC II-restricted immunodominant peptide epitope of ovalbumin). 
The experiment was performed in triplicates. The prepared mixture of stimulants and cells was 
subsequently transferred to blocked MultiScreen-IP filter plates and incubated for 36 hours at 37°C in 
an 5% CO2 humidified incubator avoiding any further movements. IFN-secreting cells were detected 
following the manufacturer’s instructions. The spots were counted with an ELISpot Reader (Eli.Scan; 
software ELI. Analyse). Wells with too many spots to be reliably counted were set to a maximum 
value of 1500 spots, which represents the maximum spot count reliably determined by the software in 
the used settings. 
2.2.3.8. Flow cytometry 
Flow cytometry is a method to characterize single cells for their size, granularity, and fluorescence. It 
enables the detection of surface proteins as well as intracellular antigens by labeling with fluorophore-
conjugated antibodies directed against the marker of interest. It is based on the detection of scattered 
light and fluorescence signals emitted by cells passing a laser beam. 
A prerequisite for the staining procedure and the subsequent measurement is a single-cell suspension. 
To obtain this, adherent cell lines were detached using trypsin/EDTA, unhitched by vigorous pipetting 
(dendritic cells) or scraped off (macrophages). Trypsin/EDTA could be used as no trypsin-sensitive 
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epitopes were examined. If surface markers on primary cells, e.g. mouse splenocytes or human 
lymphocytes, should be analyzed, erythrocytes were lysed with 0.86% ammonium chloride solution 
prior staining. For murine blood, lysis was performed right after staining (see below). To stain cell 
surface antigens, approximately 1 - 5 x 10
5
 suspension or previously detached adherent cells were 
aliquoted per flow cytometry U-bottom tube and washed thoroughly with FACS-wash to remove the 
culture medium. Alternatively, 20 µl previously collected, fresh murine blood (2.2.5.2) were pipetted 
into a 1.4 ml flow cytometry tube and filled up with 500 µl FACS-wash. The cells were spun down at 
1200 rpm, 4°C for 5 minutes (Heraeus Multifuge 3SR
+
) and the supernatant was discarded except for 
50 µl - 100 µl in which the cells were resuspended in again. In case of MST1R detection, however, 
cells were initially incubated in 100 µl ice-cold methanol for 5 min at -20°C, washed twice with PBS 
w/o Ca
2+
/Mg
2+
 containing 1% (w/v) BSA and blocked with PBS w/o Ca
2+
/Mg
2+
 containing 10% (v/v) 
FCS and 300 mM glycine before proceeding with the staining procedure. When staining whole blood 
or immune cells, an FcR-blocking reagent was applied for 15 minutes at room temperature in order to 
block the unspecific binding of Fc receptor expressing cells to the antibodies. Then, 
antibody/antibodies were added in the required dilution (Table 7). Antibodies conjugated with 
different fluorochromes and diverse specificities could be used to stain the same sample (multicolor 
staining). Moreover, every staining approach included an unstained sample (mock), single-stained 
samples, if applicable, and the respective isotype controls. Isotype controls are antibodies of the same 
isotype as the primary antibody, which are conjugated to the same fluorophore but without specificity 
for the antigen of interest. They were applied in the same concentration as the corresponding 
antibodies. Subsequently, the samples were incubated for 20 min – 1 hour at 4°C in the dark. If the 
used antibody was not directly conjugated to a fluorophore, cells were washed thoroughly with FACS-
wash and followingly incubated with a labelled secondary antibody (1 hour, 4°C, in the dark). 
Whenever such a two-step staining procedure was conducted, a secondary antibody only control was 
performed as well. In case of murine blood, red blood cells were lysed with 700 µl 1x FACS Lysing 
Solution by Becton Dickinson (15 min, RT) and lymphocytes were pelleted as aforementioned. After 
staining, all cells were washed twice with FACS-wash before fixation with 100 µl – 300 µl FACS-fix 
(Table 5) took place. Cells expressing fluorophores, e.g. after transfection or transduction, did not 
necessarily have to be stained but could be subjected to flow cytometry analysis after being washed 
thoroughly and fixed with FACS-fix. All samples were either directly analyzed or stored in the fridge 
until measured in the LSRII SORP cytometer by Becton Dickinson. Lymphocytes should be measured 
within 24 hours, all other samples could be stored up to one week at 4°C in the dark. Normally, 
10.000 cells were read in the FSC-SSC gate. However, organ-derived samples from humanized NSG 
mice injected with CD4-LV required measurement of 1 million events in the FSC-SSC gate to ensure 
appropriate GFP detection. Compensation of multicolor stained samples was performed directly at the 
LSRII SORP cytometer (FACSDiva software) or later using FCS Express. For homogeneous cell 
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populations, doublet exclusion was performed. The obtained data were analyzed using the FACSDiva 
or FCS Express software. 
 
2.2.4. Virological methods 
2.2.4.1. Amplification of recombinant measles virus 
To amplify MVwt323-GFP(N), Vero-hSLAM cells were seeded into four 15 cm dishes at 5 x 10
6
 cells 
per dish and cultivated for 4 hours at 37°C. Then, cells were infected with passage 3 MVwt323-GFP(N) 
at MOI 0.03. To assure even infection of cells, the culture medium was removed, mixed with virus 
suspension and pipetted back onto the cells. Infected cells were cultured for 2-3 days at 37°C until 
nearly all cells were infected. Then, cell-associated virus was harvested. For that purpose, the culture 
medium was removed and replaced by 0.5 ml Opti-MEM. Cells were detached using a cell scraper and 
the suspension was subsequently transferred into a 15 ml reaction tube and quick-frozen in liquid 
nitrogen for approximately 3 minutes. The freezing step leads to cell disruption and thus release of 
cell-associated virus. The suspension was either stored at -80°C or directly thawed (but not heated) at 
37°C in a water bath. Cell debris was subsequently removed by centrifugation for 5 min at 3,000 rpm 
and 4°C (Heraeus Multifuge 3SR
+
). The virus-containing supernatant was then aliquoted at 300 µl in 
Cryo-tubes and stored at -80°C. 
2.2.4.2. Titration of recombinant measles virus 
For titration of each MVwt323-GFP(N) virus stock, Vero-hSLAM cells were seeded into 2 96-well 
plates at 1 x 10
4
 cells per well three hours before titration. The viruses were diluted from 10
-1
 to 10
-12
 
in duplicates by initially mixing 270 µl DMEM without FCS with 30 µl virus suspension followed by 
a serial 1:10 dilution. Cells were infected by transferring 30 µl of virus-dilution in 8 replicates to the 
cells. The cells were cultivated for 4 days at 37°C and infection of each replicate was determined by 
microscopic analysis of GFP fluorescence. Virus titers were calculated by the TCID50 method 
according to Spearman and Kärber (Spearman, 1908; Kärber, 1931) and the final titer was determined 
by averaging the duplicate values. The TCID50/ml gives the dilution of 1 ml virus, which has a 
probability of 50% to infect susceptible cells. The detection limit of this method is defined with 
1 x 10
2
 TCID50/ml.  
2.2.4.3. Production and concentration of lentiviral vectors 
HIV-1 derived lentiviral vectors were produced in HEK-293T packaging cells. For that purpose, the 
cells were transiently transfected with transfer vector, packaging plasmid and Env expression 
construct(s) using polyethylenimine as described in 2.2.3.3. The amount and kind of plasmid DNA 
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needed for the production of the different gene and protein transfer vectors deployed in the present 
thesis are listed in Table 19. 24 hours after transfection the medium was carefully exchanged to 16 ml 
new DMEM (+15% FCS and 2 mM L-glutamine) per T175 flask. The next day, vector-containing 
supernatant was harvested and filtered using a 0.45 µm Minisart
®
 syringe filter or, for larger volumes, 
the 0.45 µm Stericup
®
 & Steritop™ vacuum-driven filtration system. For titer determination of un-
concentrated vector, 1 ml of the filtered supernatant was aliquoted and stored at -80°C. The remaining 
medium was filled into 36 ml ultracentrifuge tubes at 32 ml per tube. Then, 4.5 ml 20% sucrose 
solution were cautiously layered below and vectors were pelleted at 28,000 rpm, 4°C for 3 hours using 
a SW28 rotor in an Optima™ L-70K ultracentrifuge. Alternatively, pelletizing was achieved by low-
speed centrifugation in a Heraeus Multifuge 3SR
+
 bench-top centrifuge (50 ml or 250 ml tubes with 
sucrose cushion, centrifugation at 4,300 rpm, 4°C, 25 hours). The supernatant was discarded and the 
tubes were carefully wiped with fuzz-free cloth to remove residual fluid. Subsequently, the vector 
pellets were solved in prechilled PBS w/o Ca
2+
/Mg
2+
 or Opti-MEM
®
 (120 µl for VSV-G pseudotyped 
vectors, 85 µl for MV H+F pseudotyped ones). The tubes were placed on ice on a shaking device for 
1-2 hours. Afterwards, vectors were resuspended by pipetting approximately 60 times up and down 
and pooled, if more than one ultracentrifugation tube containing a certain vector type was present. In a 
last step, vectors were aliquoted into 1.5 ml (low binding) tubes and stored at -80°C.  
For VSV-G or MVwt H and F-pseudotyped vectors, harvest and concentration could be repeated the 
next day if new medium was added to the packaging cells right after the first harvest. In contrast to 
that, CD4-LV and CD8-LV only allowed for a single harvest due to stronger syncytia formation. 
 
Table 19: Transfection scheme for lentiviral vector production. 
Plasmid [µg] 
Gene transfer vectors
a
 Protein transfer vectors
a
 
VSV-
LV 
MVwt-
LV 
CD4-
LV 
VSV-
Cargo-
LV 
MVwt-
Cargo- 
LV 
Bald-
Cargo-
LV 
VSV/MVwt-
Cre-LV
b
 
E
n
v
 
pMD.G2 6.13 - - 3.98 - - 3.98 
pCG-Hwt323Δ18 - 4.04 - - 1.49 - 1.49 
pCG-H-αCD4 - - 0.9 - - - - 
pCG-Fwt323Δ30 - 6.73 - - 2.49 - 2.49 
pCG-FcΔ30 - - 4.49 - - - - 
p
ac
k
ag
ab
le
 
v
ec
to
rs
 
transfer vector: 
pSEW 
pSEW-Cre 
pSEW-TurboFP635 
pS-luc2-GFP-W 
17.5 
+ 
+ 
+ 
- 
15.17 
+ 
+ 
+ 
+ 
15.17 
- 
- 
- 
+ 
12.73 
- 
- 
+ 
- 
12.73 
- 
- 
+ 
- 
14.36 
- 
- 
+ 
- 
12.73 
- 
- 
+ 
- 
p
ac
k
ag
in
g
 
p
la
sm
id
s 
pCMVΔR8.9 11.38 9.06 14.44 9.15 9.15 10.32 12.2 
packaging plasmid with 
cargo: 
pcDNA3.gpGFP.4xCTE 
pcHIV1_MA_P_GFP 
pcHIV1_MA_P_Ova 
pcHIV1_MA_P_Cre 
 
- 
- 
- 
- 
- 
 
- 
- 
- 
- 
- 
 
- 
- 
- 
- 
- 
 
9.15 
+ 
+ 
+ 
+ 
 
9.15 
+ 
+ 
+ 
+ 
 
10.32 
+ 
+ 
+ 
- 
 
6.1 
- 
- 
- 
+ 
a
 +/-, indicate if a certain plasmid was generally used for the generation of the specified vector type.
 b
 brackets, 
either VSV-G or MVwt-GP encoding expression constructs were used. 
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2.2.4.4. Titration of vectors 
All PTVs were titrated on adherent CHO-hSLAM cells whereas CD4-LV and was titrated on Molt4.8 
suspension cells. The titer of VSV-LVCre was determined on HT1080-Cre cells and MVwt-LV was 
either titrated on Raji or CHO-hSLAM cells. One day before titration, adherent cells were seeded 
resulting in 70% - 80% confluency at the time point of transduction, e.g. 2 x 10
4
 CHO-hSLAM cells 
per 96-well or 9 x 10
4
 CHO-hSLAM cells per 48-well. Suspension cells were seeded likewise right 
before titration, e.g. 3 x 10
4
 Molt4.8 cells in 50 µl medium per 96-well. To determine the number of 
adherent cells at the time point of titration, the cells of one previously seeded well were detached with 
Trypsin/EDTA and subsequently counted. For titration, vectors were serially diluted 1:10 in culture 
medium in 6 steps and either directly added to suspension cells or, in case of adherent cells, right after 
the old medium was removed. Titration took place in 150 µl medium per 96-well with no further 
medium addition or 250 µl medium per 48-well with subjoining of 500 µl culture medium 
approximately 5 hours after transduction. 3 days after transduction, transduction efficiency was 
analyzed by flow cytometry (2.2.3.8). The titers were calculated according to the formula below, 
including only dilutions where 1% - 20% of cells were transduced. 
 
Titer [t.u./ml] = (% transduced cells) x (number of cells at time point of transduction) x 1000 
                       (Applied volume of vector [µl]) 
2.2.4.5. Transduction of adherent or suspension cells 
Adherent cells were seeded one day before transduction in 6 - 96-well plates so that cells would be 
~70% - 80% confluent at the time of transduction, e.g. 6 x 10
4
 CHO-K1 cells per well of a 48-well-
plate. The cells of one well were counted right before transduction. For suspension cells, the cell 
number was determined and cells were seeded into a well plate just before transduction using as little 
medium as possible, e.g. 50 µl per 48-well or 100 µl per 24-well. In order to transduce the cells with a 
specific multiplicity of infection (MOI), the volume of vector to be applied to the given number of 
cells was calculated according to the following formula: 
 
Volume (ml) = MOI x cell number 
           titer  
Transduction was conducted in as little medium as possible, but as much as necessary to reliably cover 
the cells, e.g. 150 µl per 48-well or 300 µl per 24-well. Vector stocks were freshly thawed before 
transduction and mixed by pipetting up and down. The vector was premixed with fresh culture 
medium by pipetting and the cells were subsequently incubated with the vector mix for approximately 
4 hours. As a matter of course, the culture medium was removed from adherent cells before addition of 
vector. Then, the vector-containing medium was replaced by normal growth medium or normal 
growth medium was added up to the volume usually used for cultivation. Protein transfer was 
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analyzed 4 hours after transduction by flow cytometry (2.2.3.8) or Western Blot (2.2.2.3). As robust 
transgene expression is reached 48 - 72 hours post transduction, gene transfer was assessed by flow 
cytometry 3 days after transduction. 
Transduction of primary unstimulated PBMC and thereof derived activated T cells with CD4-LV was 
conducted in presence of 4 µg/ml protamine sulfate. Protamine sulfate is a polycation that should 
minimize the charge repulsion between vector particles and cell surface and thus increase transduction 
efficiency (Cornetta and Anderson, 1989). Moreover, a spin occulation was performed. Therefore, the 
vector was added to the cells and the culture plate was immediately centrifuged at 1,200 rpm, 32°C 
(Heraeus Multifuge 3SR
+
) for approximately 90 minutes. Then, the plate was either transferred to the 
incubator for 3 hours before addition of new T cell medium or medium was instantly subjoined. 
Transgene expression was analyzed 3 days after transduction as described above.  
 
2.2.5. In vivo mouse experiments 
All animal experiments were performed in compliance with the German animal protection law and 
following the recommendations of the Federation of European Laboratory Animal Science 
Associations (FELASA). Mice were bred in-house under specified pathogen-free (SPF) conditions and 
housed in individually ventilated cages (IVC). All animals used in experiments were about 6 to 12 
weeks old. The health status of the mice was checked regularly.  
2.2.5.1. Isoflurane gas anesthesia of mice 
Mice were anesthetized using isoflurane gas anesthesia in a special isoflurane anesthesia unit. 
Isoflurane was the narcotic of choice as it is only minimally metabolized by the liver and is therefore 
less toxic for the animals (Fish, 2008). Initially, the induction chamber was flushed with 5% (v/v) 
isoflurane. Then, mice were placed in the chamber and the isoflurane content was reduced to 2.5% 
(v/v). The animals were left in the unit until entirely narcotized. Mice were usually awake and alert a 
few minutes after being taken out of the induction chamber. 
2.2.5.2. Blood collection from the orbital sinus 
Mice were anesthetized using isoflurane (2.2.5.1) and laid on their sides on a table. The loose skin in 
the neck of the animals was tightened with thumb and index finger. The grasp should be strong enough 
to accumulate the blood and immobilize the mice but not result in occlusion of the trachea. When the 
eyeballs were protruding out of the eye sockets, the tip of a thin Pasteur pipette was inserted in the 
medial canthus of one eye under the eyeball, directed in a 45° angle towards the middle of the eye 
socket. The pipette was gently rotated until blood was entering it and then slightly moved backwards. 
When the desired amount of blood was withdrawn, mice were released and blood flow was stopped by 
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briefly applying light pressure on the eye with a gauze swab, if necessary. The blood was collected in 
lithium-heparin Microtainer tubes purchased from BD. 
2.2.5.3. Xenograft transplantation 
To generate so-called “humanized mice”, immunodeficient NOD-scid IL2Rγ-/- (NSG) mice were 
repopulated with human peripheral blood mononuclear cells (PBMC). Human PBMC were isolated 
and, if applicable, activated as previously described (see 2.2.3.4). The cells were subsequently washed 
with PBS w/o Ca
2+
/Mg
2+
 and counted. Then, the desired cell number was solved in PBS w/o 
Ca
2+
/Mg
2+
 and well resuspended before administration. Cells were injected intravenously (2.2.5.4) in a 
total volume of 200 µl into 6-8 weeks old NSG mice. In case of unstimulated PBMC 5 x 10
7
 cells, in 
case of activated T cells 1.5 x 10
7
 cells were injected per mouse. Repopulation was monitored by 
analyzing the percentage of human CD45
+
 cells in the peripheral blood of the animals. Usually, 10% - 
20% human CD45
+
 lymphocytes were detected 3 days after injection of cells. PBMC-repopulated 
NSG mice were closely monitored for signs of graft versus host disease (GvHD), e.g. loss of weight, 
rough fur, apathy, abnormal/ unphysiological posture and isolation from the group. If GvHD set in 
during the course of an experiment, animals were euthanized to prevent suffering.  
2.2.5.4. Intravenous or intraperitoneal vector injection 
For intravenous vector injection, mice were placed under a heat-lamp in order to dilate the veins by 
warming of the animals. Then, the mice were transferred to a mouse-restrainer and vector or solvent 
was injected with a 30 G cannula in one of the lateral tail veins. The solution was pre-warmed to room 
temperature and free from air bubbles. The maximal volume applied was 200 µl. To perform 
intraperitoneal vector injection, mice were manually restrained and held with their heads pointing 
downwards. This position ensured a cranial shift of the inner organs and thus the formation of an 
empty cavity in the lower abdominal region. Vector or solvent were injected with a 30 G cannula in 
the lower right or left quadrant of the abdomen to avoid injury of inner organs. The injected volume 
did not exceed 200 µl. After both, intravenous and intraperitoneal injection, mice were put back in 
their cage and their state of health was observed for several minutes. 
2.2.5.5. In vivo imaging 
For in vivo imaging, mice were injected intraperitoneally with 150 µg D-luciferin/ g body weight (see 
2.2.5.4). 4 min after injection of the substrate, mice were transferred into a pre-floated anesthesia 
chamber with 2.5% (v/v) isoflurane for 3 min - 4 min. The animals were subsequently placed into the 
IVIS Spectrum imaging device where anesthesia was maintained individually by nose-cone masks also 
delivering 2.5% (v/v) isoflurane. The mice were imaged in ventral position first, then turned to dorsal 
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position. Luminescence acquisition took place at approximately 8 min – 18 min after substrate 
injection when the substrate distribution was at steady state. 
In case of final imaging, the animals were recorded as described above (common parameters: 60 sec 
exposure time, F-Stop 1, binning 8, subject height 1.5) and subsequently sacrificed. Ventral, the skin 
was detached from the body and pinned to a polystyrene board with cannulas. After imaging again 
(subject height 4), axillary and submandibular lymph node like structures as well as spleen, thymus 
and, if applicable, other luminescing organs were removed (2.2.5.7) and the gut was arranged in a 
circular manner around the mice. The organs as well as the in such a way prepared animals were 
imaged one last time (organs: subject height 0.3, mice: subject height 4). 
2.2.5.6. Vaccination with protein transfer vectors 
6 to 8 weeks old IFNAR
-/-
 and SLAM
ki
 mice were intraperitoneally injected (2.2.5.4) with 1 µg 
recombinant ovalbumin or Bald-Ova-LVKatushka, MVwt-Ova-LVKatushka or VSV-Ova-LVKatushka adjusted 
to contain 1 µg ovalbumin. The amount of MVwt-GFP-LVKatushka was normalized to capsid protein 
content of MVwt-Ova-LVKatushka. Opti-MEM injected animals served as mock controls. Mice were 
primed, and boosted 4 weeks later as described. The animals were sacrificed on day 32, i.e. four days 
after boosting, their spleens were harvested and splenocytes were isolated (2.2.5.7). The number of 
IFN-γ secreting, antigen-specific T cells among splenocytes was determined by an ELISpot assay 
(2.2.3.7). 
2.2.5.7. Removal of organs and preparation of single-cell suspensions   
Prior to removal of organs, mice were sacrificed by cervical dislocation. Then, the animals were 
disinfected using 70% ethanol and placed on their backs. The ventral midline was incised and the skin 
was retracted and pinned to a polystyrene board with cannulas. Axillary and inguinal lymph node like 
structures were spotted and removed. The intestinal cavity was opened up and thymus, spleen, and 
further lymph node like structures were harvested and placed in medium until processing (on ice, if no 
further cultivation but flow cytometry analysis was intended). The location of lymphatic organs in the 
mouse is depicted in Figure 7. If desired, femur and tibia of the animals were removed for bone 
marrow preparation.  
To isolate splenocytes, the spleen was put in a dish with RPMI-1640 medium and its capsule was 
slightly scarified with a 100 µl pipette tip. Then, a 2 ml pipette was used to crush the spleen and with 
this extract the cells. The suspension was subsequently passed through a 70 µm cell strainer which was 
rinsed once with 15 ml medium to collect remaining cells. Alternatively, the entire spleen was placed 
on the 70 µm cell strainer, mashed with the plunger end of a syringe and pushed through the strainer. 
The cells were centrifuged for 5 minutes at 1200 rpm (Heraeus Multifuge 3SR
+
) and the pellet was 
resuspended in 2 ml Red Blood Cell Lysis Buffer (5 min, room temperature) to lyse erythrocytes. 
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Then, ≥ 5 ml of PBS w/o Ca2+/Mg2+ or medium were added and the splenocytes were spun down again 
as described above. The cells were resuspended in the desired volume of FACS-wash for flow 
cytometry analysis (2.2.3.8), MACS buffer for magnetic cell separation (2.2.3.5) or RPMI-1640 
medium supplemented with 10% FCS and 1% penicillin/streptomycin/L-glutamine for cultivation 
purposes.  
To gain bone marrow cells, femur and tibia of the animals were removed, thoroughly cleaned from 
muscle tissue and briefly sterilized in 70% ethanol. The ends of the bones were cut off and the bones 
were flushed with 5 ml medium per bone, e.g. dendritic cell medium (see Table 5), using a syringe and 
a 25 G needle. A single cell suspension was obtained by vigorous pipetting. The cells from one leg 
were pooled and pelleted at 1200 rpm for 5 min (Heraeus Multifuge 3SR
+
). The cell pellet was then 
solved in 1.5 ml Red Blood Cell Lysis Buffer and incubated for 1 min at room temperature. After 
washing with 10 ml medium or FACS-wash, the cells isolated from one mouse were resuspended in 
10 ml medium for further cultivation or FACS-wash for immediate flow cytometry analysis.  
 
  
Figure 7: Location of lymph nodes, 
thymus and spleen in the mouse. Lymph 
node like structures in green were 
removed during final imaging of the 
animals. Figure modified after Dunn, 
1954. 
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3. Results 
This thesis describes the generation and characterization of lentiviral vectors (LVs) engineered to 
enable selective protein or gene transfer into signaling lymphocyte activation molecule (SLAM)-
positive antigen presenting cells (APCs) or CD4-positive T lymphocytes, respectively. Targeting of 
these vectors is based on pseudotyping with measles virus (MV) glycoproteins (GPs), either exploiting 
the natural tropism of wild-type hemagglutinin (H) for SLAM, or displaying a designed ankyrin repeat 
protein (DARPin) specific for human CD4 on receptor blind H. After assessment of receptor-
specificity, SLAM-targeted vectors were shown to stimulate cellular immune responses upon model 
antigen ovalbumin (Ova) protein transfer into APCs in vitro and in vivo. Similarly, CD4-targeted 
vectors were demonstrated to enable specific and efficient gene delivery into CD4
+
 cells in vitro and as 
the first lentiviral vector also in vivo upon systemic application. 
3.1. Targeted protein transfer into SLAM+ cell lines and antigen 
presenting cells 
3.1.1. MV Hwt tropism – identification of Nectin-4 as EpR 
As outlined above, signaling lymphocyte activation molecule (SLAM)-targeted lentiviral vectors 
should be generated enabling specific modification of SLAM
+
 antigen presenting cells (APCs). The 
desired specificity for SLAM should be achieved by pseudotyping lentiviral vectors with MVwt 
glycoproteins (GPs), which use SLAM (CD150) as the main cell entry receptor (Tatsuo et al., 2000). 
However, besides CD150 an epithelial receptor (EpR) for MVwt hemagglutinin was predicted (see 
1.2.2). To define all target cell receptors and thus target cell populations for MVwt-GPs and assess 
potential SLAM-independent off-target effects, identification of the unknown EpR had been crucial. 
All experiments associated with the search for the EpR were performed using recombinant wild-type 
IC-B strain derived measles virus expressing GFP in pre N position (MVwt323-GFP(N)) which was 
amplified and titrated as described in 2.2.4.1 and 2.2.4.2.  
Potential receptor proteins had already been spotted by a mRNA-based, genome-wide expression 
analysis comparing MVwt323 permissive epithelial cell lines (H358, H441, HT-1376) with non-
permissive ones (H23, H522, T24, SCaBER). The underlying data had been derived from an 
microarray by Dr. Mühlebach, Paul-Ehrlich-Institut (Mühlebach et al., 2011). Then, receptor-negative 
and therefore non-permissive Chinese hamster ovary (CHO) cells were transfected by S. Prüfer, Paul-
Ehrlich-Institut, with expression plasmids encoding 30 EpR candidates (cloned by A. Schnoor Cancio 
and S. Prüfer). These 30 selected EpR candidates were surface-exposed proteins, preferentially 
expressed in the permissive cell lines or with interesting biological properties. 48 hours after 
transfection, cells were infected with GFP-expressing MVwt323 at MOI 1 by S. Prüfer. Out of these 30 
Results 
56 
 
transmembrane proteins 29 did not confer susceptibility to MVwt323 infection. The same was true for 
22 proteins tried in a previous screen (by Dr. Leonard, Mayo Clinic, USA) based on an already 
published mRNA-microarray (Wagner et al., 2007). Only upon transfection of a Nectin-4 expression 
plasmid, infection with MVwt323 and syncytia formation was observed by. S. Prüfer (Figure 9A). All 
other transfected CHO cells expressing the respective proteins, confirmed within this thesis for 
MST1R as an example by flow cytometry, remained resistant. 
To clearly attribute the observed susceptibility to MVwt323 infection to Nectin-4 expression, Nectin-4 
should be detected in transfected cells. However, in initial attempts, testing four different anti-Nectin-4 
antibodies in Western Blot analysis (antibodies GTX116900 by GeneTex, ab57873 by abcam, 
H00081607-M01A and H00081607-B01P, both by Abnova), no specific signals were detected (data 
not shown). As an alternative, Nectin-4 expression should be confirmed by flow cytometric analysis. 
For that purpose, the performance of two primary antibodies recognizing Nectin-4 (N.4.40 kindly 
provided by Dr. Lopez; Fabre et al., 2002 and LS-C37483 purchased from LifeSpan BioSciences) was 
evaluated by flow cytometry (2.2.3.8). Both antibodies were specific for Nectin-4 expressed by 
MVwt323 permissive H358 cells while no binding to MVwt323 non-permissive H23 cells was observed 
(Figure 8). However, a higher percentage of H358 cells stained positive with the anti-Nectin-4 
antibody obtained from LifeSpan BioSciences than with N.4.40 from Dr. Lopez despite ten-times 
lower concentration of the former antibody. Moreover, cells incubated with the anti-Nectin-4 antibody 
from LifeSpan BioSciences were characterized by a higher mean fluorescent intensity (MFI) than cells 
stained by N.4.40. Therefore, the antibody purchased from LifeSpan BioSciences was used for all 
further analyses.  
 
 
Figure 8: Detection of Nectin-4 by flow 
cytometry. MVwt323 permissive (H358) or 
none-permissive (H23) epithelial cells were 
stained with two different primary 
antibodies against human Nectin-4 to 
establish a detection protocol. Antibody 1: 
N.4.40 (10 µg/ml) kindly provided by Dr. 
Lopez; antibody 2: LS-C37483 (1 µg/ml) 
purchased from LifeSpan BioSciences. 
Secondary antibody: PE-conjugated goat 
anti-mouse Ig. 
 
Using the established staining protocol, Nectin-4 expression in transfected CHO cells susceptible to 
MVwt323 infection was confirmed by flow cytometry analysis (Figure 9A, lower panel).  
As this finding pointed at Nectin-4 as putative EpR, Nectin-4 expression was also examined in the 
seven epithelial cell lines used in the mRNA expression screen for receptor candidates. Indeed, the 
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permissive cell lines H358, H441, and HT-1376 all stained positive for Nectin-4 whereas the non-
permissive cell lines did not express Nectin-4 at all (H23, H522, and T24) or on a considerably lower 
level than the permissive ones (SCaBER) (Figure 9B). The hypothesis of Nectin-4 being the EpR was 
further supported by transfection of H358 cells with an siRNA specific for the nectin-4 mRNA and 
infection with MVwt323 (MOI 0.5) 48 hours after transfection by S. Prüfer. The knock-down of Nectin-
4 by approximately 90%, as confirmed in the framework of this thesis by flow cytometric analysis of 
siRNA transfected cells, nearly ablated the subsequent viral infection (Figure 9C).  
 
 
Figure 9: Identification of Nectin-4 
as putative EpR. (A) Nectin-4 
serves as MV entry receptor. CHO-
K1 cells were not transfected (mock) 
or transfected with expression 
plasmids for Nectin-4 and 
macrophage stimulating 1 receptor 
(MST1R). Cells were infected with 
MVwt323-GFP(N) at MOI 1 (top). The 
expression of Nectin-4 and MST1R 
was confirmed by flow cytometry 
(bottom). (B) Flow cytometric 
analysis of Nectin-4 expression in 
epithelial cell lines. H358, H441, and 
HT-1376 are permissive for MV 
infection, whereas H23, H522, T24, 
and SCaBER are non-permissive. 
(C) Knockdown of Nectin-4 
expression impedes MV infection. 
H358 cells were mock transfected 
(control) or transfected with Nectin-
4-specific siRNA 4_1. 48 h after 
transfection, H358 cells were 
infected with MVwt323-GFP(N) at 
MOI 0.5. Flow cytometry analysis 
confirmed down-regulation of 
Nectin-4 (right panel). Figure 
modified after Mühlebach et al., 
2011. 
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Nectin-1, Nectin-2, and PVR (polio virus receptor), all belonging to the PVR/ nectin family which also 
comprises Nectin-4, are used as receptors by alpha-herpesviruses (Nectin-1 and Nectin-2), and 
poliovirus (PVR) (Mendelsohn et al., 1989; Campadelli-Fiume et al., 2000). As it is, moreover, not 
uncommon that related proteins interact with the same virus, the question arose whether also other 
PVR/ nectin family members could serve as MV receptors. To address this issue, CHO-derived cell 
lines stably expressing Nectin-1, Nectin-2, Nectin-4 or PVR were received by a collaboration 
laboratory (Dr. Lopez, INSERM, France) and the respective transgene expression was confirmed by 
flow cytometry analysis (2.2.3.8). CHO-Nectin-3 were not included as Nectin-3 had already been 
tested in a previous screen and did not confer permissiveness to MV infection (Mühlebach et al., 2011). 
All transgenic cell lines expressed the respective nectin at similar or higher density than CHO-
Nectin-4 (Figure 10, lower panel). When these cells were infected by S. Prüfer with MVwt323-GFP(N), 
green fluorescing cells and syncytia formation were only observed in CHO-Nectin-4 cells (Figure 10, 
upper panel). Thus, none of the other nectins did enable MVwt323 infection meaning that only Nectin-4 
has receptor properties.  
 
 
Figure 10: Nectin-4 is the only PVR/ nectin family member which serves as MV receptor. Chinese hamster 
ovary (CHO) cells stably expressing different PVR/ nectin family members were infected with MVwt323-GFP(N) 
(top row). Transgene expression of cells was confirmed by flow cytometry (bottom row). Figure modified after 
Mühlebach et al., 2011. 
 
An often observed phenomenon upon virus infection is the down-regulation of the respective cellular 
receptor in infected cells. Therefore, to analyze if also Nectin-4 is down-regulated upon infection with 
MVwt323, the bladder epithelial cell line HT1376 and the lung epithelial cell line H358 were infected 
with MVwt323 at MOI 1. Two hours later, the fusion inhibiting peptide FIP [200 µM] (Richardson et al., 
1980) was added to prevent syncytia formation which would hamper flow cytometric analysis of 
surface protein expression levels. 48 hours after infection, Nectin-4 expression was analyzed by flow 
cytometry (2.2.3.8). MVwt323 infection indeed induced an approximately 5-fold reduction of the 
median Nectin-4 surface expression compared to uninfected control cells (Figure 11). This finding 
further strengthened the evidence of Nectin-4 being the EpR. 
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Figure 11: Downregulation of Nectin-4 
after MV infection. H358 lung epithelial 
cells or HT-1376 bladder epithelial cells were 
infected with MVwt323-GFP(N) at MOI 1. 2 h 
later, fusion inhibiting peptide FIP [200 µM] 
was added. Nectin-4 expression levels were 
determined 48 h after infection by flow 
cytometry. Figure modified after Mühlebach 
et al., 2011. 
 
Taken together, the obtained data strongly suggested adherens junction protein Nectin-4 as the 
epithelial receptor for MVwt323. Besides, further experiments confirmed Nectin-4 as the epithelial 
receptor for MV wild-type and vaccine strains (Mühlebach et al., 2011). 
3.1.2. Optimizing the production of GFP-PTVs 
After identification of Nectin-4 as secondary receptor for MVwt323, this thesis concentrated on 
production of lentiviral vectors as protein carriers in the next step.  
Retroviral vectors have not only been shown to transfer their genome, but also heterologous cargo 
proteins into transduced cells if those are genetically fused to the structural proteins of the respective 
vector particles (Voelkel et al., 2010). Thereby, a promising novel concept of protein delivery for 
transient cell modification was introduced. Here, protein transfer vectors (PTVs) derived from HIV-1 
should be used for targeted antigen-transfer into antigen presenting cells (APC), allowing vaccination 
with a new platform technology. First, a protocol for the generation of cargo protein transferring 
particles needed to be set up to establish the production of LV particles allowing maximum protein 
and gene delivery into transduced cells. To this end, HEK-293T cells were transfected (2.2.3.3, 
Lipofectamine
®
 2000 transfection) with varying ratios of unmodified packaging plasmids to packaging 
plasmids additionally encoding GFP fused to matrix within the Gag polyprotein, together with 
constant amounts of VSV-G expression plasmid and transfer vector comprising the turboFP635 
marker gene sequence, which codes for the red-fluorescent Katushka protein (Figure 12). 
Subsequently, HT1080 cells were transduced with the resulting vector-containing supernatants and 
PTV-mediated protein or gene delivery into HT1080 cells were visualized by flow cytometric analysis 
of GFP or Katushka fluorescence, respectively (2.2.3.8).    
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Figure 12: Generation of lentiviral protein transfer vectors. Lentiviral protein transfer vectors (PTVs) were 
generated by transient transfection of HEK-293T cells with packaging plasmids (encoding the structural proteins 
of the vector) with or without cargo protein encoding sequence, transfer vector (harboring the transgene) and env 
expression plasmid, coding for the envelope protein. 2 d after transfection, vector-containing supernatant was 
harvested and particles were either directly used or concentrated by ultracentrifugation through a 20% sucrose 
cushion. CA, capsid; IN, integrase; LTR, long terminal repeat; MA, matrix; NC, nucleocapsid; P, promoter; pA, 
polyadenylation signal; PR, protease, RT, reverse transcriptase; Ѱ, packaging signal.  
 
Increasing the relative amounts of cargo-encoding gag-gfp/pol compared to gag/pol for vector 
production positively correlated with GFP transfer into transduced target cells, and reciprocally 
correlated with turboFP635 marker gene delivery (Figure 13). However, when no wild-type gag/pol 
was supplemented for particle generation, i.e. the vectors were composed of Gag-GFP/Pol only, GFP 
transfer into HT1080 cells was significantly limited and gene transfer was not observed at all (Figure 
13), indicating absence of functional particles. The optimal ratio of GFP protein and turboFP635 gene 
transfer was obtained for PTV particles produced in HEK-293T cells transfected with equal amounts 
of Gag-GFP/Pol and Gag/Pol encoding packaging plasmids (Figure 13). Thus, this 1:1 ratio was 
further used for PTV generation. The only exception were PTVs transferring Cre recombinase. For 
such vectors, the optimum was determined at a ratio of 2:1 for gag/pol to gag-cre/pol within the 
Bachelor thesis of Johannes Reusch (Reusch, 2013).  
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Figure 13: Impact of the ratio of untagged gag/pol 
to gag-gfp/pol for PTV generation on protein and 
gene transfer into transduced target cells. Vector 
particles were produced with the indicated ratios of 
gag/pol to gag-gfp/pol, gag/pol (No GFP) or gag-
gfp/pol (no G/P) packaging plasmids. The total 
amount of DNA used for transfection of packaging 
cells was kept constant for all ratios. 72 h after 
transfection of packaging cells, unconcentrated, 
vector-containing supernatant was cleared and 
immediately used to transduce HT1080 cells. HT1080 
cells incubated with vector-free cell culture medium 
served as negative control (NC). 4 h after 
transduction, protein transfer was assessed by flow 
cytometric analysis of GFP fluorescence. Transfer of 
the turboFP635 marker gene was quantified 72 h after 
transduction by flow cytometric detection of red-
fluorescing Katushka marker protein. Maximum 
protein or gene transfer (% transduced of all cells) of 
three independent experiments was set to 1, all other 
transduction rates were calculated accordingly. 
Results are depicted as mean ± SEM (n = 3). Figure 
modified after Uhlig et al., 2015. 
 
 
To assess if the decreasing infectivity of particles produced with increasing amounts of gag-gfp/pol 
(Figure 13) may be due to altered steric needs of the Gag-GFP polyprotein entailing changes in 
particle structure, a set of vectors should be generated and morphologically analyzed. For that purpose, 
HEK-293T cells were transfected (2.2.4.3) with VSV-G expression plasmid, transfer vector pSEW-
TurboFP635 and either only gag/pol, equal amounts of gag-gfp/pol and gag/pol or only gag-gfp/pol 
packaging plasmid(s). Then, vector-producing packaging cells were fixed with 10% glutaraldehyde 
and handed to Anke Muth and Regina Eberle, both Paul-Ehrlich-Institut, who kindly performed 
electron microscopic (EM) analysis of ultrathin sections of those. The fixed packaging cells were 
expected to be associated with a high density of assembling and budding particles. 
Whereas lentiviral gene transfer vectors and PTVs generated using equal amounts of gag-gfp/pol and 
gag/pol were phenotypically indistinguishable from each other by EM and present in similar quantities 
(Figure 14 and data not shown), notably less PTV particles were detected when produced in packaging 
cells transfected with only gag-gfp/pol (data not shown). The particles exclusively composed of GFP-
tagged Gag were further characterized by an aberrant morphology, including gaps in the particles’ Gag 
layer and were only pseudotyped by moderate amounts of irregularly arranged VSV-G envelope 
glycoproteins (Figure 14).  
Taken together, EM clearly demonstrated an impact of the relative amount of gag-gfp/pol used for 
transfection of HEK-293T packaging cells and hence the amount of heterologous cargo protein 
incorporated into vector particles on the morphology of originating PTVs. Particles exclusively 
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composed of GFP-tagged Gag showed morphological abnormalities. The data strengthen the 1:1 ratio 
of gag-gfp/pol to gag/pol identified as most suitable for PTV production.  
 
 
Figure 14: Electron microscopy of ultrathin slices of packaging cells releasing PTVs. HEK-293T cells were 
transfected with all plasmids necessary to produce VSV-G pseudotyped PTVs. The structure of released particles 
produced with an equal amount of gag/pol to gag-gfp/pol (1:1) was compared to particles produced with only 
gag-gfp/pol (Gag-GFP/Pol) and conventional gene transfer vectors (Gag/Pol) devoid of GFP. Arrows point at 
gaps in matrix layer and irregularly arranged VSV-G envelope glycoproteins. Figure modified after Uhlig et al., 
2015. 
 
To analyze whether titers and protein transfer efficiencies of PTVs could be further improved, HEK-
293T cells were transfected (2.2.3.3) with varying ratios of packaging plasmids to transfer vector and 
expression construct (here encoding VSV-G). Vector-containing supernatants were harvested from 
packaging cells, and CHO-hSLAM cells were transduced (2.2.4.5) with similar volumes of 
unconcentrated vector suspension or concentrated vector stock after ultracentrifugation through a 20% 
sucrose cushion. Transduction was followed by flow cytometric analysis (2.2.3.8) of GFP delivery 
(four hours after transduction) or Katushka expression (three days after transduction) indicating 
protein or gene transfer, respectively.  
Particles produced in packaging cells transfected with a relative ratio of 0.87 (VSV-G expression 
plasmid) to 1.62 (sum of Gag-(GFP)/Pol expression plasmids) to 2.5 (transfer vector) delivered GFP 
protein and turboFP635 marker gene into 11.0 ± 2.8% and 74.9 ± 34.1% of target cells, respectively 
(Figure 15, ratio A). Increasing the relative amount of Gag-(GFP)/Pol expression constructs while 
reducing envelope expression plasmid and transfer vector amount, both protein and gene transfer 
efficiencies could be further improved, as demonstrated by detection of 31.7 ± 11.6% and 92.6 ± 6.4% 
(Figure 15, ratio B) or 55.2 ± 25.5% and 95.5 ± 3.8% (Figure 15, ratio C) GFP
+
 and Katushka
+
 
HT1080 cells, respectively. Thus, the amount of gag(-gfp)/pol packaging plasmids transfected into 
HEK-293T cells in the course of vector production positively correlated with the ability of the 
resulting PTV particles to mediate GFP protein transfer into target cells. 
Since vector particles assembled in packaging cells transfected with the ratio of 2.3 (packaging 
plasmids) to 0.5 (env expression plasmid) to 1.6 (transfer vector) mediated highest protein and gene 
delivery into transduced target cells (Figure 15, ratio C), this relative plasmid ratio was kept for further 
particle productions. MVwt-GP pseudotyped PTVs were generated likewise, only the amount of 
plasmid-DNA encoding VSV-G was distributed between H (37.5%) and F (62.5%) expression 
constructs as previously described (Funke et al., 2009). 
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Figure 15: Improvement of plasmid ratios for PTV 
production. HEK-293T cells were transfected with 
the indicated relative plasmid amounts and vector 
containing supernatant was harvested 2 d later. Vector 
particles were either directly used for transduction or 
further concentrated by ultracentrifugation through a 
20% sucrose cushion. Then, CHO-hSLAM cells were 
transduced by similar volumes of each vector. 
Transduction efficiency was determined by flow 
cytometric analysis of GFP fluorescence (4 h after 
transduction) and Katushka fluorescence (72 h after 
transduction). Black bars, GFP protein transfer; white 
bars, turboFP635 gene transfer. Mean ± SEM of n = 3 
experiments performed in triplicates are shown. 
Figure modified after Uhlig et al., 2015. 
 
3.1.3. Generation of HIV-1 packaging plasmids encoding different cargo proteins  
The production of PTVs was established using the reporter protein GFP (3.1.2). As presented in the 
preceding chapter, GFP provides an appropriate tool for the initial characterization of PTVs and their 
generation since it allows easy visualization of successful protein transfer. However, GFP does not 
allow discrimination between surface adhesion of vectors and incorporated cargo proteins to the cells 
and cytoplasmic protein transfer. Moreover, it is not designed for immunological studies. For those 
purposes, the use of either the recombinase Cre, which requires nuclear localization to exert its 
function and therefore can act as indicator for intracellular protein transfer, or the model antigen Ova 
was intended. Fusion of the cargo nucleotide sequence to matrix ensures packaging into PTVs as part 
of the Gag/Pol precursor but also sequesters the matrix-cargo fusion protein at the target cell 
membrane. However, free release of cargo proteins into the target cell’s cytosol is preferable for the 
named applications, i.e. transfer of Cre recombinases being active in the nucleus or model antigen 
ovalbumin requiring processing as cytoplasmic cellular content. As Gag/Pol is posttranslationally 
cleaved by the HIV-1 protease during maturation of budding particles, separation of cargo from matrix 
protein can be achieved by inserting an additional HIV-1 protease recognition site between the 
sequence of the antigen gene and matrix. This should result in free cytosolic release of the cargo 
protein without impairing packaging into the vector particles. Initially, the functionality of such an 
inserted artificial HIV-1 protease motif was tested for the marker protein GFP, again for reasons of 
easy visualization of unaffected cargo protein function and transfer into transduced target cells.   
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For that purpose, a HIV-1 packaging plasmid encoding matrix and GFP separated by a HIV-1 protease 
site was cloned based on the plasmid pcDNA3.gpGFP.4xCTE used before, coding for the matrix-GFP 
fusion protein within the gag open reading frame (ORF) (Figure 16). First, the 3’ end of matrix and a 
second fragment composed of the gfp gene and the 5’ end of capsid were amplified by PCR (2.2.1.5) 
using the primer pairs HIVgag-ClaI(+) / MA-Prot(-) and MA-Prot-GFP(+) / HIVgag-BaeI(-), 
respectively (see Table 10). Thereby, the oligonucleotides MA-Prot(-) and Prot-Ca(+) (Table 10) 
introduced the sequence of the additional HIV-1 protease site 3’ of matrix and 5’ of gfp. In a primer-
extension PCR (Horton et al., 1989) with the flanking primers HIVgag-ClaI(+) and HIVgag-BaeI(-) 
and both PCR fragments amplified in the first round serving as templates the entire cassette consisting 
of the 3’ end of matrix, the additional protease recognition site, gfp and the 5’ end of capsid was 
assembled. The PCR product was directly ligated into pCR2.1-TOPO (2.2.1.6) and the insert of the 
resulting plasmid pCR2.1HIV1_Ma_P_GFP was sequenced (2.2.1.9), confirming the absence of 
mutations. Then, pcDNA3.gpGFP.4xCTE and pCR2.1HIV1_Ma_P_GFP, both amplified in Dam 
methylation deficient E. coli GM2163, were digested with ClaI/PfoI and the insert of 
pCR2.1HIV1_Ma_P_GFP was cloned into the backbone of pcDNA3.gpGFP.4xCTE. The newly 
generated plasmid was named pcHIV1_MA_P_GFP.  
 
 
Figure 16: Schematic overview - 
generation of pcHIV1_MA_P_GFP. To 
obtain pcHIV1_MA_P_GFP, an additional 
HIV-1 protease cleavage site (P) was 
introduced between matrix (MA) and gfp in 
the gag ORF of the packaging plasmid 
pcDNA3.g/pGFP.4xCTE. CA, capsid. Color 
code: blue, capsid; brown, HIV-1 protease 
cleavage site; green, gfp; gray, plasmid 
backbone; salmon, matrix. For the sake of 
simplicity, the scheme shows only relevant 
cleavage sites of the enzymes, even if they 
are multiple cutters.  
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To enable examination of PTVs’ immunostimulatory properties, the coding sequence for model 
antigen ovalbumin was cloned within the gag ORF flanked by two HIV-1 protease recognition sites. 
For that purpose, the 3’ end of matrix and the 5’ end of capsid were amplified by PCR (2.2.1.5) using 
the template pcMV∆R8.9 and the primer pairs HIVgag-ClaI(+) / MA-Prot(-) and Prot-ClaI(+) / 
HIVgag-BaeI(-), respectively. The plasmid pET15b-Ova served as template for the PCR-amplification 
of the ovalbumin gene (using the primers pair MA-Prot-Ova(+) / CA-Prot-Ova(-), see Table 10), those 
3’ and 5’ end were elongated by the coding sequence of a HIV-1 protease cleavage site (introduced by 
primers). All three DNA fragments were subsequently fused by a primer-extension PCR (Horton et al., 
1989) using the flanking primers HIVgag-ClaI(+) / CA-Prot-Ova(-). The PCR product was ligated into 
pCR2.1-TOPO (2.2.1.6) and the resulting plasmid pCR2.1HIV1_MA_P_Ova was sequenced (2.2.1.9), 
confirming the absence of mutations. To allow directed subcloning, pCR2.1HIV1_MA_P_Ova was 
linearized with NsiI, dephosphorylated using Antarctic phosphatase (2.2.1.6) and elongated at its 3’ 
end by a 1.64 kb gag sequence derived from NsiI cleaved pcDNA3.gpGFP.4xCTE. The insert 
orientation of the resulting plasmid pCR2.1-gag-Ova.NsiI was determined by an analytical restriction 
with ClaI and SbfI (2.2.1.4). Plasmids with the desired insert orientation were digested with ClaI/SbfI 
and the excised sequence was transferred into pcDNA3.gpGFP.4xCTE to generate 
pcHIV1_MA_P_Ova. The complete cloning strategy is depicted in Figure 17. 
 
Results 
66 
 
 
Figure 17: Schematic overview - generation of pcHIV1_MA_P_Ova. pcHIV1_MA_P_Ova encodes matrix 
(MA)-fused Ova within the gag ORF. Ova is flanked by HIV-1 protease cleavage sites (P). CA, capsid. Color 
code: brown, HIV-1 protease cleavage site; dark gray, gag fragment; green, gfp; gray, plasmid backbone; light 
blue, capsid; salmon, matrix; yellow, ovalbumin. For the sake of simplicity, the scheme shows only relevant 
cleavage sites of the enzymes, even if they are multiple cutters.  
 
pcHIV1_MA_P_Cre, the expression plasmid encoding Gag-Cre/Pol with HIV-1 protease recognition 
sites flanking Cre, was generated by Johannes Reusch within his bachelor thesis at Paul-Ehrlich-
Institut, as described in his thesis (Reusch, 2013)  
 
To evaluate cargo protein expression by the newly cloned lentiviral packaging plasmids, the respective 
plasmids were transfected into HEK-293T cells (2.2.3.3, transfection with Lipofectamine
®
 2000). 
48 hours after transfection, cells were lysed (2.2.2.1) and lysates were subjected to Western Blot 
Results 
67 
 
analysis (2.2.2.3). Lysates of non-transfected cells and cells transfected with unmodified HIV-1 
gag/pol packaging plasmid served as negative controls whereas the lysate of HEK-293T transfected 
with a Cre expression plasmid represents a positive control. 
Figure 18 shows efficient expression of all cargo proteins encoded within the gag ORF by HEK-293T 
packaging cells. Thereby, GFP, Cre, and Ova were detected at the expected molecular weight of the 
cargo protein, i.e. 27 kDa, 38 kDa or 43 kDa, respectively, and as fusion with 55 kDa Gag-polyprotein 
or 17 kDa matrix, precisely as Gag-GFP (82 kDa) and matrix-GFP (44 kDa) (Figure 18A), Gag-Cre 
(93 kDa) and matrix-Cre (55 kDa) (Figure 18B) or Gag-Ova (98 kDa) (Figure 18C). Moreover, also 
degradation products of Cre were observed at approximately 30 kDa (Figure 18B). Of note, whereas in 
lysates of HEK-293T cells transfected with pcHIV1_MA_P_GFP free GFP was present, essentially no 
free GFP was detected in lysates of HEK-293T cells transfected with pcDNA3.g/p.4xCTE, not 
encoding the artificial HIV-1 protease motif between matrix and cargo.  
Thus, Western Blot analysis revealed efficient expression of GFP, Cre, and Ova cargo proteins by the 
packaging plasmids and functionality of the HIV-1 protease site introduced between MA and cargo. 
 
 
Figure 18: Expression of cargo proteins encoded within the gag ORF of HIV-1 packaging plasmids. HEK-
293T cells were left untransfected (-) or transfected with HIV-1 packaging plasmids encoding the indicated 
Gag(-Cargo)/Pol proteins. 48 h after transfection, cells were lysed and lysates were subjected to anti-GFP (A), 
anti-Cre (B) or anti-Ova (C) Western Blot analysis (upper panels) after normalization to total protein content 
visualized by anti-α-Tubulin Western Blot analysis (lower panels). Figure modified after Uhlig et al., 2015. 
 
3.1.4. Characterization of PTVs for antigen content, morphology and titers 
The previously cloned (3.1.3) gag-cargo/pol expression plasmids were used for production of 
MVwt-GP- or VSV-G-pseudotyped PTVs or PTVs devoid of envelope glycoproteins (2.2.4.3). 
Concentrated vector particles, purified by ultracentrifugation through a 20% sucrose cushion, were 
subsequently analyzed for cargo protein incorporation, cargo content, morphology, and infectious 
titers.  
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To assess if cargo proteins were packaged into PTV particles, purified PTV preparations were 
subjected to Western Blot analysis (2.2.2.3). As controls, respective turboFP635 gene transfer vectors, 
delivering no cargo proteins, were generated and analyzed in parallel.  
Matrix-GFP (44 kDa), GFP (27 kDa), Cre (38 kDa) or Ova (43 kDa) were detected in lysates of the 
respective PTVs in agreement with the expected molecular weights (Figure 19). Additionally, in 
lysates of Cre-transferring particles, degradation products of the recombinase were observed (Figure 
19C). The data demonstrate efficient particle-incorporation of cargo proteins and successful release of 
GFP, Cre or Ova by the HIV-1 protease in particles including the artificial HIV-1 protease motif 
between matrix and cargo (Figure 19B-D), but not of MA-GFP in particles lacking this motif (Figure 
19A).  
 
 
Figure 19: Efficient incorporation of cargo proteins into protein transfer vector particles. Concentrated 
PTVs were subjected to Western Blot analysis to detect incorporation of matrix-fused GFP (MA-GFP) (A), GFP 
(B), Cre (C) and Ova (D) into vector particles (upper panels) after normalization to p24 content (lower panels). 
Vectors were pseudotyped with VSV-G (VSV) or MVwt-GPs (MV), transferred cargo proteins are indicated after 
the slash. Gene transfer vectors (VSV/- and MV/-), delivering no cargo proteins, served as negative controls. 
Figure modified after Uhlig et al., 2015. 
 
Having shown incorporation of cargo proteins into PTV particles, in principle, we next aimed to 
quantify the amount of incorporated cargo protein. As cargo protein content was especially interesting 
for Ova-PTVs, enabling direct comparison of immune-stimulatory efficiencies of Ova-PTVs and 
particle-free, recombinant Ova protein, antigen content was assessed semiquantitatively for these PTV 
particles by Western Blot analysis (2.2.2.3) or by ELISA (2.2.2.4). When comparing equal volumes of 
vector lysates by Western Blot analysis, incorporation of different amounts of Ova in various PTVs 
was observed (Figure 20). VSV-G pseudotyped PTVs were characterized by a significantly lower Ova 
content than MVwt-GP pseudotyped or bald ones, i.e. particles possessing no envelope glycoproteins 
(Figure 20).  
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Figure 20: Determination of Ova content in PTV preparations by Western Blot analysis. PTVs devoid of 
envelope glycoproteins (bald, B) or pseudotyped with VSV-G (V) or MVwt-GPs (M) were produced, harvested, 
concentrated and purified by ultracentrifugation through a 20% sucrose cushion. Ova content of vectors was 
assessed by Western Blot analysis, comparing 0.2 µl PTV stocks to a decreasing concentration of recombinant 
Ova [ng].  
 
The findings of Western Blot analysis were confirmed by ELISA revealing the Ova content of VSV-
Ova-LVKatushka to be approximately 1.8 or 2.3 times less than of MVwt-Ova-LVKatushka or Bald-Ova-
LVKatushka particles, respectively (Table 20, first column). Interestingly, whereas Bald-Ova-LVKatushka 
and VSV-Ova-LVKatushka particles were characterized by a similar Ova content when related to p24 
content (Table 20, fourth column), the cargo content of MVwt-Ova-LVKatushka was about 1.8-fold lower. 
In contrast, when the Ova content was related to transducing units (t.u.) of the vectors, MVwt-Ova-
LVKatushka contained approximately 34 times more Ova than VSV-Ova-LVKatushka (Table 20, last 
column). Taken together, these data show that 1 ml vector stock contains some microgram Ova. 
Moreover, they indicate that the amount of cargo protein which can be transferred by a given PTV 
pseudotype is influenced by the selected normalization method (e.g. normalization by volume, p24 
content or transducing units).  
 
Table 20: Determination of Ova content in PTV preparations by ELISA. 
Vector µg Ova/ ml  µg p24/ ml t.u./ ml
c
 ng Ova/ µg p24 fg Ova/ t.u.
c
 
Bald-Ova-LVKatushka 
a
 67 395 - 169 - 
MVwt-Ova-LVKatushka 
a
 52 549 7.2 x 10
7
 95 723 
VSV-Ova-LVKatushka 
b
 29 172 1.4 x 10
9
 169 21 
a
 Mean value of two independent vector stocks. 
b
 Mean value of first and second harvest of one vector stock. 
c
 t.u., transducing unit. 
 
To analyze next whether incorporation of cargo proteins into lentiviral particles or introduction of a 
protease site between cargo and matrix affects particle morphology, HEK-293T cells were transfected 
to produce PTVs (2.2.4.3), fixed with 10% glutaraldehyde and handed to Anke Muth and Regina 
Eberle (Paul-Ehrlich-Institut), who performed EM analysis of ultrathin sections of PTVs produced by 
these cells. All particles were round, approximately 120 nm in diameter and characterized by a 
consistent core. Interestingly, MA-GFP-PTVs, GFP-PTVs, and the corresponding lentiviral gene 
transfer vectors were morphologically indistinguishable (Figure 21) and could also not be 
discriminated from Ova-transferring particles (data not shown). However, bald particles or particles 
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pseudotyped with VSV-G or MVwt-GPs, respectively, could be easily distinguished. As expected, no 
envelope glycoproteins were observed for bald particles (Figure 21 A), whereas a dense layer of 
regularly arranged spikes, presumably VSV-G, surrounded VSV-G pseudotyped particles (Figure 21B, 
presumed glycoproteins marked by arrows) and several, but compared to VSV-G pseudotyped 
particles significantly less, envelope protein complexes were detected for MVwt-GP pseudotyped 
particles (Figure 21C, surface proteins marked by arrows).  
Thus, EM revealed particle morphology to be independent from incorporation of cargo proteins or the 
presence of a HIV-1 protease motif between matrix and cargo but modulated by envelope 
glycoproteins. 
 
 
Figure 21: Electron microscopy of ultrathin sections of PTVs released by HEK-293T packaging cells. EM 
analysis of HEK-293T cell transfected with the respective expression plasmids to produce MA-GFP or GFP 
protein transfer vectors or lentiviral gene transfer vectors where no additional cargo protein was encoded within 
the gag ORF. Particles are either devoid of envelope proteins (bald, A) or pseudotyped by VSV-G (VSV, B) or 
MVwt H and F (MVwt, C). Arrows exemplarily mark envelope proteins or envelope protein complexes protruding 
from the particles’ surface. Scale bar, 100 nm (as indicated). Figure modified after Uhlig et al., 2015. 
 
As incorporation of cargo proteins into lentiviral vectors was shown to modulate the infectivity of 
vector preparations (Figure 13), titers of concentrated protein transfer vectors were determined and 
analyzed for cargo protein-specific differences. Vectors were titrated on CHO-hSLAM (2.2.4.4). As 
depicted in Figure 22, determined mean titers were similar within the pseudotypes for MVwt-
pseudotyped (MVwt-MA-GFP-LVKatushka: 6.6 x 10
7
 t.u./ml, MVwt-GFP-LVKatushka: 7.4 x 10
7
 t.u./ml, 
MVwt-Ova-LVKatushka: 8.1 x 10
7
 t.u./ml) or VSV-pseudotyped PTVs (VSV-MA-GFP-LVKatushka: 
4.0 x 10
9
 t.u./ml, VSV-GFP-LVKatushka: 4.5 x 10
9
 t.u./ml, VSV-Ova-LVKatushka: 3.3 x 10
9
 t.u./ml), 
respectively. Thus, GFP or Ova cargo proteins did not affect the vectors’ infectivity. 
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Figure 22: PTV titers. Lentiviral vectors transferring 
matrix-GFP fusion proteins (MA-GFP) or GFP and 
Ova proteins proteolytically separated from matrix, 
respectively, were generated by transient transfection 
of HEK-293T packaging cells. Vectors were 
concentrated by ultracentrifugation through a 20% 
sucrose cushion and CHO-hSLAM cells were 
transduced with serial dilutions of the first vector 
harvest. Gene transfer was assessed 72 hours after 
transduction by flow cytometric determination of 
Katushka expression. Titers were calculated 
according to the number of transduced cells. Mean ± 
SD of MVwt-Cargo-LVKatushka (n = 4) or VSV-Cargo-
LVKatushka (n = 3) preparations (first harvest) is shown. 
Statistical analysis by unpaired Student’s t-test. Ns, 
not significant. 
 
 
3.1.5. Targeted protein transfer of GFP into cell lines  
After identification of the optimal conditions to generate PTVs and their biochemical characterization, 
receptor-specificity of PTVs pseudotyped by MVwt-GPs or VSV-G should be analyzed. Similar to 
respective gene transfer vectors (Funke et al., 2009), PTVs pseudotyped by truncated MVwt-GPs 
should enter only cells expressing the main MVwt cell entry receptor SLAM or the newly identified 
EpR protein Nectin-4 (3.1.1). In contrast, VSV-G pseudotyped particles should be characterized by a 
broad tropism and allow “unspecific” protein transfer into nearly all mammalian cell types as they use 
the widely expressed LDL-R as receptor for cell entry (Finkelshtein et al., 2013).  
Receptor-specificity was determined on MV-receptor transgenic CHO cell lines, positive for either 
MVwt receptors SLAM or Nectin-4, MVvac receptor CD46 or no MV receptor in case of parental 
CHO-K1. Furthermore, vector preparations were tested on naturally SLAM expressing B95a and Raji 
B cell lines. Cells were transduced with MVwt-MA-GFP-LVKatushka or VSV-MA-GFP-LVKatushka at 
MOI 1 (titrated by gene transfer, see 2.2.4.4). MA-GFP protein and turboFP635 gene transfer, i.e. 
expression of the encoded Katushka protein, were analyzed by flow cytometry (2.2.3.8) four hours or 
72 hours after transduction, respectively.   
MVwt-MA-GFP-LVKatushka particles mediated parallel protein and gene transfer specifically into SLAM 
and Nectin-4 expressing cells, i.e. CHO-hSLAM, CHO-Nectin-4, B95a, and Raji cells, but not into 
CHO-K1 cells (Figure 23). Of note, despite efficient MA-GFP delivery, gene transfer was rather 
inefficient in CHO-Nectin-4 and B95a cells. Although CHO-CD46 remained Katushka-negative after 
transduction with MVwt-MA-GFP-LVKatushka, some minor background protein transfer was observed 
into this cell line. In contrast, VSV-MA-GFP-LVKatushka revealed an opposing pattern of transduction. 
Whereas the vector efficiently delivered the turboFP635 marker gene into CHO and Raji cells, as 
expected, hardly any MA-GFP transfer was detected upon transduction with the VSV-G pseudotyped 
vector particles at MOI 1 (Figure 23). In analogy with the results for MVwt-MA-GFP-LVKatushka, the 
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cotton-top tamarin cell line B95a was resistant to lentiviral gene transfer by VSV-MA-GFP-LVKatushka. 
Similar results were obtained using PTVs transferring released GFP instead of the MA-GFP fusion 
protein (data not shown). 
Concluding, protein and gene transfer mediated by MVwt-MA-GFP-LVKatushka particles depended 
mainly on the expression of the respective receptors SLAM and Nectin-4, whereas VSV-MA-GFP-
LVKatushka broadly transduced the cells irrespective of the presence of SLAM or Nectin-4.  
 
 
Figure 23: Assessment of PTVs’ receptor-specificity. Percentage of marker protein positive cells of a CHO 
cell panel expressing either no MV receptor (CHO-K1), MV vaccine strain receptor CD46 (CHO-CD46) or 
MVwt receptors (CHO-hSLAM and CHO-Nectin-4) or naturally SLAM-positive B95a and Raji cells after mock 
transduction (negative control, NC) or transduction with concentrated matrix-GFP protein transfer vectors at 
MOI 1 (titrated by gene transfer). PTVs were pseudotyped with MVwt-GPs (M) or VSV-G (V). MA-GFP protein 
and turboFP635 gene transfer were analyzed by flow cytometry 4 h or 72 h after transduction, respectively. 
Mean ± SEM of n = 3 experiments shown. Figure modified after Uhlig et al., 2015. 
 
As just shown, transduction with VSV-MA-GFP-LVKatushka barley resulted in any protein transfer 
whereas MVwt-MA-GFP-LVKatushka efficiently delivered cargo proteins (Figure 23). Due to the higher 
infectious titers of VSV-G pseudotyped vectors (Figure 22), less VSV-MA-GFP-LVKatushka than MVwt-
MA-GFP-LVKatushka particles were needed for transduction at MOI 1. Therefore, the question arose 
whether both pseudotypes possess the same ability to transfer proteins into their target cells when 
adapted to the same particle number. To tackle this question, MVwt receptor-negative CHO-K1 and 
SLAM-positive CHO-hSLAM or B95a cells were transduced with vector stocks normalized to 80 ng 
p24 and subsequently analyzed for protein and gene transfer by flow cytometry as described above. 
Under these conditions, remarkable MA-GFP protein transfer was also observed for VSV-G 
pseudotypes, which even outperformed SLAM-targeted transfer into CHO-hSLAM cells (Figure 24). 
However, protein transfer into B95a cells was still more efficient with MVwt-MA-GFP-LVs than using 
VSV-MA-GFP-LVs. This data set demonstrates the ability of VSV-G pseudotyped PTVs to efficiently 
transfer cargo proteins into transduced cells, given sufficient particles are supplied.  
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Figure 24: Assessment of protein transfer by 
PTVs normalized to p24 content. CHO cells 
expressing no MV receptor (CHO-K1) or 
MVwt receptor SLAM (CHO-hSLAM) and 
naturally SLAM
+
 B95a were mock transduced 
(negative control, NC) or transduced with 
concentrated matrix-GFP PTVs. Vectors were 
normalized to particle count (80 ng p24). PTVs 
were pseudotyped with MVwt-GPs (M) or 
VSV-G (V). MA-GFP protein and turboFP635 
gene transfer were analyzed by flow cytometry 
4 h or 72 h after transduction, respectively. N = 
1 experiment. 
 
3.1.6. Demonstration of cytoplasmic protein transfer 
Protein delivery mediated by MA-GFP-PTVs was assessed by GFP-fluorescence of target cells (3.1.5). 
However, this experimental setting did not discriminate between protein in MA-GFP-delivering 
particles attached to the cells’ surface or actual cytoplasmic protein transfer into the respective target 
cells. For this reason, intracellular protein delivery should be demonstrated by transduction of Cre 
indicator cell lines with PTVs transferring Cre recombinase. 
Cre recombinase recognizes so-called loxP sites, i.e. specific sequence stretches in double stranded 
DNA, and excises or inverts genetic information between a pair of these recognition sites depending 
their orientation (Sternberg and Hamilton, 1981; Hamilton and Abremski, 1984). Its activity can be 
visualized in indicator cells with expression cassettes for fluorescent proteins in between a pair of loxP 
sites within the cells’ genomes. If active Cre is present in these cells, the expression cassette is excised 
and the particular fluorescence is lost. However, Cre has to be active within the cells’ nucleus to excise 
the cassettes, thus Cre activity in transduced indicator cells demonstrates transfer of the recombinase 
by PTV particles into the cytosol of transduced cells and its subsequent nuclear translocation. 
A HIV-1 derived packaging plasmid encoding Cre recombinase within the Gag polyprotein was 
cloned within the Bachelor thesis of Johannes Reusch at Paul-Ehrlich-Institut (Reusch, 2013). The 
optimal ratio of gag/pol to gag-cre/pol to generate VSV-G pseudotyped Cre protein transfer vectors 
was identified with that work to be 2:1. Moreover, initial Cre protein transfer into HT1080-Cre cells 
had also been demonstrated with VSV-G pseudotyped vectors. However, HT1080-Cre cells do not 
express MVwt receptors.   
Therefore, another Bachelor thesis (Stefanie Kugelmann, Paul-Ehrlich-Institut; Kugelmann, 2013) 
focused on the generation of a Cre-indicator cell line panel derived from CHO-K1 (SLAM
-
), 
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CHO-hSLAM or Raji (both SLAM
+
). The parental cell lines of interest were transduced by a lentiviral 
gene transfer vector transferring a loxP-flanked expression cassette for cerulean blue-fluorescing 
protein (Figure 25A), a stabilized version of CFP (Rizzo et al., 2004). The resulting CHO-K1-blue, 
CHO-hSLAM-blue or Raji-blue single cell clones are fluorescing blue, but after activity of Cre 
recombinase in these cells, they lose their blue fluorescence. 
In the present thesis, CHO-K1-blue, CHO-hSLAM-blue or Raji-blue cells were transduced with 
MVwt-Cre-LVKatushka and VSV-Cre-LVKatushka PTVs transferring Cre at MOI 15 (titrated by gene 
transfer, see 2.2.4.4), respectively, or the cre gene transfer vector VSV-LVCre. High amounts of Cre 
itself are cytotoxic (Silver and Livingston, 2001). Therefore, the control vector was applied at MOI 10, 
only, as already with this vector dose cytotoxic effects could be observed (data not shown). Reduction 
of cerulean fluorescence was assessed by flow cytometry (2.2.3.8) two weeks after transduction, which 
was previously determined to be a suitable time point since it allowed metabolic degradation of 
cerulean protein produced before excision of the cerulean ORF (data not shown).  
Indeed, CHO-K1-blue and CHO-hSLAM-blue cells transduced with VSV-LVCre had nearly lost all 
blue fluorescence 14 days after transduction. Also the vast majority of Raji-blue cells (77.4%) were 
detected to be cerulean-negative 14 days after transduction with VSV-LVCre (Figure 25B). 
Transduction with VSV-Cre-LVKatushka induced cerulean-deficiency in a fraction of CHO-K1-blue, 
CHO-hSLAM-blue, and Raji-blue cells, whereas loss of cerulean fluorescence was confined to a 
fraction of the SLAM
+
 cell lines CHO-hSLAM-blue and Raji-blue following transduction with MVwt-
Cre-LVKatushka (Figure 25B). No fading of blue fluorescence was observed for MV-receptor negative 
CHO-K1-blue cells incubated with MVwt-Cre-LVKatushka (Figure 25B). Interestingly, a higher 
percentage of CHO-hSLAM-blue and Raji-blue indicator cells lost their cerulean fluorescence after 
transduction with MVwt-Cre-LVKatushka than with VSV-Cre-LVKatushka at the same MOI (Figure 25B), 
precisely 13.0% versus 3.0% of transduced CHO-hSLAM-blue cells, and 1.9% versus 0.8% of 
transduced Raji-blue cells (after subtraction of background seen in mock transduced cells), 
respectively. 
Concluding, the observed loss of blue fluorescence indicates excision of loxP-flanked cerulean OFR, 
which is catalyzed by Cre recombinase in the nucleus. Thus, the data argue for successful PTV 
mediated transfer of Cre into the cytosol of receptor-positive target cells, followed by its nuclear 
translocation. They prove the enzymatic activity of Cre to be conserved after release from viral 
particles. 
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Figure 25: Cytoplasmic Cre 
protein transfer into indicator 
cell lines. (A) Schematic 
representation of the cerulean 
expression cassette in the genome 
of Cre indicator cell lines. The 
ORF encoding blue-fluorescing 
cerulean marker protein is 
flanked by Cre recombinase 
recognition sequences (loxP), 
enabling specific excision of 
cerulean. WPRE, woodchuck 
hepatitis virus posttranscriptional 
regulatory element. (B) Cre 
protein delivery into indicator cell 
lines. The cerulean-expressing 
Cre indicator cell lines CHO-K1-
blue (SLAM
-
), CHO-hSLAM-
blue (SLAM
+
), and Raji-blue 
(SLAM
+
) were transduced with 
Cre-PTVs at MOI 15. 14 d after 
transduction, cerulean expression 
was analyzed by flow cytometry. 
Mock transduced cells (mock) or 
cells transduced with a Cre gene 
transfer vector (MOI 10) served 
as controls. One experiment out 
of n = 3 is shown. Figure 
modified after Uhlig et al., 2015. 
3.1.7. SLAM-dependent transfer of ovalbumin by PTVs 
One major aim of this thesis was the evaluation of PTVs’ suitability for vaccination purposes. To this 
end, the chicken egg white protein ovalbumin was chosen as model antigen. Similar as for MA-GFP- 
(3.1.5) or Cre-PTVs (3.1.6), ovalbumin-PTVs’ ability to strictly transduce MV receptor-positive cells 
should initially be analyzed using receptor-transgenic CHO and naturally SLAM-expressing B cell 
lines, again. Despite the small quantities of transferred protein (Figure 20B), detection of Ova in 
lysates of transduced target cells was attempted by Western Blot analysis (2.2.2.3). 
For this purpose, cells were transduced with Ova-PTVs at MOI 1 (titrated by gene transfer, 2.2.4.4). 
Three hours after transduction lysates were prepared (2.2.2.1.). In addition, some MVwt-Ova-LVKatushka 
transduced cells were washed with PBS and subsequently incubated with citric acid buffer for two 
minutes to remove potential surface-bound vector particles prior lysis. Beside Western Blot analysis to 
monitor protein delivery, transfer of the turboFP635 marker gene was assessed by flow cytometric 
detection of Katushka fluorescence 72 hours after transduction in cultures transduced in parallel 
(2.2.3.8). 
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Ova was detected in lysates of the SLAM-positive CHO-hSLAM, B95a or Raji cells transduced with 
MVwt-Ova-LVKatushka PTVs, irrespective of citric acid buffer treatment prior lysis, whereas only 
background Ova signals were observed in CHO-K1 or CHO-CD46 cells (Figure 26A). Accordingly, 
flow cytometry revealed turboFP635 gene transfer into SLAM-expressing cells in parallel, whereas no 
transduction of SLAM-negative cell lines was observed, as expected (Figure 26B). Gene transfer 
efficiency, though, varied between the cell lines. As described also before, especially B95a cells 
revealed a certain degree of resistance to gene transfer, independent of the pseudotype used for 
transduction. In contrast, no Ova became detectable in lysates of cells transduced with the same MOI 
of VSV-Ova-LVKatushka particles (Figure 26A), although successful turboFP635 marker gene delivery 
was observed into all VSV-Ova-LVKatushka transduced cells, except B95a (Figure 26B).  
Taken together, the data show receptor-dependent protein and gene delivery by MVwt-Ova-LVKatushka 
particles. Since citric acid buffer treatment prior lysis did not reduce the quantity of Ova detected in 
respective cell lysates, cytoplasmic protein transfer must have occurred, confirming the results of the 
Cre-transfer experiments (Figure 25B). VSV-Ova-LVKatushka mediated efficient gene transfer into 
transduced cells but Ova protein delivery was below the detection limit. 
 
 
Figure 26: Receptor-dependent ovalbumin transfer into cell lines. (A) Anti-OvaWestern Blot analysis of 
receptor-transgenic CHO cells or naturally SLAM-expressing B95a and Raji cells 3 h after mock transduction (-) 
or transduction with concentrated Ova-PTVs pseudotyped with VSV-G (V) or MVwt H and F (M) at MOI 1. MC, 
incubation of MVwt-Ova-LVKatushka transduced cells with citric acid buffer prior lysis to remove unspecifically 
surface-bound particles. (B) Gene transfer in cultures transduced in parallel to (A) and analyzed 72 h post 
transduction for Katushka expression. N = 2 independent experiments. Figure derived from Uhlig et al., 2015. 
 
3.1.8. Immunostimulatory properties of Ova-PTV-transduced mDCs ex vivo 
Ovalbumin protein transfer vectors were shown to successfully mediate receptor-dependent transfer of 
their cargo protein into transduced target cells in vitro (Figure 26). In a next step, the ability of Ova-
PTVs to stimulate antigen-specific CD4
+
 and CD8
+
 T lymphocytes by directed Ova transfer into APCs 
should be assessed ex vivo. For that purpose, myeloid dendritic cells (mDCs) were generated from 
bone marrow of IFNAR
-/-
 N20 C57BL/6 (short IFNAR
-/-
) and IFNAR
-/-
 SLAM
ki
 C57BL/6 (SLAM
ki
) 
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mice as described in 2.2.3.6. Thereby, IFNAR
-/-
 mice do not express any functional MV-receptors on 
immune cells such as APCs. In contrast, SLAM
ki
 mice are characterized by a replacement of the V 
domain of murine SLAM by the V domain of human SLAM, which renders the chimeric protein a 
functional receptor for MVwt H (Ohno et al., 2007). mDCs were transduced with Ova-transferring 
PTVs and subsequently co-cultured with CD8
+
 (OT-I) or CD4
+
 (OT-II) Ova-specific T cells (2.2.3.6), 
obtained from TCR-transgenic mice (see 2.2.5.7 and 2.2.3.5). Later, co-culture supernatants were 
sampled and release of IL-2 and IFN-γ, amongst others secreted by CD4+ and CD8+ T cells upon 
activation (Schoenborn and Wilson, 2007; Boyman and Sprent, 2012), was quantified by ELISA 
(2.2.2.4). The experimental design is schematically depicted in Figure 27. 
 
 
Figure 27: Schematic depiction of the experimental set-up to determine the immunostimulatory properties 
of Ova-PTVs ex vivo. Bone marrow from IFNAR
-/-
 or SLAM
ki
 mice was isolated and used for generation of 
myeloid dendritic cells (mDCs). mDCs were activated by addition of 100 ng/ml LPS overnight (o/n), and then 
incubated with PTVs at MOI 1 or 3. After 4 h, the vectors were removed and Ova-specific CD8
+
 OT-I or CD4
+
 
OT-II T cells were added to the mDCs. 24 h or 72 h later, co-culture supernatants were sampled for the 
quantification of IL-2 and IFN-γ by ELISA. Figure modified after Uhlig et al., 2015. 
 
3.1.8.1. Analysis of APC co-stimulation by Ova-PTVs 
Viral components are known to provide “danger signals” to antigen presenting cells (Mak and 
Saunders, 2006) which are a prerequisite for the activation of APCs and thus the induction of immune 
responses. To assess the co-stimulatory capacity of Ova-PTVs (which are, structurally, viral particles) 
on APCs, mDCs were transduced with PTVs at MOI 3 and expression of CD69 and CD86, described 
to be upregulated on activated dendritic cells (Schülke et al., 2010), was analyzed by flow cytometry 
(2.2.3.8) 24 hours after transduction. Transduction of mDCs with PTVs neither led to upregulation of 
CD69 nor CD86 on the cells’ surfaces (Figure 28). In contrast, addition of LPS, a strong maturation 
stimulus, induced CD86 expression on mDCs (Figure 28), as expected. This effect was also not 
enhanced by presence of PTVs. Thus, no indication of a co-stimulatory effect of Ova-PTVs on APCs 
was found when analyzing CD69 and CD86 expression on mDCs. 
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Figure 28: Absence of DC co-stimulation by Ova-PTVs. Bone marrow-derived mDCs (pretreated with 
100 ng/ml LPS prior transduction where indicated) were incubated with PTVs at MOI 3 for 4 h. 24 h post 
transduction, expression of CD69 and CD86 in the CD11c
+
 dendritic cells population were analyzed by flow 
cytometry. One representative donor out of n = 5 (IFNAR
-/-
) or n = 6 (SLAM
ki
) is shown. Figure modified after 
Uhlig et al., 2015.   
 
3.1.8.2. Activation of Ova-specific CD8+ OT-I T cells by Ova-PTV transduced mDCs 
To determine whether Ova-PTV-transduced mDCs stimulate Ova-specific CD8
+
 T cells, the co-culture 
experiment outlined before (3.1.8) was performed with T lymphocytes isolated from OT-I C57BL/6 
mice. As already mentioned, these mice are TCR-transgenic; all CD8
+
 T cells recognize the 
SIINFEKL-peptide of ovalbumin (Ova257-264) when presented via MHC I. Upon activation T cells 
secrete IL-2 and IFN-γ.  
IL-2 and IFN-release by CD8+ T cells was exclusively induced by IFNAR-/- mDCs which had been 
preincubated with recombinant Ova protein or transduced with VSV-Ova-LVKatushka, but not with 
Bald-Ova-LVKatushka, MVwt-Ova-LVKatushka, or the GFP-transferring vectors VSV-GFP-LVKatushka or 
MVwt-GFP-LVKatushka (Figure 29A and B). Also SLAM
ki
 mDCs stimulated secretion of IL-2 and 
IFN- by OT-I T cells following preincubation with recombinant Ova protein or after transduction 
with VSV-Ova-LVKatushka (Figure 29A and B). Besides, activation of CD8
+
 Ova-specific T cells was 
triggered by MVwt-Ova-LVKatushka-transduced SLAM
ki
 mDCs in a MOI-dependent manner (Figure 
29B). Fusion inhibiting peptide FIP (Richardson et al., 1980) abolished IL-2 secretion in this setting 
(Figure 29C). Of note, SLAM
ki
 mDCs transduced with MVwt-Ova-LVKatushka induced similar IL-2 and 
IFN-secretion by CD8+ T cells as mDCs preincubated with 50 µg recombinant Ova protein, although 
only approximately 230 ng Ova were delivered by MVwt-Ova-LVKatushka at MOI 1 (Figure 29A and B). 
Moreover, IL-2 and IFN-γ production detected in co-cultures of IFNAR-/- or SLAMki mDCs 
transduced with VSV-Ova-LVKatushka (corresponding to approximately 7 ng Ova) even exceeded the 
amounts of secreted cytokines in protein-stimulated cultures (Figure 29A and B).  
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Taken together, these data argue for highly receptor-dependent transduction and glycoprotein-
mediated transfer of antigens into the cytosol of mDCs by targeted PTVs, followed by proteasomal 
processing and MHC I presentation via the endogenous antigen presentation pathway. Thereby, 
pseudotyped Ova-PTV particles were able to induce similarly strong stimulation of CD8
+
 Ova-specific 
T cells as triggered by 50 µg recombinant ovalbumin in the same setting, although delivering 
approximately 220- (MVwt-Ova-LVKatushka) to 7150-times (VSV-Ova-LVKatushka) less Ova protein. Bald 
particles, where the antigen is supposed to be absorbed via the endosomal route and presented on 
MHC II molecules, did not cause activation of CD8
+
 OT-I T lymphocytes, as expected.  
 
 
Figure 29: IL-2 and IFN-γ secretion by ovalbumin-specific CD8+ OT-I T cells after incubation with ex vivo 
transduced mDCs or untransduced mDCs in the presence of recombinant Ova. mDCs were transduced with 
GFP- or Ova-PTVs pseudotyped with MVwt-GPs (MV) or VSV-G (VSV) at MOI 1 or 3 (indicated by numbers 1 
and 3). Alternatively, mDCs were incubated with particles harboring no envelope glycoproteins (bald), which 
were adjusted to MVwt-Ova-LVKatushka by p24 values, or recombinant Ova (Ova). Secretion of IL-2 (A and C) or 
IFN-γ (B) by CD8+ Ova-specific T cells in co-culture with these mDCs was determined by ELISA. One 
representative experiment out of four (A and B) or two (C) is shown. Experiments was performed in triplicates 
or quadruplicates with each technical replicate depicted as a single dot. (C) IL-2 secretion by CD8
+
 T cells in co-
culture with mDCs transduced by MVwt-Ova-LVKatushka (MV/Ova) in normal culture medium, - or medium 
supplemented with Fusion inhibiting peptide (FIP), +. Statistical analysis by two-tailed unpaired Student’s t-test. 
*, **, ***, **** indicate P<0.05, P<0.01, P<0.001, and P<0.0001, respectively. Panels A and B modified after 
Uhlig et al., 2015. 
 
3.1.8.3. Activation of Ova-specific CD4+ OT-II T cells by Ova-PTV transduced mDCs 
Next, the potency of Ova-PTV-transduced mDCs to activate Ova-specific CD4
+
 T cells was evaluated 
in the experimental system outlined before (3.1.8). Here, IL-2 and IFN-γ secretion by Ova-specific 
CD4
+
 T cells was most vigorously induced by IFNAR
-/-
 and SLAM
ki
 mDCs incubated with soluble, 
recombinant Ova or Bald-Ova-LVKatushka particles devoid of envelope glycoproteins (Figure 30). Also 
MVwt-Ova-LVKatushka-transduced mDCs stimulated cytokine secretion by Ova-specific CD4
+
 T cells. 
This effect was particularly strong when MV-receptor-negative IFNAR
-/-
 mDCs were incubated with 
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MVwt-Ova-LVKatushka vector particles before co-cultivation with OT-II T cells (Figure 30). However, in 
contrast to CD8
+
 T cell activation by mDCs transduced with VSV-Ova-LVKatushka (Figure 29A and B), 
CD4
+
 T cells in co-culture with IFNAR
-/-
 or SLAM
ki
 mDCs transduced with VSV-Ova-LVKatushka did 
not secrete detectable levels of IL-2 or IFN-γ (Figure 30). 
Thus, CD4
+
 T cells are mainly stimulated by mDCs which have internalized Ova in a receptor-
independent manner. When no cell entry receptors are present, PTV-associated Ova is presumably 
taken up by mDCs via the endosomal route, leading to MHC-II presentation via the exogenous antigen 
presenting pathway which enables antigen-recognition by Ova-specific CD4
+
 T cells. 
 
 
Figure 30: Activation of CD4
+
 Ova-specific OT-II T cells after incubation with ex vivo transduced mDCs 
or untransduced mDCs in the presence of recombinant Ova. mDCs were transduced with GFP- or Ova-PTVs 
pseudotyped with MVwt-GPs (MV) or VSV-G (VSV) at MOI 1 or 3 (indicated by numbers 1 and 3). 
Alternatively, mDCs were incubated with particles harboring no envelope glycoproteins (bald), which were 
adjusted to MVwt-Ova-LVKatushka by p24 values, or recombinant Ova (Ova). Activation of CD4
+
 T cells was 
measured as secretion of IL-2 (A) or IFN-γ (B) by ELISA. One representative experiment out of two is shown 
(n = 2). Experiments was performed in triplicates or quadruplicates with each technical replicate depicted as a 
single dot. Statistical analysis by two-tailed unpaired Student’s t-test. Ns, *, ***, **** indicate not significant, 
P<0.05, P<0.001, and P<0.0001, respectively. Figure modified after Uhlig et al., 2015. 
 
3.1.9. Vaccination with Ova-PTVs  
mDCs transduced with Ova-PTVs were shown to be potent activators of Ova-specific CD8
+
 T 
lymphocytes in ex vivo co-culture experiments (Figure 29A and B). Next, Ova-PTVs’ ability to 
stimulate antigen-specific, cytotoxic T cells should be assessed also in vivo. For this purpose, 6-8 
weeks old IFNAR
-/-
 and SLAM
ki
 mice were vaccinated (2.2.5.6), following the scheme depicted in 
Figure 31. Briefly, the animals were intraperitoneally inoculated with medium (mock), 1 µg 
recombinant Ova or vector stocks normalized to a content of 1 µg ovalbumin at day 0 (prime) and day 
28 (boost). Control vector MVwt-GFP-LVKatushka, not transferring Ova but GFP, was adjusted to p24 
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content of MVwt-Ova-LVKatushka. After sacrificing the animals four days after boosting, spleens were 
harvested and splenocytes isolated (2.2.5.7). IFN-γ secretion of Ova-specific T cells was quantified by 
ELISpot (2.2.3.7) after recall using recombinant Ova, Ova257- 264 or Ova323-339, the MHC I and MHC II-
restricted immunodominant peptide epitopes of ovalbumin, respectively.  
 
 
Figure 31: Experimental immunization scheme. Mice were intraperitoneally injected with different 
experimental vaccines and boosted 28 d after priming. 4 d after boosting, mice were sacrificed and splenocytes 
were isolated. The number of antigen-specific T cells among splenocytes of vaccinated mice was determined by 
IFN-γ ELISpot analysis. Figure modified after Uhlig et al., 2015.  
 
Splenocytes from IFNAR
-/-
 mice immunized with VSV-Ova-LVKatushka contained a significant number 
of activated, IFN-γ releasing cells (685.9 ± 750.8 reactive T cells/ 106 splenocytes after restimulation 
with Ova), but no or hardly any IFN-γ secreting splenocytes were obtained from IFNAR-/- mice 
injected with Opti-MEM (mock), recombinant Ova, Bald-Ova-LVKatushka, MVwt-GFP-LVKatushka or 
MVwt-Ova-LVKatushka (Figure 32A). In splenocytes isolated from SLAM
ki
 mice vaccinated with Bald-
Ova-LVKatushka (101.0 ± 118.0 reactive T cells/ 10
6
 splenocytes after restimulation with Ova), 
MVwt-Ova-LVKatushka (212.8 ± 288.2 reactive T cells), or VSV-Ova-LVKatushka (121.4 ± 134.9 reactive T 
cells) IFN-γ secreting T cells were abundant, whereas no IFN-γ producing T cells were found in 
splenocytes from the other experimental SLAM
ki
 mouse cohorts (Figure 32B). Of particular note, 
IFN-γ secretion of splenocytes derived from both vaccinated IFNAR-/- and SLAMki mice was not 
influenced by the stimuli used for antigen-specific recall (Figure 32). 
 
To assess why T cell reactivity was unaffected by the stimuli used for recall, frozen splenocytes from 
vaccinated mice were thawed, pooled according to vaccine and separated into untouched pan T cells 
and the APC-containing retentate by magnetic cell sorting (MACS, see 2.2.3.5). The purified T cells 
were incubated in medium lacking IL-2 overnight to tranquilize the potentially activated cells. Then, T 
lymphocytes were co-cultured with syngeneic mDCs, which had been generated from bone marrow 
cells of previously untreated IFNAR
-/-
 or SLAM
ki
 mice (2.2.3.6), in the presence of recombinant Ova, 
Ova257- 264 or Ova323-339, or murine JAWSII cells, transgenic for ovalbumin (JAWSII-Ova) (Bodmer, 
2015), or not (JAWSII). Ova-specific T cells activation was assessed by IFN-γ-ELISpot analysis 
(2.2.3.7). 
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Figure 32: IFN-γ secretion by 
splenocytes from PTV-vaccinated 
mice. IFNAR
-/-
 (A) or SLAM
ki
 (B) mice 
were injected with Opti-MEM (mock), 
recombinant ovalbumin (rOva), Bald-
Ova-LVKatushka (Bald/Ova), MVwt-GFP-
LVKatushka (MV/GFP), MVwt-Ova-
LVKatushka (MV/Ova) or VSV-Ova-
LVKatushka (VSV/Ova) according to the 
immunization scheme depicted in Figure 
31. Splenocytes were freshly isolated 
from vaccinated animals and subjected 
to ELISpot analysis to determine the 
number of IFN-γ secreting, stimulated T 
cells among splenocytes. For antigen-
specific recall, recombinant Ova protein 
(Ova) or immunodominant Ova-peptides 
for induction of CD4
+
 or CD8
+
 T cell 
responses, Ova323-339 or Ova257-264, 
respectively, were added. Plain medium 
(negative control, -) and Concanavalin A 
(positive control, ConA) served as 
controls. > indicates a spot count > 1100. 
Results are expressed as mean ± SEM of 
5-6 individual animals (n = 5-6) 
measured in triplicates. Statistical 
analysis by Mann-Whitney-test 
(unpaired values between different 
animal groups) or Wilcoxen-test (paired 
values of one animal group). Ns, not 
significant; **, P<0.01. Figure derived 
from Uhlig et al., 2015. 
 
 
Similarly to freshly isolated splenocytes (Figure 32A), purified T cells from IFNAR
-/-
 mice immunized 
with VSV-Ova-LVKatushka secreted IFN-γ in co-culture with pulsed, syngeneic mDCs. Of note, the 
pronounced IFN-γ release by these T cells was triggered by syngeneic mDCs pulsed with Ova (303.3 
± 187.7 reactive T cells/ 10
6
 T cells) and Ova257-264 (446.7 ± 156.3 reactive T cells/ 10
6
 T cells), but 
was not evoked when recall was performed with Ova323-339-loaded mDCs (Figure 33A, compare to 
IFN-γ secretion of T cells co-cultured with syngeneic mDCs in the absence of antigen). In contrast, no 
or hardly any IFN-γ releasing T cells were detected in co-cultures of pulsed, syngeneic mDCs with T 
lymphocytes from the other experimental groups, i.e. IFNAR
-/-
 mice injected with Opti-MEM (mock), 
recombinant Ova, Bald-Ova-LVKatushka, MVwt-GFP-LVKatushka or MVwt-Ova-LVKatushka (Figure 33A). 
Also purified T cells obtained from vaccinated SLAM
ki
 mice injected with Opti-MEM, recombinant 
Ova, Bald-Ova-LVKatushka, and MVwt-GFP-LVKatushka did not release IFN-γ when co-incubated with 
pulsed, syngeneic mDCs (Figure 33B). Interestingly, pulsed, syngeneic mDCs induced IFN-γ 
secretion by T cells derived from MVwt-Ova-LVKatushka-vaccinated SLAM
ki
 mice but, again, no 
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correlation between T cell activation and the stimuli used for recall was observed (Figure 33B). In 
contrast, T cells from VSV-Ova-LVKatushka-vaccinated SLAM
ki
 mice were clearly stimulated by Ova257-
264-loaded mDCs (276.7 ± 20.8 reactive T cells/ 10
6
 T cells) but not by mDCs pulsed with recombinant 
Ova or Ova323-339 (Figure 33B).  
 
 
Figure 33: IFN-γ secretion by purified 
T cells in co-culture with antigen-
pulsed syngeneic mDCs. IFNAR
-/-
 (A) 
or SLAM
ki
 (B) mice were injected with 
Opti-MEM (mock), recombinant 
ovalbumin (rOva), Bald-Ova-LVKatushka 
(Bald/Ova), MVwt-GFP-LVKatushka 
(MV/GFP), MVwt-Ova-LVKatushka 
(MV/Ova) or VSV-Ova-LVKatushka 
(VSV/Ova) according to the 
immunization scheme depicted in Figure 
31. Splenocytes were harvested, pooled 
and untouched T cells were isolated by 
magnetic cell separation using a Pan T 
cell isolation Kit. The next day, T cells 
were co-incubated with mDCs generated 
from non-vaccinated syngeneic mice 
pulsed with recombinant Ova protein 
(Ova) or immunodominant Ova-peptides 
for induction of CD4
+
 or CD8
+
 T cell 
responses, Ova323-339 or Ova257-264, 
respectively. mDCs incubated with plain 
medium (negative control, -) and 
Concanavalin A (positive control, ConA) 
served as controls. The number of IFN-γ 
secreting, stimulated T cells was 
determined by IFN-γ ELISpot. > 
indicates a spot count > 550. Mean ± 
SEM of triplicate values shown. 
Statistical analysis by unpaired Student’s 
t-test. Ns, *, **, ***, **** indicate not 
significant, P<0.05, P<0.01, P<0.001, 
and P<0.0001, respectively. Figure 
modified after Uhlig et al., 2015. 
 
 
Incubation of purified T cells from vaccinated IFNAR
-/-
 or SLAM
ki
 mice with unmodified JAWSII 
dendritic cells did not induce IFN-γ secretion by T cells (Figure 34). Similar to Ova-pulsed syngeneic 
mDCs (Figure 33A), also transgenic JAWSII-Ova cells triggered only activation of T cells from 
IFNAR
-/-
 mice injected with VSV-Ova-LVKatushka (Figure 34A). For most vaccine groups, this pattern 
was also found for T cells from vaccinated SLAM
ki
 mice incubated with JAWSII-Ova cells (Figure 
34B). However, in addition to VSV-Ova-LVKatushka-treated animals, also T cells from MVwt-Ova-
LVKatushka-injected SLAM
ki
 mice seemed to be activated in co-culture with JAWSII-Ova (Figure 34B), 
although statistical significance was not reached. 
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Figure 34: IFN-γ secretion by murine T cells in co-culture with antigen presenting dendritic cells. 
Splenocytes of IFNAR
-/-
 (A) or SLAM
ki
 (B) mice injected with Opti-MEM (mock), recombinant ovalbumin 
(rOva), Bald-Ova-LVKatushka (Bald/Ova), MVwt-GFP-LVKatushka (MV/GFP), MVwt-Ova-LVKatushka (MV/Ova) or 
VSV-Ova-LVKatushka (VSV/Ova) were harvested, pooled and untouched T cells were isolated using a Pan T cell 
isolation Kit. The following day, T cells were co-incubated with JAWSII dendritic cells (NC) or JAWSII 
dendritic cells genetically engineered to express ovalbumin (JAWSII-Ova; Ova). IFN-γ secreting, stimulated T 
cells were determined by IFN-γ ELISpot. Mean ± SEM of triplicates shown. Statistical analysis by two-tailed 
unpaired Student’s t-test. **, P<0.01; ***, P<0.001. Figure modified after Uhlig et al., 2015. 
 
After investigating if the observed recall-independent IFN-γ secretion by splenocytes derived from 
certain groups of PTV-vaccinated mice (Figure 32) was a result of persistent T cell activation, it 
should be assessed if also long-lasting antigen-presentation by APCs might have played a role.  
For this purpose, the APC-containing retentate fraction of splenocytes after MACS separation was co-
cultured with freshly isolated splenocytes from C57BL/6 mice (no Ova-specific T cells), OT-I mice 
(CD8
+
 Ova-specific T cells) or OT-II mice (CD4
+
 Ova-specific T cells). OT-I and OT-II T cells’ Ova-
specific reactivities were confirmed in co-culture with JAWSII-Ova cells, in parallel (data not shown). 
IFN-γ-ELISpot analysis revealed activation of at least OT-I splenocytes incubated with the APC-
containing retentate from VSV-Ova-LVKatushka-immunized IFNAR
-/-
 mice (Figure 35A). 
 
Taken together, vaccine experiments indicate preferential induction of antigen-specific, cytotoxic T 
cell responses by APCs transduced with Ova-transferring PTVs in a receptor-dependent manner. 
APCs seem to present PTV-delivered Ova over several days, which favoured persistent stimulation of 
T cells, accounting for the initially observed stimulation-independent IFN-γ secretion by freshly 
isolated splenocytes from IFNAR
-/-
 mice injected with VSV-Ova-LVKatushka and SLAM
ki
 mice 
immunized with VSV-Ova-LVKatushka, MVwt-Ova-LVKatushka or Bald-Ova-LVKatushka. 
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Figure 35: IFN-γ secretion by splenocytes co-cultivated with APCs isolated from PTV-vaccinated mice. 
Splenocytes of IFNAR
-/-
 (A) or SLAM
ki
 (B) mice injected with Opti-MEM (mock), recombinant ovalbumin 
(rOva), Bald-Ova-LVKatushka (Bald/Ova), MVwt-GFP-LVKatushka (MV/GFP), MVwt-Ova-LVKatushka (MV/Ova) or 
VSV-Ova-LVKatushka (VSV/Ova) were harvested, pooled and fractioned into pan T cells and the APC-containing 
retentate by magnetic cell sorting. The APC-containing retentate was then co-cultured with splenocytes derived 
from C57BL/6 (BL/6) or OT-I or OT-II mice, characterized by no, CD8
+
 or CD4
+
 Ova-specific T cells, 
respectively. The number of stimulated T cells was determined by IFN-γ ELISpot. The experiment was 
performed in triplicates, mean ± SEM are shown. Figure modified after Uhlig et al., 2015. 
 
3.2. Targeted gene transfer into CD4+ T lymphocytes 
3.2.1. Generation of a CD4-targeted vector 
In this thesis, a CD4-specific targeting vector should be generated based on the highly flexible 
targeting system introduced by Funke et al. (Funke et al., 2008). Here, the CD4-specific DARPin 29.2, 
which was kindly provided by Prof. Trkola, University of Zurich, was employed as binding domain. 
The protein was described to specifically interact with human CD4 without provoking detectable 
effects on cell viability and stimulation (Schweizer et al., 2008). In the course of an internship in the 
Buchholz lab at Paul-Ehrlich-Institut, Christian Osterburg PCR-amplified the coding sequence of the 
CD4-specific DARPin 29.2 and cloned it into the pCG-Hmut backbone (encoding the cytoplasmic tail-
truncated Hmut protein Funke et al., 2008) via SfiI/NotI. The resulting plasmid pCG-H-αCD4, 
encoding MVNse-derived HmutΔ18 fused to the DARPin 29.2 (Figure 36A), was used in this thesis for 
the generation of CD4-LV. 
Surface expression of envelope glycoproteins on packaging cells is required to ensure their 
incorporation into lentiviral particles. To assess the surface expression of H-αCD4, HEK-293T cells 
were seeded in 6-well plates and transfected with 5 µg pCG-H-αCD4 or 5 µg pCG-1, the empty 
expression plasmid, which served as negative control. 48 hours later, cells were subjected to flow 
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cytometric analysis. 77.9% of transfected HEK-293T cells stained positive for histidine-tagged 
H-αCD4, demonstrating strong surface expression of H-αCD4 in packaging cells (Figure 36B).  
 
 
Figure 36: Characterization of CD4-LV. (A) Schematic depiction H-αCD4. The natural receptor tropism of 
MVNse hemagglutinin (H) is ablated by four point mutations in the ectodomain (ED), as indicated by asterisks, 
and the CD4-specific Designed Ankyrin Repeat Protein 29.2 (CD4-DARPin) is fused to the C-terminus of Hmut. 
A histidine tag (6 His) is located at the DARPin’s C-terminus. N-terminal truncation of the cytoplasmic tail of 
Hmut by 18 amino acids (CTΔ18) allows stable incorporation into lentiviral particles. TM indicates the 
transmembrane domain. (B) Surface expression of H-αCD4. HEK-293T cells were transfected with pCG-H-
αCD4 (black line) or the empty expression plasmid pCG-1 (gray area). 48 h after transfection, cells were stained 
with anti-His-PE antibody and subsequently analyzed by flow cytometry. One representative experiment out of 
n = 3 shown. (C) Incorporation of H-αCD4 and F into lentiviral particles. To assess the incorporation of H-αCD4 
and F into lentiviral particles, concentrated CD4-LV was subjected to Western Blot analysis using antibodies 
against H, F and p24. MVwt-LV, displaying no additional binding domain, was used as control. (D) Average titer 
of concentrated CD4-LV. CD4-LV containing supernatant of HEK-293T packaging cells was harvested, 
concentrated and titers were determined on Molt4.8 cells (n = 11). Error bars represent mean ± SD. Panels A-C 
derived from Zhou et al., 2015. 
 
Incorporation of the engineered MV envelope glycoproteins H-αCD4 and F into LV particles was 
examined by Western Blot analysis. To generate the resulting CD4-LV particles, HEK-293T cells 
were transfected with pCMVΔR8.9 (packaging plasmid), pS-luc2-GFP-W (transfer vector encoding 
firefly luciferase and sfGFP), pCG-FcΔ30 and pCG-H-αCD4 (MV Env encoding plasmids) as 
described in 2.2.4.3. H and F expression plasmids were employed in the ratio of 1:5, which resulted in 
high titer stocks (data not shown). Vector-containing supernatant was concentrated by 
ultracentrifugation through a 20% sucrose-cushion and concentrated CD4-LV was loaded on a SDS-
polyacrylamide gel. MVwt-LV served as a positive control. The membrane was probed for H, F and 
HIV-1 p24. HwtΔ18 was detected at approximately 75 kDa according to its expected molecular weight 
(Funke et al., 2008), whereas H-αCD4 resulted in a signal at about 90 kDa, reflecting the fusion of 
HmutΔ18 with the CD4-specific DARPin 29.2 (Figure 36C). MV-GPs were efficiently incorporated 
into MVwt-LV and CD4-LV particles, respectively. However, albeit detecting similar amounts of F, 
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CD4-LV was reproducibly characterized by a lower H and higher p24 content than MVwt-LV. This 
might either reflect less incorporation of H-αCD4 into vector particles compared to Hwt or be due to a 
steric blocking effect of the DARPin on the antibody epitope. 
Finally, the titer of concentrated CD4-LV was assessed on Molt4.8 leukemia cells. The mean titer of 
11 concentrated preparations was 2.3 ± 1.8 x 10
8
 t.u./ml (Figure 36D).  
3.2.2. Specificity of CD4-LV 
As the biochemical characterization of H-αCD4 expression in HEK-293T packaging cells and its 
incorporation into CD4-LV provided satisfactory results (3.2.1), the specificity of CD4-LV for its 
target receptor was tested on cell lines in the next step. To this end, Molt4.8 and Raji cells were 
separately transduced with CD4-LVLuc,GFP at MOI 1. Molt4.8 is a human T cell line, expressing both 
CD4 and CD8. In contrast to that, the human Burkitt’s lymphoma cell line Raji is negative for CD4. 
Three days after transduction, the percentage of transduced, GFP-expressing cells was measured by 
means of flow cytometry. Flow cytometry revealed exclusive transduction of CD4
+
 but sparing of 
CD4
-
 cells (Figure 37A). This speaks for the high specificity of CD4-LV for its target receptor CD4 on 
cell lines.   
Moreover, the specificity of CD4-LV was assessed in human PBMC consisting of a naturally mixed 
population of CD4
+
 and CD4
-
 primary human T lymphocytes. For that purpose, human PBMC were 
isolated from buffy coats by density centrifugation using Histopaque
®
-1077 and T cells were 
subsequently activated by anti-CD3 and anti-CD28 antibodies and 100 IU/ml IL-2 (2.2.3.4). Using this 
stimulation approach, the vast majority of PBMC is composed of CD3
+
 T cells after three days of 
incubation. These cells were then transduced with CD4-LVLuc,GFP at MOI 1. Three days later, the 
percentage of GFP
+
/CD4
+
 and GFP
+
/CD4
-
 cells was evaluated by flow cytometry. As shown in Figure 
37B, CD4-LV exclusively transduced CD4
+
 but not CD4
-
 T cells. Transduction efficiency on CD4
+
 T 
cells was determined with 39.0 ± 11.9% for n = 6 donors and was dependent on the respective donor. 
Concluding, CD4-LV displayed high selectivity for its target receptor also on primary cells. 
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Figure 37: Specificity of CD4-LV. (A) Specificity of 
CD4-LV on cell lines. CD4
-
 Raji and CD4
+
 Molt4.8 
cells were separately transduced with CD4-LVLuc,GFP 
(MOI 1) or left untransduced (ut). The percentage of 
GFP-expressing cells was determined by flow 
cytometry 3 d after transduction. (B) Specificity of 
CD4-LV on primary PBMC. Buffy coat-derived 
human PBMC were stimulated with anti-CD3/CD28 
antibodies and recombinant human IL-2 for 3 d before 
transduction with CD4-LVLuc,GFP (MOI 1). 
Untransduced cells (ut) represent the negative control. 
The percentage of GFP
+
 cells was determined by flow 
cytometry 3 d after transduction. Surface expression 
of CD4 was visualized by staining with an APC-
conjugated antibody directed against human CD4. 
One representative donor out of six (n = 6) is shown. 
Panel A derived from Zhou et al., 2015. 
 
 
3.2.3. Transduction of resting T helper cells 
Lentiviruses and thereof derived lentiviral vectors are capable of transducing a variety of non-
proliferating cells (Weinberg et al., 1991; Lewis et al., 1992; Naldini et al., 1996). Nonetheless, there 
are a few particularly resting cell types exempted for commonly used vectors like VSV-LV, e.g. 
quiescent lymphocytes (Amirache et al., 2014). Recently, it has been shown, however, that LVs 
pseudotyped with MV vaccine strain or wild-type glycoproteins can overcome this block and 
productively transduce resting lymphocytes (Frecha et al., 2008a; Frecha et al., 2009; Zhou et al., 
2011). Moreover, vectors pseudotyped with MV glycoproteins engineered to target CD19 and CD20 
surface molecules were able to transduce receptor-positive resting B cells while inducing minimal 
activation of the cells (Kneissl et al., 2013). Therefore, the question arose whether also CD4-LV is 
able to transduce resting CD4
+
 T cells and if so, how efficient resting CD4
+
 lymphocytes are 
transduced in comparison to activated ones.  
To tackle this question, PBMC were isolated from fresh donor blood by density centrifugation using 
Histopaque
®
-1077 (2.2.3.4). Then, PBMC were either left unstimulated and directly transduced by 
spin occulation with CD4-LVLuc,GFP at MOIs 2 and 10 in T cell medium (TCM) containing no IL-2, or 
stimulated (see 2.2.3.4) before spin occulation with CD4-LVLuc,GFP (MOIs 2, 10) in TCM 
supplemented with 100 IU/ml IL-2. The activation state of the lymphocytes at the time point of 
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transduction was assessed by staining for CD25, the α-chain of the IL-2 receptor which is upregulated 
upon stimulation of T cells (Janeway et al., 2008). Transduction efficiency was analyzed by 
quantification of GFP
+
 cells in the CD4
+
 population by flow cytometry. Three days after transduction, 
unstimulated PBMC were thoroughly washed in PBS and subsequently activated using anti-CD3 and 
anti-CD28 antibodies, and 100 IU/ml IL-2 in order to enable long-term cultivation. 
In the freshly isolated PBMC, only about 1.5% of CD4
+
 cells stained positive for CD25 (Figure 38A), 
whereas activation of PBMC by anti-CD3/CD28 antibodies and IL-2 was confirmed by solid CD25 
expression (Figure 38B). CD4-LV specifically transduced 8.1% of the unstimulated CD4
+
 T cells in 
PBMC at an MOI of 2 (Figure 38C, day 3). Stable transgene expression was confirmed six days after 
transduction by flow cytometric detection of 7.9% GFP
+
/CD4
+
 lymphocytes. As expected, CD4-LV 
(MOI 2) transduced stimulated T cells more efficiently than unstimulated ones (approximately 5-fold 
increased transduction efficiency, see Figure 38C). Interestingly, a temporary down-regulation of the 
CD4 surface expression was observed following transduction with CD4-LV (Figure 38D). This was 
especially pronounced for unstimulated cells and the more distinct the more vector particles were 
applied (compare MOI 2 and 10, Figure 38D). Over time, an increase in CD4 surface expression back 
to levels observed for untransduced control cells was monitored.  
Taken together, the data show the ability of CD4-LV to stably transduce primary resting T cells and 
exclude pseudotransduction. However, transduction efficiency in resting T lymphocytes was lower 
than in stimulated ones. 
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Figure 38: Transduction of resting primary PBMC. (A) Examination of CD25 expression in freshly isolated 
PBMC. PBMC derived from fresh donor blood were stained for CD4 and CD25 and subjected to flow cytometry 
analysis. One representative donor out of three is shown (n = 3). (B) Examination of CD25 expression in 
activated PBMC. PBMC were stimulated by anti-CD3/CD28 antibodies and IL-2 for 3 d and subsequently 
examined for CD4 and CD25 expression by flow cytometry. One representative donor out of three is shown (n = 
3). (C) Transduction of unstimulated PBMC. To determine the ability of CD4-LV to transduce resting T cells, 
freshly isolated PBMC were left untransduced (ut) or transduced with CD4-LVLuc,GFP at MOI 2. 3 d after 
transduction, half of the cells were analyzed by flow cytometry for the percentage of GFP
+
 cells in the CD4
+
 
population. The other half was thoroughly washed in PBS and cultured in the presence of anti-CD3/CD28 
antibodies and 100 IU/ml IL-2 for three more days. Then, the percentage of GFP
+
 cells in the CD4-gated 
population was determined by flow cytometry again. In parallel, PBMC from the same donor were stimulated for 
three days and then transduced with CD4-LVLuc,GFP at the same MOI. 7 d after transduction, the percentage of 
GFP
+
/CD4
+
 cells was determined by flow cytometry. One representative donor out of three is shown (n = 3) (D) 
Surface expression of CD4. Unstimulated and stimulated PBMC were transduced with CD4-LVLuc,GFP at MOI 2. 
At the indicated time points after transduction, CD4-expression was assessed by flow cytometry. One 
representative donor out of three is shown (n = 3). Panels C and D modified after Zhou et al., 2015. 
 
3.2.4. Transduction of macrophages  
CD4 is not only expressed on T helper cells but also present on monocytes and macrophages (Lee et 
al., 1999). Therefore, the question arose if also these cell types become transduced by CD4-LV, which 
was tested in the present thesis for human macrophages. 
Two different macrophages types, named M1 and M2 macrophages, were kindly provided by Meike 
Thomas (van Zandbergen group, Paul-Ehrlich-Institut). M1 or classically activated macrophages are 
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activated through Toll-like receptors and IFN-γ and are characterized as pro-inflammatory. The more 
heterogeneous M2 or alternatively activated macrophage population is induced by IL-4 or IL-13 and 
has anti-inflammatory properties (Mosser and Edwards, 2008; Jetten et al., 2014). The cells were 
generated from buffy coat-derived PBMC by plastic adherence (incubation of 5 x 10
6
 PBMC per T25 
flask in the presence of 1% human plasma for 1.5 hours) and subsequent cultivation of adherent cells 
in the presence of either 10 ng/ml GM-CSF (M1 macrophages) or 30 ng/ml M-CSF (M2 macrophages) 
for six days.  
In a first step, both macrophage types were analyzed for surface expression of the target receptor CD4 
as well as the monocyte/macrophage marker CD14 by flow cytometry. Flow cytometry revealed 
expression of CD4 both in M1 and M2 macrophages (Figure 39). However, M1 macrophages showed 
considerably lower levels of CD4 than M2 macrophages. This observation is in line with a previous 
report demonstrating M1 polarization to be associated with a down-regulation of CD4 (Cassol et al., 
2009). 
 
 
Figure 39: Expression of CD4 and CD14 
by M1 and M2 macrophages. 
Macrophages were generated from PBMC 
by plastic adherence and subsequent 
cultivation in the presence of GM-CSF or 
M-CSF. The cells were stained for the 
surface markers CD4 and CD14 and 
analyzed by flow cytometry. 
M1 and M2 macrophages were transduced with CD4-LVLuc,GFP at MOIs of 1 and 10, respectively. 
Additionally, macrophages were pre-incubated with HIV-2 protein Vpx transferring PBj-VLP vpx 
(kindly provided by Meike Thomas, van Zandbergen group Paul-Ehrlich-Institut) at MOI 1 for two 
hours before transduction with CD4-LVLuc,GFP MOI 10. PBj-VLP vpx pre-treated cells served as 
positive controls as Vpx leads to the degradation of the HIV-1 restriction factor SAMHD1, a dNTP 
triphosphohydrolase that reduces the levels of intracellular dNTPs and therefore hampers HIV-1 
reverse transcription (Berger et al., 2011; Laguette et al., 2011). Transduction efficiency was analyzed 
by laser scanning microscopy (9 days after transduction) and flow cytometry (12 days after 
transduction).  
The data indicate that both, M1 and M2 macrophages, can be transduced by CD4-LV (Figure 40). For 
M1 macrophages, comparable transduction of about 30% was observed with CD4-LV at MOI 10 
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independent of the pre-incubation with PBj-VLP vpx. Transduction of M1 macrophages with CD4-LV 
at MOI 1 resulted in approximately 10-fold lower transduction efficiency compared to CD4-LV at 
MOI 10. M2 macrophages were found to be considerably more susceptible to CD4-LV upon pre-
incubation with PBj-VLP vpx than without Vpx pretreatment (70% versus 2% GFP
+
 cells after 
transduction with CD4-LV MOI 10). Incubation of M2 macrophages with CD4-LV at MOI 1 did 
barely lead to any transduction.  
Taken together, both M1 and M2 macrophages can be transduced by CD4-LV albeit transduction 
efficiencies strongly varied. Addition of Vpx increased transduction efficiency in M2 but not M1 
macrophages. 
 
 
Figure 40: Transduction of M1 and M2 macrophages by CD4-LV. M1 and M2 macrophages were generated 
from PBMC by plastic adherence and subsequent cultivation in the presence of 10 ng/ml GM-CSF or 30 ng/ml 
M-CSF, respectively. Macrophages remained untransduced (ut) or were transduced with CD4-LVLuc,GFP at the 
indicated MOIs with or without preincubation with PBj-VLP vpx (MOI 1) for 2 h. Transduction efficiency was 
analyzed by microscopy (9 d after transduction) and flow cytometry (12 d after transduction). The percentage of 
GFP
+
 transduced cells is indicated. The experiment was performed once (n = 1). 
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3.2.5. Systemic application of CD4-LV in PBMC-reconstituted mice 
In vitro, the tropism of CD4-LV had been restricted to CD4
+
 target cells (Figure 37). Additionally, 
potent CD4-LV stocks could be generated (Figure 36D), characterized by an at least 10-fold higher 
titer than CD8-LV which mediated successful gene transfer after local administration (Zhou et al., 
2012). Meeting these requirements, the in vivo targeting potential of systemically injected CD4-LV 
was examined. As the implemented DARPin 29.2 is highly specific for human CD4 and does not 
recognize the murine version (Schweizer et al., 2008), specificity could not be assessed in a 
conventional mouse system. However, immunodeficient NOD-scid IL2γ-/- (NSG) mice can be 
repopulated with human PBMC or human HSC in order to develop a (functional) human immune 
system within these animals (Shultz et al., 2012). Therefore, these mice represent a suitable in vivo 
model to test the specificity and biodistribution of CD4-LV. To enable both, non-invasive 
biodistribution studies over time, and simple detection of transduced cells by flow cytometry, CD4-
LVLuc,GFP vectors were employed. The bicistronic genome transferred by these particles encoded firefly 
luciferase and sfGFP (Abel et al., 2013). Both transgenes are under control of a SFFV promoter and 
were separated by a T2A site (Figure 43A).  
3.2.5.1. Establishing the animal model 
Before the specificity and biodistribution of CD4-LV in PBMC-repopulated NOD-scid IL2Rγ-/- mice 
could be tested, this humanized mouse model had to be established in our laboratory. In order to assess 
repopulation kinetics dependent on the application route, five immunodeficient NSG mice were 
intravenously (i.v.) or intraperitoneally (i.p.) injected with 1 x 10
8
 PBMC, respectively. The cellular 
composition of freshly isolated buffy coat-derived PBMC was exemplarily evaluated for one random 
donor (Figure 41A). At day 5 and 7 post injection of PBMC, peripheral blood was withdrawn (2.2.5.2) 
and analyzed for the percentage of human CD45
+
 lymphocytes by flow cytometry (2.2.3.8). Moreover, 
also the abundance of distinct human cell populations in the blood of PBMC-repopulated NSG mice 
was assessed by flow cytometry, staining for the T cell marker CD3, the B cell antigen CD19 and 
CD14, present on the surface of monocytes and macrophages. 
As shown in Figure 41B, intravenous cell application proved to be superior to intraperitoneal 
administration with 2 - 3 fold more human CD45
+
 cells detectable in the peripheral blood. Besides, 
flow cytometric analysis revealed the vast majority of engrafted cells to be T cells (Figure 41C) which 
is in line with literature (Shultz et al., 2012). However, as in vivo specificity and biodistribution of the 
T cell-tropic CD4-LV should be assessed, PBMC-repopulated NSG mice represented a suitable animal 
model for initial tests.  
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Figure 41: Humanization of NOD-scid IL2Rγ-/- mice with primary human PBMC. (A) Flow cytometric 
characterization of freshly isolated PBMC from a random donor for the percentage of T cells (CD3
+
), monocytes 
and macrophages (CD14
+
) as well as B cells (CD19
+
). Gray: unstained control, black lines: antibody staining. 
(B) Determination of the percentage of human CD45
+
 cells in the peripheral blood of NOD-scid IL2Rγ-/- mice 
intraperitoneally (i.p.) or intravenously (i.v.) injected with human PBMC. Results are depicted as mean ± SEM. 
(C) Blood of a humanized animal analyzed for the expression of human CD45 and human CD3 9 d after i.p. 
injection of 1 x 10
8
 PBMC. 
As expected, the animals succumbed to graft versus host disease (GvHD) when a certain level of 
human lymphocytes was reached within their bodies. Imminent death was to be expected when 
approximately 60% human CD45
+
 cells were present in the peripheral blood (data not shown). 
Animals injected with 1 x 10
8 
PBMC reached nearly 50% human CD45
+
 cells in the peripheral blood 
seven days after injection (Figure 41B). Thus, the number of PBMC to be injected had to be reduced 
in order to extend the observation period in further experiments. However, administering too few 
PBMC would delay the optimal time point for vector injection (reached for 10% - 20% human CD45
+
 
cells in the peripheral blood according to own experience values). Therefore, the PBMC number was 
adjusted to 5 x 10
7
 unstimulated and 1.5 x 10
7
 stimulated PBMC which show faster repopulation 
kinetics. Successful engraftment was observed for mice of different ages, the oldest animals being 
18 weeks old at the time point of cell injection (data not shown).    
3.2.5.2. Intravenous administration of CD4-LV 
6-8 weeks old immunodeficient NSG mice were i.v. injected with 5 x 10
7
 freshly isolated unstimulated 
PBMC or 1.5 x 10
7
 stimulated PBMC solved in 200 µl PBS. Activation of PBMC was performed as 
described in 2.2.3.4. Some of the stimulated PBMC were depleted for CD4
+
 T cells before injection 
(see 2.2.3.5 and Figure 42). When approximately 10% - 20% human CD45
+
 cells were present in 
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blood (commonly on day three), animals were injected with 200 µl CD4-LVLuc,GFP the next day or the 
next two consecutive days (Figure 43A). The administered CD4-LVLuc,GFP dilutions in PBS 
corresponded to 5 x 10
6
 t.u. or 8 x 10
7
 t.u. per mouse. Humanized animals injected with PBS or 
unhumanized animals injected with CD4-LVLuc,GFP served as negative controls. An overview over the 
different groups and their treatment is given in Figure 43B.   
 
 
Figure 42: Residual CD4
+
 T cells after CD4-
depletion
 
of activated PBMC. PBMC from two 
different donors were activated by anti-CD3/CD28 
antibodies and IL-2 for 3 d and subsequently 
depleted for CD4
+
 cells using microbeads. To 
determine the percentage of CD4
+
 T cells before 
and after depletion, cells were stained with APC-
conjugated anti-CD4 antibody and analyzed by flow 
cytometry. Figure modified after Zhou et al., 2015. 
 
Assessment of in vivo distribution of CD4-LV by in vivo imaging of luciferase activity  
In vivo distribution of CD4-LVLuc,GFP was monitored by imaging luciferase activity. Following vector 
administration, luciferase activity was detected in both, animals humanized with unstimulated PBMC 
(Group D and E) and mice engrafted with activated PBMC (Group F) (Figure 43C-F). Strong 
luciferase activity was found in lymphoid organs like spleen, thymus and lymph node like structures 
(Figure 43F). Besides, luciferase activity was observed in the skin, liver and lung of the animals 
(Figure 43E and data not shown) and depended on the state of graft versus host disease (GvHD). 
Luciferase expression correlated positively with vector dose as stronger luciferase activity was 
detected in animals repopulated with unstimulated PBMC and injected with 8 x 10
7
 t.u. CD4-LV 
(Group E) than in animals injected with 5 x 10
6
 t.u. CD4-LV (Group D) (Figure 43C, D and F). 
However, as already observed in vitro (Figure 38), higher transduction efficiency and therefore 
luciferase activity was detected in mice which received stimulated PBMC (Group F) compared to 
animals engrafted with unstimulated PBMC (Group E), when the same vector dose was applied. In 
mice repopulated with CD4-depleted PBMC and also injected with 8 x 10
7
 t.u. CD4-LV (Group C), 
overall luciferase activity was significantly reduced compared to animals engrafted with unstimulated 
or stimulated PBMC (Figure 43C-F). In these animals, luciferase activity was present in spleen and 
spine or buttocks region and positively correlated with the number of residual CD4
+
 cells in the 
respective CD4-depleted PBMC-engraftment (left animal in Group C (Figure 43) engrafted with 
donor 1 (Figure 42); right animal in Group C (Figure 43) engrafted with donor 2 (Figure 42)). In 
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humanized control animals, which received no vector (Group A), no luciferase activity could be 
observed upon injection of the substrate luciferin. Also in unhumanized mice injected with CD4-
LVLuc,GFP (Group B) only negligible spleen and spine signals just above the detection limit on the 
logarithmic scale were present (Figure 43C).  
Taken together, these data demonstrate in vivo transduction with CD4-LVLuc,GFP to be clearly 
dependent on the presence and activation state of its target cells.  
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Figure 43: In vivo luminescence imaging of PBMC-engrafted mice i.v. injected with CD4-LVLuc,GFP. (A) 
Experimental set-up. NOD-scid IL2Rγ-/- mice were intravenously injected with either 5 x 107 unstimulated 
PBMC or 1.5 x 10
7
 PBMC stimulated with anti-CD3/CD28 and IL-2 for 3 d. Stimulated PBMC may additionally 
have been depleted for CD4
+
 cells (Group C). One day after flow cytometric detection of 10-20% human CD45
+
 
cells in the peripheral blood of the animals, 200 µl CD4-LV transferring the reporter genes luciferase (luc2) and 
gfp (sfGFP) was administered systemically. The two genes are connected via a T2A linker and are expressed 
under control of the spleen focus-forming virus (SFFV) promoter. 6-10 d after vector injection, luciferase 
activity was monitored by in vivo imaging (C-F) and transduction efficiency was quantified by flow cytometry. 
Luciferase signal intensity in panels C-F is expressed as photons/second/square centimeter/steradian 
(p/sec/cm2/sr). (B) Legend for the group designations used in subpanels C-F. (C-D) Whole body imaging of 
humanized mice injected with CD4-LV in dorsal (C) and ventral view (D). Mice were imaged 6-10 d after vector 
administration. Images of two representative animals from each group are shown. (E) In vivo imaging of mice 
after dissection. Animals were dissected and spleen, thymus, and lymph node like structures were removed and 
imaged separately. Additionally, lung, heart, and liver were removed (all groups except Group D). Intestinal 
tracts were arranged in a circle around the animals. (F) Luciferase activity in explanted lymphoid organs. 
Luminescence of spleen (S), thymus (T), and lymph node like structures (LN) was acquired by in vivo imaging. 
Panels C and F derived from Zhou et al., 2015.  
 
Quantification of transduction events in blood and spleen by flow cytometry  
Transduction efficiency of CD4-LVLuc,GFP in blood and spleen was quantified by flow cytometric 
detection of GFP
+
 cells. In order to ensure proper read-out of the percentage of GFP
+
 transduced cells, 
it was absolutely necessary to analyze as much cells as possible, e.g. 1 million splenocytes. All GFP-
expressing cells were characterized as human CD45-positive lymphocytes (Figure 44 and data not 
shown for Groups C-E).  
 
 
Figure 44: No off-target transduction of murine 
cells by CD4-LV in PBMC-repopulated animals. 
Mice were treated as described for Group F in Figure 
43A. 7 d after systemic administration of CD4-LV, 
mice were sacrificed and cells isolated from blood and 
spleen were stained for human CD45 to distinguish 
mouse and human cells. The percentage of transduced 
cells was determined by flow cytometry. One 
representative data set out of six individual mice 
shows GFP
+
 cells in the human and murine cell 
population.  
 
Within the CD45
+
 human lymphocyte population, CD4-LVLuc,GFP selectively transduced CD3
+
/CD4
+
 
human lymphocytes while sparing CD3
+
/CD4
-
 human T cells (Figure 45A, and data not shown for 
Groups C and D). The percentage of transduced cells in blood and spleen of animals repopulated with 
unstimulated PBMC averaged between approximately 0.5% (Group D) and 1.0% (Group E), and 
reached up to 16.6% and 9.2% in blood and spleen of mice humanized with stimulated PBMC (Group 
F), respectively (Figure 45B).  
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Taken together, also in vivo CD4-LV showed clear target cell specificity. It preferentially transduced 
more activated cells. 
 
 
Figure 45: In vivo transduction of CD4
+
 T cells in PBMC-engrafted mice. 6-10 d after intravenous vector 
injection, animals were sacrificed and cells isolated from blood and spleen were stained for human CD45, human 
CD3 and human CD4. The percentage of GFP
+
 cells in the human CD45
+
/CD3
+
/CD4
-
 and CD45
+
/CD3
+
/CD4
+
 
population was determined by flow cytometry. (A) Quantification of transduction events within the human 
CD45
+
/CD3
+
/CD4
-
 and CD45
+
/CD3
+
/CD4
+
 population. (B) Summary of in vivo transduction efficiency. Each 
mouse is represented by a dot. Results are depicted as mean. *, **, ***, **** and ns indicate P<0.05, P<0.01, 
P<0.001, P<0.0001 and not significant, respectively. Data were analyzed using the two-tailed unpaired Student’s 
t-test. Figure modified after Zhou et al., 2015.  
 
3.2.6. In vivo targeting of CD4+ cells in HSC-reconstituted mice 
In the previous experiment PBMC-repopulated animals were used to assess the in vivo targeting 
potential of CD4-LV. However, in these mice mainly T cells developed from unstimulated PBMC or 
stimulated T cells were injected. Moreover, the observation period was limited due to GvHD. In order 
to evaluate the targeting properties of CD4-LV in a model better reflecting the natural immune system 
and its diverse cell types which additionally allows long-term monitoring of transgene expression, 
animals reconstituted with human hematopoietic stem cells (HSC) were used in the next step.  
Systemic administration of CD4-LVLuc,GFP into HSC-reconstituted NSG mice was performed in 
collaboration with Dr. Udo Hartwig, University of Mainz, according to the experimental set-up shown 
in Figure 46A. For this purpose, Dr. Hartwig kindly engrafted 5-6 weeks old NSG mice with human 
CD34
+
 HSC. Reconstitution of human immune cells was regularly monitored by flow cytometry and 
mice with 5-15% human CD4
+
 T cells and 5-35% of human CD19
+
 B cells in the peripheral blood 
were included in the experiment (data not shown). As stimulated T cells were shown in vitro and in 
vivo to be more prone to CD4-LV transduction than unstimulated ones (see 3.2.3 and 3.2.5.2), T cells 
were activated by i.v. injection of 10 µg OKT-3 five days prior systemic administration of 1.5 x 10
7
 t.u. 
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CD4-LVLuc,GFP. In vivo distribution of CD4-LVLuc,GFP was monitored by imaging luciferase activity 
over the period of 26 days.  
 
 
Figure 46: In vivo luminescence imaging of HSC-engrafted mice i.v. injected with CD4-LVLuc,GFP. (A) 
Experimental set-up. 5-6 weeks old NOD-scid IL2Rγ-/- mice were irradiated with 150 cGy and intravenously 
(i.v.) injected with 1 x 10
6
 adult CD34
+
 HCS per mouse the next day. Approximately 95 d after injection of HSC, 
when stable engraftment of CD45
+
 cells was demonstrated in the peripheral blood, each animal was i.v. injected 
with 10 µg OKT-3 to stimulate T cells. Five days later, 1.5 x 10
7
 transducing units CD4-LV transferring 
luciferase and gfp reporter genes were i.v. injected per mouse. Transgene expression was monitored on day 7, 14 
and 21 by luciferase imaging and on day 26 by luciferase imaging and flow cytometric detection of GFP
+
 cells. 
(B) Whole body in vivo luminescence imaging of CD4-LV-injected animals. CD4-LV-injected mice were 
imaged at the indicated time points. One mouse (labeled by asterisk) had to be sacrificed before the scheduled 
end of the experiment due to splenic hyperplasia. (C) In vivo luminescence imaging of organs explanted from 
CD4-LV-injected mice. Mice were sacrificed 26 d after vector injection and luciferase activity in lymphoid 
organs was acquired by in vivo imaging. Each image shows spleen (S) and lymph node like structures (LN) 
isolated from an individual mouse. Luciferase signal intensity in panels B and C is expressed as 
photons/second/square centimeter/steradian (p/sec/cm
2
/sr). Panels B and C derived from Zhou et al., 2015. 
 
Luciferase activity was detected in all five animals injected with CD4-LVLuc,GFP (Figure 46B). Overall 
signal intensity increased within the first 14 days after vector injection and then remained constant to 
the end of the observation period. One week after vector administration, the strongest luminescence 
was observed in spleen, whereas at later observation points luciferase activity had spread within the 
entire torso. However, 26 days after vector injection, strongest luciferase activity was detected in the 
explanted spleens of dissected mice (Figure 46C). The data demonstrate stable transgene expression 
over the observation period of 26 days, which was especially pronounced in lymphoid organs. 
 
Transduction events in blood, spleen, and bone marrow were assessed by flow cytometry. The analysis 
revealed exclusive transduction of up to 570 or 800 single human CD45
+
 lymphocytes in spleen and 
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bone marrow (after substraction of negative control), respectively, but no transduction of murine cells 
(Figure 47).  
 
 
Figure 47: No off-target transduction of murine 
cells in HSC-repopulated animals. Mice were 
treated as described in Figure 46A. 26 d after 
systemic administration of CD4-LV, mice were 
sacrificed and cells isolated from spleen and bone 
marrow were stained for human CD45 to distinguish 
mouse and human cells. The percentage of 
transduced cells was determined by flow cytometry. 
One data set out of four individual mice shows GFP
+
 
cells in the human and murine cell population. 
 
In blood, no human lymphocytes could be detected (data not shown). However, in spleen and bone 
marrow selective transduction of approximately 2% of CD4
+
 cells but no transduction of CD4
-
 cells in 
the human CD45
+
/CD3
+
 population was observed after a single injection of CD4-LV (Figure 48A). To 
identify the phenotype of transduced T cells, cells were stained for CD45RA (naïve T cells) and 
CD45RO (memory T cells). Here, a clear preference of CD4-LV for memory T cells was found in 
both tissues (Figure 48B and C). Concluding, CD4-LV displayed high selectivity for CD4
+
 human T 
cells, and predominantly T lymphocytes with memory phenotype, in vivo. 
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Figure 48: In vivo targeting of CD4
+
 T cells in HSC-engrafted mice. NOD-scid IL2Rγ-/- mice were treated as 
described in Figure 46A. 26 d after systemic administration of CD4-LV, mice were sacrificed and spleen and 
bone marrow were removed. The percentage of transduced cells (A) and their phenotypes (B and C) was 
determined by flow cytometry. Control: humanized animal which received no CD4-LV. (A) Quantification of 
transduction events in spleen and bone marrow. One data set out of four individual mice showing the percentage 
of CD4
+
/GFP
+
 cells in the CD45
+
/CD3
+
 gate is depicted. (B) Quantification of transduced naïve and memory T 
cells. The percentage of GFP
+
 cells in the naïve (CD45RA
+
) and memory (CD45RO
+
) T cell subsets was 
determined by flow cytometry. (C) Summary of transduction efficiency in four individual mice (n = 4). Results 
are depicted as mean ± SEM. * and ns indicate P<0.05 and not significant, respectively. Data were analyzed 
using the two-tailed unpaired Student’s t-test. Figure modified after Zhou et al., 2015.  
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4. Discussion 
Viral vectors have proven to be powerful tools for basic research and medical application, including 
gene therapy and vaccination. One major achievement concerning the safety and specificity of these 
vectors is entry-targeting. Entry-targeting is either based on pseudotyping with naturally occurring 
heterologous envelope proteins with desired narrow receptor specificity or engineered envelope 
glycoproteins selectively binding to a receptor of choice. In this thesis, both strategies of vector 
targeting were exploited using modified measles virus glycoproteins pseudotyped lentiviral vectors. 
Pseudotyping with truncated MVwt-GPs led to a predominant tropism for SLAM-expressing cells and 
therefore enabled protein transfer into SLAM
+
 APCs, whereas engineered MVNSe-derived 
glycoproteins displaying a CD4-specific DARPin on receptor-blind H allowed specific gene delivery 
into CD4
+
 immune cells. 
4.1. Targeted protein transfer into SLAM+ cells 
Dendritic cells are considered the most potent type of APCs (Gaspari and Tyring, 2008). They are 
powerful inducers of B and T lymphocyte immune responses (Banchereau and Steinman, 1998) and as 
such attractive targets for vaccination approaches.  
Therefore, major effort has been devoted to introduce antigens specifically into DCs. Since DCs are 
non-dividing, the ability of LVs to transduce mitotically inactive cells is most advantageous and 
successful lentiviral DC-targeting, exploiting surface molecules like the C-type lectin DC-SIGN (Yang 
et al., 2008), SLAM (Humbert et al., 2012) or MHC II (Ageichik et al., 2011; Ciré et al., 2014), has 
already been reported. Of note, all these endeavors focused on lentiviral transfer of antigen-encoding 
sequences, but not of antigens as such. Hence, transduced DCs have to express the encoded antigen 
before processing and presenting it on MHC I and MHC II complexes in order to induce T and B cell 
responses. Despite the principle success of DC-targeting and subsequent triggering of immune 
responses, a major limitation of these approaches is the relative resistance of DCs to lentiviral gene 
transfer, requiring high vector doses or co-delivery of Vpx to obtain satisfactory transduction rates 
(Humbert et al., 2012). Moreover, insertional mutagenesis due to vector genome’s integration into host 
cell chromosomes imposes an inherent risk of such gene transfer for vaccines.  
An attractive alternative to circumvent these hurdles might be the exploitation of retroviral particles 
for protein delivery into target cells, as already successfully shown for fluorescent proteins (GFP, CFP, 
mRFP, YFP) or enzymes (Flp recombinase, -lactamase) (Maetzig et al., 2012). Such protein transfer 
represents a transient cell modification, which does not influence the genomic integrity of the target 
cell and does not require de novo protein synthesis, as complete proteins are delivered. Also blocks to 
lentiviral gene transfer do not apply, since these blocks act on post-entry replication steps, when the 
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vector components including the transferred protein have been released into the transduced cell’s 
cytosol. 
Due to the constraints of lentiviral gene delivery into DCs, the present thesis aimed to establish 
lentiviral protein transfer vectors for vaccination and provide proof of concept using model antigen 
Ova-transferring particles, especially considering APC-targeted, MVwt-GP pseudotyped vectors. 
4.1.1. Setting up the vector system 
This project intended to examine the potency of lentiviral vectors for targeted delivery of foreign 
proteins into APCs to induce antigen-specific immune responses. Initially, optimal conditions for the 
generation of protein transfer vectors exhibiting the desired characteristics needed to be determined, 
since such vectors had not been published, yet.  
 
DC-targeting should rely on pseudotyping of LVs with MV-GPs, specifically interacting with SLAM, 
which is expressed on activated immune cells, including mature DCs (Bleharski et al., 2001; Kruse et 
al., 2001). Humbert and colleagues already demonstrated the suitability of MV vaccine strain 
glycoprotein-pseudotyped LVs, specifically recognizing CD46 and SLAM, for DC-targeted 
vaccination approaches (Humbert et al., 2012). Also MV wild-type glycoproteins use SLAM as cell 
entry receptor, but do not recognize CD46 (Tatsuo et al., 2000), which improves vector specificity 
(Funke et al., 2009). Of note, titers of MVwt-LV have previously been shown to exceed those of 
MVvac-LV (Funke et al., 2009), which is another advantage of pseudotyping with MVwt-GPs. However, 
besides SLAM a third, epithelial receptor for MV had been proposed when this PhD project was 
started (Leonard, V.H.J. et al., 2008), to whose identification as the adherens junction protein Nectin-4 
the present thesis has contributed (Figure 9, Figure 10, Figure 11 and Mühlebach et al., 2011). In 
parallel, Nectin-4 was also described as epithelial cell receptor for MV vaccine and laboratory strains 
by Noyce et al. (Noyce et al., 2011). Notably, SLAM-transgenic CHO cells were approximately five-
fold more efficiently infected with MVwt323 than transgenic CHO-Nectin-4 cells, speaking for 
preferential infection of SLAM-expressing over Nectin-4 expressing cells (Mühlebach et al., 2011). 
Furthermore, immunological experiments in this thesis were based on human SLAM but not human 
Nectin-4 transgenic mice and thereof derived mDCs. Although murine Nectin-4 can serve as 
functional MV receptor, it is used less efficiently than its human homolog (Noyce et al., 2011), and, 
most importantly, it is not expressed on immune cells. Since SLAM is expressed on immune cells and 
therefore allows targeting of the respective cell populations, SLAM played the major role in this thesis. 
 
Retroviral vectors have been described as transfer vehicles for heterologous proteins (Voelkel et al., 
2010). Prerequisite for such protein delivery is the genetic fusion of cargo proteins to viral structural 
proteins. Thereby, several positions of the gag/pol ORF, e.g. 5’ of matrix (Aoki et al., 2011) or 3’ of 
nucleocapsid or integrase (Voelkel et al., 2010), have been shown to tolerate introduction of foreign 
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protein encoding sequences. Others, such as 3’ of gag, however, have rather been avoided in order to 
preserve the frameshift signal indispensable for Gag/Pol production (Aoki et al., 2011). Especially 
promising results have been obtained by insertion of heterologous protein encoding sequences 
between matrix and capsid (Voelkel et al., 2010), prompting the use of this approach also in this thesis’ 
work (Figure 12).  
Interestingly, retroviral PTVs did not only transfer heterologous cargo proteins, but also maintained 
their ability to deliver transgenes (Voelkel et al., 2010). We aimed to generate similar bifunctional LV 
particles, exploiting marker gene transfer to enable easy titration of vector particles and experimental 
read-out. In order to yield maximum protein and gene transfer into transduced cells, the optimal ratio 
of gag/pol to gag-cargo/pol during PTV-production was determined. Lentiviral PTVs generated in this 
thesis possessed the fundamental ability to transfer genetic information into transduced target cells 
(Figure 13), as expected. Here, a clear correlation between particle composition and ability to mediate 
successful gene transfer was observed (Figure 13, Figure 15). Strikingly, gene transfer was ablated 
when particles were generated using only gag-gfp/pol for particle production. This loss-of-function 
was associated with evident morphological abnormalities of the particles like reduction and irregular 
arrangement of envelope glycoproteins and discontinuities in the Gag-shell (Figure 14). However, this 
was not entirely unexpected, as also other reports indicated phenotypical changes, i.e. similar 
discontinuities in the Gag-layer, of VLPs produced with only HIV-1 Gag-GFP, which were attributed 
to the GFP polypeptide (Pornillos et al., 2003; Larson et al., 2005). Moreover, several studies showed 
beneficial effects or the necessity of wild-type Gag/Pol supplementation for generation of functional, 
i.e. infective and/or morphologically normal, particles (Sherer et al., 2003; Müller et al., 2004; Larson 
et al., 2005). It corresponds well to the data acquired here revealing equal amounts of gag-gfp/pol and 
wild-type gag/pol being optimal for PTV production (Figure 13). This ratio has already been 
successfully used for generation of γ-retroviral (Voelkel et al., 2010) and lentiviral (Müller et al., 2004) 
protein delivering particles, the latter in early marking experiments aiming to obtain fluorescently 
labeled HIV-1 derivatives exhibiting wild-type morphology and infectivity as tools for HIV-1 research.  
 
Besides GFP, also other cargo proteins can be transferred by PTVs (Maetzig et al., 2012). In this thesis, 
successful incorporation of GFP, Cre recombinase or ovalbumin was demonstrated (Figure 19). 
Depending on the respective cargo protein, release from its viral fusion partner can be necessary to 
allow proper function. Especially when the protein of interest exerts its function in membrane-distal 
compartments of the cell, release from membrane-anchored MA is indispensable. Introduction of an 
additional retroviral protease recognition site between the cargo and its viral fusion partner releases the 
heterologous protein from γ-retroviral (Voelkel et al., 2010), and also from lentiviral particles, as also 
documented for GFP, Cre or Ova in this thesis (Figure 18, Figure 19). Interestingly, GFP-PTVs 
harboring or lacking an engineered HIV-1 protease site were phenotypically indistinguishable from 
one another and from the parental lentiviral gene transfer vectors MVwt-LV or VSV-LV if generated in 
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appropriate gag/pol to gag-cargo/pol ratios (Figure 21). Thus, particle generation and morphology is 
not negatively influenced by the artificial HIV-1 protease site separating MA and cargo, as expected, 
since successful production of functional γ-retroviral particles including an additional retroviral 
protease site between MA and cargo had been described before (Voelkel et al., 2010).  
 
How many cargo proteins can be transferred by lentiviral particles? An average immature HIV-1 
particle is comprised of about 5,000 Gag molecules (Briggs et al., 2004). Thus, particle generation 
with equal amounts of gag/pol and gag-cargo/pol should theoretically include 2,500 Gag molecules 
tagged with a heterologous protein and therefore allow incorporation of 2,500 cargo molecules per 
single vector particle. To get an idea if the theoretical value of 50% tagged Gag molecules indeed 
represents payload protein abundance in vector preparations, Ova-transferring PTVs were examined 
for their Ovalbumin content. On average, MVwt-Ova-LVKatushka preparations contained only 95 ng Ova/ 
µg p24 (Figure 20B), corresponding to a labeling efficiency of 5.3%, when calculating with a 
molecular weight of 42.8 kDa for Ova. For VSV-Ova-LVKatushka 169 ng Ova/ µg p24 were measured 
(Figure 20B), which equals 9.6% Ova-tagged Gag proteins. These data point at augmented 
incorporation of wild-type Gag/Pol into PTV particles, which might be due to steric constraints of the 
tagged protein. 
Determining the amount of Ova per transducing unit, 723 fg Ova/ t.u. MVwt-Ova-LVKatushka and 21 fg 
Ova/ t.u. VSV-Ova-LVKatushka were found (Figure 20B). Thereby, 723 fg Ova equal 1.0 x 10
7
 Ova 
molecules, whereas 21 fg Ova correspond to 3.0 x 10
5
 molecules. Labeling efficiencies of 5.3% and 
9.6%, respectively, suggest 1.9 x 10
8
 and 3.1 x 10
6
 Gag molecules per transducing unit in total. These 
molecule numbers would suffice to yield 3.8 x 10
4
 MVwt-Ova-LVKatushka and 6.3 x 10
2
 VSV-Ova-
LVKatushka particles, keeping in mind that one HIV-1 derived particle contains approximately 5,000 Gag 
molecules (Briggs et al., 2004). Thus, only one in 3.8 x 10
4
 MVwt-Ova-LVKatushka and one in 6.3 x 10
2
 
VSV-Ova-LVKatushka particles is active in gene transfer. Therewith, VSV-Ova-LVKatushka meets the 
expectations of average retroviral infectivity, specified by one infectious retroviral particle in 100 to 
1,000 physical particles (Maetzig et al., 2012), while MVwt-Ova-LVKatushka is evidently less infective. 
VSV-G is very stable and pseudotyping LVs with this glycoprotein gives rise to high titer stocks 
(Burns et al., 1993), whereas titers of MVwt-GP pseudotyped particles are usually 1-2 log-levels lower 
(Figure 22) as also previously described (Anliker et al., 2010). Thus, vector titers and infectivity are 
strongly affected by the envelope glycoproteins used for pseudotyping (Kahl et al., 2004; Steidl, 2004) 
and differences in the range of log-levels are not uncommon (Kahl et al., 2004), also for protein 
transfer vector particles. 
4.1.2. Mechanistical analysis of targeted PTVsꞌ function 
Protein transfer vector particles were pseudotyped with MVwt-GPs to allow specific APC-targeting, 
and VSV-G, which can be considered the gold standard to evaluate the performance of other vector 
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pseudotypes. MVwt-GPs recognize the receptors SLAM (Tatsuo et al., 2000) and Nectin-4 (3.1.1; 
Mühlebach et al., 2011; Noyce et al., 2011) whereas VSV-G specifically interacts with members of the 
widespread expressed LDL receptor family (Finkelshtein et al., 2013), enabling its broad tropism. 
Conservation of MV receptor-specificity has already been shown for lentiviral gene transfer vectors 
pseudotyped with MVvac-GPs (Funke et al., 2008) and MVwt-GPs (Funke et al., 2009). In line with this, 
dependency of cell-entry on receptor-envelope glycoprotein interactions was also demonstrated for 
protein and gene delivery by PTVs generated during this thesis’ work on MV receptor-transgenic 
Chinese hamster ovary (CHO) cell lines or naturally SLAM-expressing B95a/ Raji B cell lines (Figure 
23, Figure 25, Figure 26). CHO cells themselves do not express any MV receptors and therefore 
represent a suitable tool to assess the impact of transgenetically expressed, putative receptors on 
susceptibility to MV infection (Buchholz et al., 1996) or transduction of LVs pseudotyped with 
engineered MV-GPs (Münch et al., 2011). Of note, although substantial protein transfer was detected 
for cotton-top tamarin cell line B95a transduced with MVwt-GP pseudotyped particles, these cells were 
rather resistant to gene transfer at an MOI of 1 (Figure 23, Figure 26B). A plausible explanation is 
provided by expression of HIV-1 restriction factor Trim5α in cotton-top tamarin cells (Goldschmidt et 
al., 2008). Trim5α favors species-specific premature disassembly of viral capsids, and thus prevents 
reverse transcription of viral RNA (Stremlau et al., 2006). Protein transfer, however, is not hampered 
by Trim5α, and no interaction of the restriction factor with the protein payload is to be expected since 
cargo proteins are cleaved off the capsid by action of the viral protease during particle maturation. 
Also for CHO-Nectin-4 only limited gene delivery was observed upon transduction with MVwt-MA-
GFP-LVKatushka. However, this is in line with the preferential infection of CHO-hSLAM over CHO-
Nectin-4 cells by MVwt323 (Mühlebach et al., 2011), the virus the glycoproteins used for pseudotyping 
of LV particles are derived from. The background MA-GFP protein transfer into CHO-CD46 cells by 
MVwt-MA-GFP-LVKatushka may be explained by the overlap of the binding site of MV vaccine and 
laboratory strain receptor CD46 on MV hemagglutinin with the one of Nectin-4 (Zhang et al., 2013).  
 
In contrast to considerable protein transfer by MVwt-MA-GFP-LVKatushka, protein transfer by VSV-G 
pseudotyped particles was barely observed upon normalization to MOI 1 (Figure 23). As already 
mentioned in 4.1.1, VSV-G is very stable and gives rise to highly infectious vector stocks (Burns et al., 
1993), whereas titers of MVwt-GP pseudotyped LVs are much lower (Figure 22; Anliker et al., 2010). 
Thus, overall less VSV-MA-GFP-LVKatushka than MVwt-MA-GFP-LVKatushka particles needed to be 
applied for transduction at MOI 1. Among the total number of MVwt-GP pseudotyped particles used 
for transduction, consisting of infectious and non-infectious particles, there may be particles 
containing no genetic information. Those are hence not included in the calculation of infectious titers 
(determined by gene transfer). However, if they possess functional glycoprotein complexes, such 
VLPs are able to transfer cargo proteins into the cytosol of receptor-positive cells, what might account 
for the high protein delivery capacity of MVwt-GP pseudotypes normalized to MOI 1 (Figure 23). 
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Moreover, particle composition of VSV-G and MVwt-GP pseudotyped particles may differ, i.e. more 
cargo proteins might be incorporated into MVwt-GP pseudotyped LV particles than into VSV-G 
pseudotyped ones. Besides, also the entry pathway may affect PTVs’ ability to transfer cargo proteins. 
In contrast to MV and thereof derived pseudotypes relying on pH-independent fusion of viral and 
plasma membrane (Plemper, 2011), VSV and thereof derived pseudotypes enter host cells via the 
endocytic pathway (Matlin et al., 1982). Thus, cargo proteins delivered by VSV-G pseudotyped 
vectors may be subjected to degradation in late endosomes, resulting in lower protein transfer 
capacities of VSV-G pseudotyped vector particles.  
However, when adjusted to particulated protein (80 ng p24), also VSV-MA-GFP-LVKatushka particles 
demonstrated the ability to mediate substantial protein transfer (Figure 24) and even outperformed 
MVwt-GP pseudotyped PTVs in CHO cells under these conditions. This indicates a critical influence 
of the normalization method on relative protein and gene transfer efficiencies of PTVs. 
 
In accordance with other studies reporting intracellular transfer of native, functional proteins like 
enzymes and transcription factors (Voelkel et al., 2010; Aoki et al., 2011; Kaczmarczyk et al., 2011; 
Wu and Roth, 2014), in this thesis cargo proteins were also delivered into target cells and shown to be 
bioactive. Transfer of Cre recombinase into receptor-positive indicator cell lines led to excision of a 
loxP-flanked cerulean expression cassette (Figure 25B), implying nuclear translocation and catalytic 
activity of the enzyme. Also the model antigen Ova was delivered into the cytosol of receptor-
expressing cells, as indicated by immunoblot analysis detecting similar amounts of Ova in PTV-
transduced cells with and without citric acid buffer pretreatment (Figure 26A), which is a common 
method to remove surface-bound virions (Voelkel et al., 2012).  
 
Interestingly, receptor-positive mDCs transduced with MVwt-Ova-LVKatushka and VSV-Ova-LVKatushka 
triggered predominantly CD8
+
 Ova-specific T cells (compare Figure 29A, B with Figure 30A, B). Of 
note, transduction of mDCs with MVwt-Ova-LVKatushka in the presence of fusion inhibiting peptide FIP, 
which blocks MV-GP induced membrane fusion (Richardson et al., 1980), completely abolished 
stimulation of co-cultured CD8
+
 Ova-specific T cells (Figure 29C). In contrast, mDCs incubated with 
soluble Ova and Bald-Ova-LVKatushka stimulated mainly CD4
+
 Ova-specific T lymphocytes (compare 
Figure 29A, B with Figure 30A, B). Taken together, these data demonstrate receptor-dependent 
cytosolic uptake of antigens into APCs upon transduction with PTVs harboring envelope 
glycoproteins. Subsequently, antigens are proteasomally processed and presented on MHC I molecules 
via the endogenous antigen presentation pathway. Soluble or solely particle-associated Ova, however, 
is taken up endosomally, processed in acidified late endosomes or lysosomes and presented on MHC 
II molecules via the exogenous antigen presentation pathway. This proposed mode of action of PTVs 
is summarized in Figure 49 of the present thesis.   
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Figure 49: Proposed model for uptake, processing and presentation of soluble and particulate antigens by 
APCs. Antigens (red) are incorporated into PTV particles as part of the Gag polyprotein and subsequently 
released by HIV-1 protease mediated cleavage during particle maturation. Interaction of viral Env (blue) with the 
respective cellular receptors (orange) leads to receptor-mediated endocytosis and pH-dependent membrane 
fusion (VSV-G pseudotyped particles, (1)) or pH-independent membrane fusion at the cell’s surface (MV-GP 
pseudotyped particles, (2)) followed by cytosolic release of antigens into transduced APCs. Antigens are 
proteasomally processed (3), loaded onto MHC I molecules (4) and finally presented via the endogenous 
antigen-presentation pathway (5). Without specific Env-receptor interactions, soluble (6) or particulate antigens 
(7) are endocytosed, cleaved by proteases in late endosomes (8), loaded onto MHC II molecules (9) and 
presented via the exogenous antigen presentation pathway (10). Figure modified after Uhlig et al., 2015. 
 
Strikingly, also SLAM
-
 mDCs incubated with MVwt-Ova-LVKatushka were able to stimulate CD4
+
 T 
cells (Figure 30, see cytokine secretion by Ova-specific T cells in co-culture with mDCs of IFNAR
-/-
 
mice incubated with MVwt-Ova-LVKatushka). This might be due to target receptor-independent 
endocytosis of these particles by APCs. These “particulated antigens” are subsequently processed and 
presented via the exogenous antigen presentation pathway (Figure 49, to the right). Target receptor-
independent endosomal uptake of lentiviral and γ-retroviral particles by different human cell lines has 
been described before, also for MVvac-GP pseudotyped LVs (Voelkel et al., 2012). Although in this 
thesis hardly any protein or gene transfer was observed into receptor-negative cell lines (Figure 23, 
Figure 25, Figure 26 and data not shown for bald particles), target receptor-independent antigen uptake 
is conceivable since APCs are known for their high capacity to endocytose antigens. Even though such 
antigen uptake is primarily attributed to immature APCs, recent work demonstrated also mature DCs 
being capable of doing so (Platt et al., 2010). Here, uptake was mostly restricted to antigens captured 
by endocytotic receptors. Interestingly, MV wild-type and vaccine strains (Witte et al., 2006) and 
MVvac-LVs (Humbert et al., 2012) have been reported to attach to the C-type lectin DC-SIGN, but do 
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not actively enter DC-SIGN-expressing cells. As DC-SIGN is involved in receptor-mediated 
endocytosis (Engering et al., 2002; Cambi et al., 2009), one could speculate that attachment of MVwt-
Ova-LVKatushka to murine DC-SIGN in SLAM-negative APCs might favor endocytotic particle uptake 
and presentation of Ova peptides via the endogenous antigen presentation pathway (Figure 49, to the 
right). However, until now it is not known if/how MV or MV-LV particles bind to murine DC-SIGN 
(Takaki et al., 2014).  
4.1.3. Vaccine properties of PTVs 
The promising results regarding specificity and immunostimulatory potential of PTVs obtained in 
vitro prompted the assessment of PTV-induced immune stimulation in vivo. In vivo studies with MV 
are usually performed in MV receptor-transgenic mice (Mrkic et al., 1998; Ohno et al., 2007) or 
naturally MV receptor-positive non-human primates (Myers et al., 2007), which are susceptible to MV 
infection. Thus, immunogenicity of MVwt-GP pseudotyped PTVs was assessed in SLAM
ki
 mice, 
characterized by replacement of the murine V domain of SLAM against the human one (Ohno et al., 
2007), to which MV H can bind (Sato et al., 2012). IFNAR
-/-
 mice, the parental strain to SLAM
ki
 mice, 
served as MV receptor-negative control animals.  
 
Following vaccination of these mice with MVwt-GP and VSV-G pseudotyped Ova-PTVs, receptor-
dependent, but antigen-specific recall-independent activation of splenocytes was observed four days 
after booster immunization (Figure 32). To elucidate recall-independent activation of antigen-specific 
T cells, thawed and pooled splenocytes of each vaccinated animals’ group were separated into T cells 
and other cells, containing APCs. T lymphocytes, when incubated overnight in medium containing no 
IL-2, reacted to antigen recall whereas control T cells did not (Figure 33, Figure 34). This indicates 
persisting antigen-specific activation of splenocytic T lymphocytes four days after booster 
immunization. A similar phenomenon has already been reported by Haglund et al., who observed 
persistent activation of HIV-1 Env-specific CD8
+
 T cells five days after boosting with recombinant 
VSV expressing HIV-1 Gag or HIV-1 Gag and Env (Haglund et al., 2002). Moreover, in our study the 
APC-containing retentate obtained after MACS separation of PTV-vaccinated mice’s splenocytes 
stimulated Ova-specific naïve T cells from TCR-transgenic OT-I mice (Figure 35). The data suggest 
constant antigen processing and presentation, which might be possible due to intracellular storage of 
particulate antigens in APCs. Interestingly, lysosome-like antigen storage organelles, different from 
MHC I and II loading compartments, have been described in mature DCs (van Montfoort et al., 2009). 
These organelles provide continuous antigen supply and thus enable long-term CD8
+
 T lymphocyte 
cross-priming by DCs, as measured by proliferation of antigen-specific T cell for up to 14 days after 
injection of pulsed DCs in vivo (van Montfoort et al., 2009). Presumably, PTV-associated Ova was 
stored within these organelles. It will be interesting to investigate potential differences in processing 
and storage of PTV-associated versus proteinaceous antigens in further experiments.   
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Immunization with VSV-Ova-LVKatushka (Figure 33, Figure 34, Figure 35A) led to predominant 
stimulation of CD8
+
 T lymphocytes in vivo. A similar trend was also observed for MVwt-Ova-
LVKatushka (Figure 34; JAWSII-Ova cells were previously shown to stimulate CD8
+
 but not CD4
+
 TCR-
transgenic T cells (Bodmer, 2015)). This is in accordance with the in vitro data showing induction of 
Ova-specific CD8
+
 T cell but hardly any CD4
+
 T cell responses by receptor-positive mDCs transduced 
with the pseudotyped PTVs (Figure 29 and Figure 30). Thus, the data indicate cytoplasmic transfer of 
Ova upon transduction with pseudotyped PTVs, followed by antigen processing and presentation via 
the endogenous antigen presentation pathway (Figure 49, to the left). The picture is similar to the one 
found after immunization with lentiviral gene transfer vectors. Here, predominant induction of CD8
+
 T 
lymphocyte responses is expected since the particles deliver antigen-encoding sequences into APCs, 
which provide the template for de novo synthesis of proteins in the cytoplasm and subsequent MHC I 
presentation. Indeed, lentiviral gene transfer vectors induce mainly CD8
+
 T lymphocyte responses, 
independent if broadly transducing VSV-G pseudotypes (Esslinger et al., 2002; Palmowski et al., 2004) 
or APC-specific vectors were employed (Yang et al., 2008; Ageichik et al., 2011). 
 
To allow direct comparison of immunogenicity among differently pseudotyped PTVs and of PTVs 
with recombinant protein, antigen content of all vector preparations and protein was normalized to 
1 µg Ova per injection. Adjusted that way, approximately 34-times more transducing units of VSV-
Ova-LVKatushka than MV-Ova-LVKatushka PTVs were administered due to higher infectivity of VSV-G 
pseudotypes (Figure 20B, right column). This likely explains the stronger stimulation of antigen-
specific T cells, and especially CD8
+
 CTLs, upon injection of VSV-Ova-LVKatushka (Figure 33, Figure 
34). Expectedly, both MVwt-GP and VSV-G pseudotyped PTVs induced stronger APC-mediated 
stimulation of splenocytes/ T cells than recombinant Ova (Figure 32, Figure 33, Figure 34). Similar 
observations have already been made with other antigens. HIV-1 Env (McBurney et al., 2007) or 
glycosylphosphatidylinositol-conjugated Her2 (Patel et al., 2015), for example, triggered a more 
vigorous cellular or cellular and humoral immune response, respectively, when presented on VLPs 
than the corresponding soluble proteins. Contrary to the assumption that VLPs do cause strong 
immune stimulation due to the structural and antigenic similarity to the virus they are derived from 
(Grgacic. and Anderson, 2006), no PTV-mediated upregulation of CD69 or CD86 on murine mDCs 
was observed (Figure 28). However, CD69 and CD86 are not the only markers for activation of 
dendritic cells. Since PTVs were able to induce CD8
+
 T lymphocyte responses in vitro and in vivo 
(Figure 29, Figure 33, Figure 34), some activation of DCs must have occurred. 
 
Taken together, PTVs were able to deliver the model antigen Ova into receptor-positive APCs, leading 
to the stimulation of antigen-specific T cells, and especially CD8
+
 T lymphocytes, in vitro and in vivo. 
Thereby, PTVs showed promise for vaccination approaches requiring the induction of a strong cellular 
immune response. 
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4.2. Targeted gene delivery into CD4+ T cells 
CD4
+
 T cells play a key role in coordinating adaptive immune responses, including the support of 
CD8
+
 cytotoxic T cell and B cell effector functions. Moreover, they are involved in various diseases 
like HIV-1 infection/AIDS, cancer or autoimmune disorders (Broux et al., 2012; Kamphorst and 
Ahmed, 2013). Hence, CD4
+
 T cells are important target cells for gene therapy and immunotherapy 
approaches.  
State of the art for the genetic modification of CD4
+
 T lymphocytes by lentiviral vectors is the 
isolation of these cells from the patient’s body, followed by ex vivo modification, expansion and 
reinfusion into the patient (Levine et al., 2006). Thus, genetic manipulation of CD4
+
 cells is both 
costly and laborious. Moreover, the procedure can be associated with altered characteristics, e.g. 
phenotypical and functional changes (Sauce et al., 2002a; Sauce et al., 2002b; Marktel et al., 2003), 
reduced in vivo persistence or proliferation of autologous cells (Naldini, 2011) and may cause poor 
clinical responses. The exclusive and stable genetic modification of CD4
+
 cells by LVs in vivo, 
however, would open new therapeutic avenues and is thus highly desirable. Ideally, transduction 
should not be restricted to activated lymphocytes, which is true for commonly applied LVs (Maurice 
et al., 2002; Frecha et al., 2009), but also, at least to a certain degree, extend to naïve, resting CD4
+
 T 
cells. These lymphocytes, which may persist over years in patients, possess the capacity to respond to 
new antigens, providing long-lasting immune reconstitution to patients, and are therefore of great 
interest as gene therapy targets (Verhoeyen et al., 2009).  
When this PhD project was initiated, no vector mediating highly selective and efficient in vivo gene 
transfer into CD4
+
 lymphocytes after systemic administration had been described. Therefore, this 
thesis aimed to generate a CD4-targeted vector suitable for in vivo gene delivery approaches. Since 
CD4
+
 T cells are distributed throughout the entire body, an entry-targeted vector was established to 
allow systemic vector application without modification of non-target cells.   
4.2.1. Surface-engineered lentiviral vectors and their targets 
At present, there are two flexible entry retargeting systems for LVs available, either based on 
engineered MV-GPs or engineered Sindbis virus glycoproteins. Whereas the first strategy has shown 
absolute specificity for a wide range of target receptors of human or murine origin (see Table 21), 
preferential target cell transduction accompanied by substantial off-target transduction was 
demonstrated for the latter (Zhang et al., 2010). Due to the leakiness of the mutations introduced in the 
Sindbis virus E2 protein to abolish the natural receptor binding, these LVs require combination with 
transcriptional targeting in order to achieve high target specificity (Pariente et al., 2007). Thus, the 
retargeting system based on MV-GPs, as used in this thesis, can be considered superior to the one 
using Sindbis virus GPs with respect to selectivity.  
 
Discussion 
112 
 
With the MV-GP based retargeting system, scFvs, natural protein ligands or DARPins have been fused 
to blinded MV hemagglutinin to confer specificity of LVs for a receptor of choice (for an overview see 
Table 21). It has been shown that the biophysical properties of the targeting ligand, including stability, 
the tendency to aggregate, and its affinity, are pivotal for the successful generation of targeted LVs 
(Friedel et al., 2015). Hence, DARPins are especially suited as binding domains as they are 
characterized by tremendous stability, a low tendency to aggregate, and affinities in the low nanomolar 
or picomolar range (Plückthun, 2015).  
 
Table 21: Characteristics of MV-LV and thereof derived surface-engineered lentiviral vectors.  
Targeting 
domain 
Vector  
Target 
receptor 
Transduction 
of resting 
lymphocytes? 
In vivo 
application? 
Reference 
- MVvac-LV 
huSLAM, 
huCD46 
yes n.d.
a
 
(Frecha et al., 2008a; 
Frecha et al., 2009;  
Zhou et al., 2011) 
Natural 
protein ligand 
EGF-LV
b
 
IL-13-LV
b
 
huEGFR 
huIL-13R 
n.a.
c
 
n.d.
a
 
n.d.
a
 
s.c.
d
, i.c.
e
 
(Funke et al., 2008) 
(Ou et al., 2012) 
scFv 
CD20-LV
b
 
GluA-LV
f
 
CD105-LV
b
 
 
CD133-LV
b
 
MHC II-LV
b
 
CD8-LV
b
 
mCD105-LV
b
 
CD19ds-LV
b
 
CD30-LV
b
 
huCD20 
muGluR 
huCD105 
 
huCD133  
muMHC II 
huCD8 
muCD105 
huCD19 
huCD30 
yes 
n.a.
c
 
n.a.
c
 
 
n.a.
c
 
n.d.
a
 
no 
n.a.
c
 
yes 
n.a.
c
 
n.d.
a
 
intracerebral 
systemic 
 
systemic 
systemic 
only local 
systemic 
n.d.
a
 
n.d.
a
 
(Funke et al., 2008) 
(Anliker et al., 2010) 
(Anliker et al., 2010;  
Abel et al., 2013) 
(Anliker et al., 2010) 
(Ageichik et al., 2011) 
(Zhou et al., 2012) 
(Abel et al., 2013) 
(Kneissl et al., 2013) 
(Friedel et al., 2015) 
DARPin 
D9.29-LV
b
 
CD4-LV
b
 
huHer2/neu 
huCD4 
n.a.
c
 
yes 
systemic 
systemic 
(Münch et al., 2011) 
this thesis 
a
 n.d., not determined. 
b
 Targeting relies on modified MVNSe vaccine strain H. 
c
 n.a., not applicable. 
d
 s.c., 
subcutaneous. 
e
 i.c., intracranial. 
f
 Targeting relies on modified MVwt H. 
 
The CD4-specific LV generated in this thesis relied on a CD4-specific DARPin as binding moiety. 
H-αCD4 was shown to be well expressed in HEK-293T packaging cells (Figure 36B), leading to its 
efficient incorporation into CD4-LV particles (Figure 36C). Titers of CD4-LV were on average at least 
10-fold higher than those of the other lymphocyte-targeted vectors, i.e. CD20-LV, CD19ds-LV, and 
CD8-LV (Funke et al., 2008; Zhou et al., 2012; Kneissl et al., 2013). Although augmented 
transduction due to particular properties of the CD4 receptor itself cannot be ruled out, the used 
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DARPin is the more likely reason. Likewise, higher titers of DARPin-displaying than scFv-
incorporating particles have already been reported for Her2/neu-targeted LVs (Münch et al., 2011). 
Thus, the respective binding domain also influences the in vivo performance of a given vector, which 
critically depends on high vector yields. Recently, a CD8-targeted vector, displaying an OKT3-derived 
scFv, has been introduced by our laboratory, which is highly selective for its target cells and able to 
transfer complex genes like tumor antigen-specific TCR sequences into CD8
+
 T lymphocytes (Zhou et 
al., 2012). However, although local injection led to specific in vivo transduction of CD8
+
 T cells, 
vector titers were too low to result in significant numbers of transduced CD8
+
 cells upon systemic 
administration (Zhou and Buchholz, unpublished data; and own data not shown). Nonetheless, albeit 
DARPin-displaying particles are commonly characterized by higher titers, there are also targeted 
vectors relying on scFv-display, which mediate satisfying in vivo gene delivery upon systemic 
administration, as demonstrated for mCD105-LV (Table 21). 
 
Due to its broad tropism and high stability, LVs are often pseudotyped with VSV-G. However, one 
major drawback of VSV-LV is its inability to mediate efficient gene transfer into resting lymphocytes, 
i.e. lymphocytes in the G0 phase of the cell cycle, which has been attributed to the very low expression 
of its receptor LDL-R on these cells (Amirache et al., 2014). Thus, transduction with VSV-LV 
depends on upregulation of LDL-R, which is achieved by pre-activation of lymphocytes.  
In contrast, LVs pseudotyped with glycoproteins of the MVNSe variant of the MV vaccine strain 
Edmonston B were shown to efficiently transduce resting T and B cells, respectively, without inducing 
cell cycle entry (Frecha et al., 2008a; Frecha et al., 2009). Thereby, interaction with both, CD46 and 
SLAM, was required for adequate gene transfer into resting lymphocytes (Frecha et al., 2011; Zhou et 
al., 2011). In line with these findings, MVwt-LV, not recognizing CD46, was not able to transduce 
resting T cells (Zhou et al., 2012).  
Accordingly unexpected at first, also some targeted LVs, where CD46 and SLAM recognition by 
MVNSe hemagglutinin was abolished, have been reported to enable transduction of resting lymphocytes 
(see Table 21) (Funke et al., 2008; Kneissl et al., 2013). Of note, transgene expression was detected in 
about 60% and 20% (two days post transduction) or 30% and 10% (six days post transduction) of 
unstimulated B lymphocytes after transduction with CD20-LV and CD19ds-LV (both MOI 2), 
respectively (Kneissl et al., 2013). Also CD4-LV was able to deliver transgenes into resting 
lymphocytes, as demonstrated by detection of approximately 8% GFP
+
/CD4
+
 T cells three and six 
days after incubation with vector particles at MOI 2 (Figure 38C). Here, no decline of GFP-positive 
CD4
+
 cells was observed over time, indicating stable transduction without pseudotransduction. 
However, compared to the gene transfer rate by CD20-LV and CD19ds-LV, gene delivery in resting 
CD4
+
 T cells was relatively low. This might be due to the action of SAMHD1, a dNTP triphospho-
hydrolase abundantly expressed in resting CD4
+
 T cells, monocytes and dendritic cells, which depletes 
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the pool of free dNTPs and therefore prevents reverse transcription of viral RNA in these cells 
(Baldauf et al., 2012).  
What is the underlying mechanism enabling transduction of resting lymphocytes by targeted LVs 
pseudotyped with engineered MV-GPs not recognizing SLAM or CD46? Here, transduction seems to 
be dependent on activating stimuli induced by targeted LVs. It has been suggested that incorporated 
scFvs transfer features of their parental antibody to vector particles, e.g. activation of cells upon 
antibody-antigen interaction (Zhou et al., 2012; Kneissl et al., 2013). Antibodies directed against 
CD20, for instance, were described to stimulate B lymphocytes and initiate cell cycle progression from 
G0 to G1 (Golay et al., 1985). Similarly, also for CD20-LV minimal activation and transition from G0 
to G1 phase of cell cycle was observed (Kneissl et al., 2013), which likely enabled efficient 
transduction of resting cells without the requirement of pre-activation. In contrast, engagement of CD4 
on DCs by a CD4-specific DARPin selected in parallel to DARPin D29.2 did not cause activation of 
these cells, as determined by expression of the co-stimulatory molecule CD80 (Schweizer et al., 2008). 
Also in our study, no significant difference in the expression of the activation marker CD25 was 
observed between untransduced and CD4-LV (MOI 2) transduced lymphocytes three days after 
transduction (data not shown). However, contrary to the data by Schweizer et al. reporting no change 
in CD4 density at the surface of CD4
+
 T cells upon incubation with DARPin D29.2 (Schweizer et al., 
2008), pronounced CD4 down-regulation following transduction with CD4-LV was observed in the 
present thesis (Figure 38D). CD4 is closely linked to the cell activation pathway (Kornfeld et al., 1988; 
Pelchen-Matthews et al., 1989) and the observed internalization of CD4 upon CD4-LV transduction 
strongly suggests cell signaling. Thus, it is likely that CD4-LV, similar to CD20-LV and CD19ds-LV, 
at least minimally activated the cells, which conferred susceptibility of the resting lymphocytes to 
lentiviral transduction.  
However, transduction efficiency in quiescent lymphocytes was clearly lower than in activated 
primary human PBMC (Figure 38C). The positive correlation between CD4-LV transduction 
efficiency and activation state of its target cells was also confirmed in vivo, since higher luciferase 
activity and more transduction events were found in mice engrafted with stimulated than with 
unstimulated PBMC (Figure 43 C-D, Figure 45). This is likely owed to various post-entry blocks to 
HIV-1 infection or transduction with thereof derived LVs in resting T lymphocytes (Zack et al., 1990; 
Yoder et al., 2008; Baldauf et al., 2012), which do not apply in activated T cells, thus allowing their 
more efficient transduction. 
4.2.2. Targeting CD4+ cells with γ-retroviral and lentiviral vectors 
Attempts aiming at targeted γ-retroviral or lentiviral transduction of CD4-expressing cells involved 
transcriptional as well as entry targeting endeavors. Using transcriptional targeting, Marodon and 
colleges reported transgene expression in primary human CD4
+
 T cells as well as in CD4
+
 T cells, 
dendritic cells and macrophages derived from human HSC, which had been transduced with a LV 
Discussion 
115 
 
transferring GFP under control of CD4 gene-specific promoter and enhancer sequences (Marodon et 
al., 2003). Despite being vastly absent in B lymphocytes, transgene expression was not restricted to 
CD4
+
 T lymphocytes but also detected in CD8
+
 T lymphocytes. Here, the percentage of CD4
+
 and 
CD8
+
 GFP-expressing cells was even similar, and addition of the CD4 gene silencing element to the 
vector regulatory sequences could only reduce but not completely ablate transgene expression in CD8
+
 
cells.  
Entry targeting attempts mostly concentrated on exploiting the natural tropism of HIV-1 Env, which 
was used to pseudotype MLV-derived γ-retroviral vectors (Mammano et al., 1997; Schnierle et al., 
1997) or HIV-1 derived lentiviral vectors (Poznansky et al., 1991; Shimada et al., 1991; Agosto et al., 
2009; Geng et al., 2014). Of note, LVs pseudotyped with CXCR4-tropic HIV-1 Env did allow 
efficient gene transfer into resting CD4
+
 T lymphocytes while preserving their natural quiescent state 
(Agosto et al., 2009; Geng et al., 2014). Additionally, also SIVmac Env pseudotyped MLV-derived 
vectors have been employed to mediate CD4-specific gene transfer (Indraccolo et al., 1998). However, 
vectors pseudotyped with HIV-1 or SIVmac Env can be neutralized by HIV-1-specific antibodies 
present in HIV-1 seropositive patients, which would limit their application for HIV-1 gene therapy 
(Stitz et al., 2000). Therefore, also SIVagm Env pseudotyped MLV-derived vectors, resistant to 
neutralizing antibodies, have been developed to allow selective genetic modification of CD4
+
 cells 
(Stitz et al., 2000). Besides HIV-1 and SIV Env, exhibiting a natural tropism for CD4
+
 cells, 
engineered Sindbis virus envelope proteins, conjugated to a CD4-specific antibody, have been used to 
pseudotype HIV-1 derived vectors (Morizono et al., 2001; Liang et al., 2009). However, transgene 
expression following transduction with these vectors was enriched in but not limited to CD4
+
 cells in 
vitro. In contrast, CD4-LV, relying on the MV-GP based retargeting system, did not transduce CD4
-
 
Raji cells or primary human CD8
+
/CD4
-
 lymphocytes in the naturally mixed PBMC population while 
efficiently transducing CD4
+
 cells in vitro (Figure 37).  
 
Similar to CD4-LV, most CD4-targeted vectors indeed showed target specificity on cell lines and 
primary T cells. However, transduction efficiencies were rather moderate and in vivo gene delivery 
was not assessed. So far, only one other study reported CD4-specific gene transfer in vivo (Schüle et 
al., 2006). There, gene delivery was mediated by a MLV-derived γ-retroviral vector pseudotyped with 
CD4/CXCR5-tropic HIV-1 envelope proteins, termed [MLV(HIV)]. Administered intraperitoneally 
into mice double transgenic for human CD4 and human CCR5, about 0.3% of the 
(hu)CD4
+
/(hu)CCR5
+
 target cells in the peritoneal cavity were transduced, whereas upon intravenous 
injection into the same mice only single, sporadic transduction events could be observed in spleen and 
liver but not in peripheral blood. Interestingly, average titers of 3 x 10
6
 t.u./ml for concentrated 
[MLV(HIV)] necessitated three to four vector injections in order to infuse 1 x 10
6
 (i.v. administration) 
or 8 x 10
6
 (i.p. administration) t.u./mouse, respectively.  
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In contrast, CD4-LV with a concentrated titer of 2.3 ± 1.8 x 10
8
 t.u./ml required only a single 
administration to inject the applied 8 x 10
7
 t.u./ NSG mouse engrafted with human PBMC or 1.5 x 10
7
 
t.u./ NSG mouse engrafted with human HSC, respectively. In both mouse models, CD4-LV showed 
high specificity for its target cells, as demonstrated by gene transfer into human CD4
+
/CD3
+
 but not 
into human CD4
-
/CD3
+ 
cells or cells of murine origin (Figure 44, Figure 45A, Figure 47, Figure 48A). 
Systemic application of CD4-LV into PBMC-engrafted NSG mice resulted in up to 16.6% of 
GFP
+
/CD4
+
 T lymphocytes in the peripheral blood (Figure 45B), and was thus way more effective 
than injection of [MLV(HIV)]. In this model, strong luciferase activity was detected in lymphoid 
organs where T lymphocytes are supposed to concentrate (Figure 43 C, D, F). Additionally, luciferase 
activity was also observed in skin, liver, and lung of the animals (Figure 43 E). This is in line with the 
literature where the named organs are described as the first targets for infiltrating human lymphocytes 
in the course of GvHD (Ferrara et al., 1996; Schroeder and DiPersio, 2011). Supporting this 
hypothesis, in human HSC-engrafted mice, where human T cells are tolerant to the mouse 
environment, basically no luminescence in skin and liver and only weak signals in lung were observed 
(data not shown). 
Which factors influence transduction efficiency and in vivo distribution of CD4-LV? A positive 
correlation between transduction efficiency and target receptor surface density was previously reported 
for targeted LVs pseudotyped with engineered MV-GPs (Anliker et al., 2010; Münch et al., 2011; 
Abel et al., 2013) or engineered Sindbis virus glycoproteins (Liang et al., 2009). In line with this, 
CD4-LV efficiently transduced CD4
+
 T cells in spleen, lymph node like structures, and blood of HSC-
engrafted NSG mice, which are characterized by a high CD4 density, whereas thymus-derived CD4
+
 
cells with lower CD4 receptor density were hardly transduced (Zhou et al., 2015). The same pattern 
was observed for naïve and memory CD4
+
 T cells, with naïve lymphocytes, exhibiting a lower CD4 
density (Zhou et al., 2015), less efficiently transduced by CD4-LV (Figure 48B and C and Zhou et al., 
2015).  
Besides receptor surface density, also blood circulation kinetics are pivotal for in vivo transduction and 
vector biodistribution. Accordingly, low velocity of blood flow in the sinuses of the liver has been 
suggested as one reason for enhanced gene delivery with a lentiviral vector targeting the endothelial 
cell marker CD105 (Abel et al., 2013). Also in the capillaries of the bone marrow the blood flow is 
substantially slowed down, which presumably increased the likelihood of productive interaction 
between CD4-LV and its receptor. This might have compensated for the lower CD4 density in this 
organ (Zhou et al., 2015) and accounted for the transduction of bone marrow-derived CD4
+
 T cells 
(Figure 48 and Zhou et al., 2015). 
Taken together, this thesis describes the first lentiviral vector enabling specific and efficient CD4
+
 T 
lymphocyte targeting both in vitro and in vivo.  
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However, besides CD4
+
 T cells, also dendritic cells,
 
monocytes, and macrophages express CD4. 
Similar to resting CD4
+
 T lymphocytes, transduction of these cell types with common LVs is known to 
be rather inefficient due to the presence of HIV-1 restriction factors like APOBEC3 (Peng et al., 2007) 
or the dNTP triphoshohydrolase SAMHD1 which hinders reverse transcription of viral RNA in resting 
CD4
+
 T cells (Baldauf et al., 2012) and human dendritic and myeloid cells (Laguette et al., 2011).  
Interestingly, CD4-LV was able to transduce M1 and M2 macrophages generated from human PBMC 
(Figure 40). M1 macrophages were characterized by lower CD4 receptor density than M2 
macrophages (Figure 39), in line with literature describing M1 polarization to be accompanied by CD4 
down-regulation (Cassol et al., 2009). Based on the above mentioned experiences with receptor-
targeted LVs, which preferentially transduced cells with higher target receptor density (Anliker et al., 
2010; Münch et al., 2011; Abel et al., 2013) and also the observations made with CD4-LV on T 
lymphocytes (Zhou et al., 2015), M2 macrophages would have been expected to be more prone to 
lentiviral gene transfer than M1 macrophages. However, approximately 30% of M1 macrophages were 
transduced by CD4-LV at MOI 10, whereas only about 2% gene delivery into M2 macrophages was 
observed in the same setting (Figure 40). Interestingly, pre-incubation with VLPs delivering the 
accessory viral protein X (Vpx), naturally encoded by HIV-2 and some SIV strains, which induces 
proteasomal degradation of SAMHD1, led to increased transduction of M2 (about 70% transduced 
cells) but not M1 macrophages (Figure 40). This would argue for a SAMHD1 mediated restriction of 
lentiviral transduction in M2 macrophages. However, no significant differences in SAMHD1 levels 
between M1 and M2 macrophages, which could explain the experimental data, are described (Cobos 
Jiménez et al., 2012). Thus, further investigations are needed to elucidate the mechanisms causing 
different susceptibility of M1 and M2 macrophages to lentiviral transduction.   
Concluding, CD4-LV could transduce human macrophages generated from PBMC although gene 
transfer was less efficient than in CD4
+
 T lymphocytes, requiring higher MOIs of CD4-LV or pre-
treatment with Vpx.  
4.3. Lentiviral vectors for immunotherapy 
Immunotherapy aims to treat diseases by eliciting, amplifying or suppressing immune reactions. 
Thereby, immunotherapeutic efforts may address autoimmune disorders, transplant rejection, chronic 
inflammation, infectious diseases or cancer (Steinman and Mellman, 2004). Since both PTVs and 
CD4-LV target immune cell subsets with pivotal functions in the orchestration of immune responses, 
also these vector types may become interesting tools for immunotherapy. 
 
What would adequate indications for PTV- and CD4-LV-based immunotherapy be? 
In this proof of principle study, transfer of the model antigen Ova by PTVs triggered stimulation of 
cellular immunity, and more precisely predominant activation of CD8
+
 T cells (Figure 29A and B, 
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Figure 33, Figure 35). Thus, PTV vaccines seem to be especially suited for indications requiring the 
induction of strong antigen-specific CD8
+
 cytotoxic T cell responses, like cancer immunotherapy.  
Traditionally, the pivotal role of CD8
+
 T lymphocytes in anti-tumor immunity has been acknowledged. 
However, mounting evidence underscores the relevance of CD4
+
 T cell responses in cancer 
immunotherapy (Muranski and Restifo, 2009). Indeed, CD4
+
 T cell help has been reported to be 
indispensable for induction of functional CD8
+
 CTL effector cells from naïve precursors (Bennett et 
al., 1998; Ridge et al., 1998; Schoenberger et al., 1998) and generation of CD8
+
 T memory cells in 
vivo (Janssen et al., 2003; Shedlock and Shen, 2003; Sun and Bevan, 2003). Moreover, CD4
+
 T 
lymphocytes themselves can directly kill tumor cells upon recognition of antigen-peptides presented 
on MHC II molecules (Hunder et al., 2008; Weigand et al., 2012). However, although most tumor 
cells are MHC I-positive, expression of MHC II molecules is rather rare. To circumvent MHC II 
restriction, CD4
+
 T cells have lately been engineered to express chimeric antigen receptors (CARs), in 
which the antigen-binding moiety of an antibody is fused to intracellular T cell signaling domains. 
These cells exhibited direct cytotoxicity towards target cancer cells (Hombach et al., 2001; Hombach 
et al., 2006). Transfer of CAR-encoding genes is clearly also a field of application of CD4-LV. In fact, 
following transduction with the CD4-LV vector introduced in this thesis, Her2/neu-CAR expressing 
CD4
+
 T cells lysed Her2/neu
+
 tumor cells and produced high amounts of Th1 cytokines in a short-term 
in vitro killing assay (Zhou et al., 2015).  
Besides applying the two vector types on their own, it might be interesting to combine APC-targeted 
PTVs and CD4-LV to cause strong anti-tumor effects. Thereby, immunogenicity of PTVs transferring 
tumor-associated antigens might be additionally boosted by co-delivery of immunostimulatory nucleic 
acids, potentially increasing vaccination success. Moreover, further combination with CD8-LV, which 
has been previously generated in our laboratory (Zhou et al., 2012), might have beneficial effects on 
anti-tumor immune responses. In line with this, parallel use of TCR-engineered CD8
+
 and CD4
+
 for 
tumor therapy has already been described to be more effective than either cell type alone (Kuball et al., 
2005).  
In addition to cancer immunotherapy, also HIV-1 gene therapy is well in scope of therapeutic 
applications of CD4-LV. Accordingly, CD4-LV transduced T cells, engineered to express the 
membrane-anchored HIV-1 entry inhibitor maC46, were protected against HIV-1 infection in vitro 
(Zhou et al., 2015). Within the plethora of anti-HIV-1 strategies interfering with different steps of 
HIV-1 life cycle, blocking HIV-1 already at the stage of cell entry is especially desirable. maC46 
expression conferred a clear selective advantage upon HIV-1 challenge, which is in line with previous 
in vitro and in vivo data (Kimpel et al., 2010) and which will be of prime importance in clinical trials 
since only a minor fraction of the HIV-1 target cell population in men can be genetically modified.  
Moreover, CD4-LV is suitable to induce CD4
+
 regulatory T cells by transfer of FoxP3 or IL-10 genes 
in vitro and in vivo (Zhou, Pfeiffer and Buchholz, unpublished data and Zhou et al., 2015). Tregs are 
major players in the suppression of immune responses and their induction is highly desirable in 
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diseases like allergies or autoimmune disorders. Also GvHD can be suppressed by Tregs, with 
implications on organ transplantation in human patients.  
However, before the vectors can enter clinical trials, preclinical animal studies have to confirm the 
suitability of PTVs and CD4-LV for the named therapeutic applications in vivo. Moreover, several 
hurdles, like production of sufficient amounts of high titer stocks, pre-existing MV-specific immunity 
and dependency of transduction on activation state/ phenotype of the cells, have to be overcome:  
 
1) Production of sufficient amounts of high titer stocks.  
Currently, both PTVs and CD4-LV are produced by transient PEI-transfection of adherent HEK-293T 
packaging cells seeded in single T175 flasks. After harvest, filtrated, vector-containing cell culture 
supernatant is concentrated by ultracentrifugation through a 20% sucrose cushion. Thus, the procedure 
is laborious, costly and only limited amounts of vector-containing supernatant can be processed at a 
given point of time, which restricts final vector yield. 
In recent successful gene therapy trials, relying on ex vivo correction of autologous cells prior 
reinfusion, approximately 1 x 10
9
 – 4 x 1010 infectious units of vector per patient were applied (Sanber 
et al., 2015). The antigen content of approved vaccines or vaccines in clinical trials commonly lies 
between few µg (Johnson et al., 2014) and several µg/few mg (Kim et al., 2014; Zandberg et al., 2015) 
per injection. Hence, to provide sufficient quantities of vector for clinical trials and commercialization, 
LV production clearly needs scale-up. Suitability of transiently PEI-transfected, serum-free suspension 
cultures and ultrafiltration or affinity chromatography purification for large-scale LV production has 
been described before (Segura et al., 2007) and has to be implemented. Interestingly, titers of various 
vectors produced by suspension cells were reported to exceed those of adherent-cell culture based ones 
(Ghani et al., 2006; Durocher et al., 2007), which is highly desirable for clinical application.   
If titers should be not sufficiently high, multiple injections at consecutive days, injection of large 
volumes of vector or local injections, e.g. in tumors, might ensure therapy success. Moreover, also 
autologous transfer of ex vivo modified APCs or CD4
+
 T lymphocytes might be an option to 
compensate for lower vector titers. However, in vivo application is clearly preferable as in vitro 
cultivation of cells can significantly affect their properties (Marktel et al., 2003) and in vivo 
modification would turn personalized medical products into universally applicable drugs. 
 
2) Pre-existing MV-specific immunity.  
Despite the appealing data obtained in vitro and in mouse studies, successful clinical application of 
LVs pseudotyped with (engineered) MV-GPs may be hampered by the pre-existing MV-specific 
immunity in humans developed in response to natural infection or vaccination. Strengthening these 
concerns, in vitro experiments showed neutralization of MV-LV by human serum (Lévy et al., 2012). 
Thereby, the human humoral immune response was described to be mainly directed against H, and 
here primarily against the immunodominant epitopes “Noose” and “NE” (Ertl et al., 2003), while anti-
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F antibodies hardly contributed to humoral anti-MV immunity (de Swart, Rik L et al., 2005). Mutating 
the two immunodominant epitopes of H abolished binding of Noose- and NE-specific antibodies 
without loss of vector activity but did not suffice to achieve complete escape from polyclonal MV-
specific antibodies in human sera (Lévy et al., 2012). Additional introduction of an extra glycosylation 
site, found in certain emerging MVwt strains, however, also prevented neutralization by polyclonal 
antibodies in human sera while leaving the transductional potency of the vectors unaffected (Lévy et 
al., 2012).   
Interestingly, also receptor-targeted vectors, where Noose and NE epitopes are unmutated and no 
additional glycosylation site is inserted, have been reported to partially escape neutralizing antibodies 
in human plasma (Kneissl et al., 2012). Here, protection from neutralizing antibodies was attributed to 
the four point mutations introduced to ablate interaction with the natural MV receptors, which most 
likely destroyed immunogenic epitopes, since antibodies are often directed against the SLAM binding 
site (Ertl et al., 2003). Moreover, a shielding effect of the displayed binding domain was proposed.  
Another possibility to circumvent anti-MV immunity is provided by the transfer of the targeting 
system to envelope proteins of animal paramyxoviruses, which are non-pathogenic to humans, as 
recently described for LVs pseudotyped with CD20-targeted Tupaia paramyxovirus glycoproteins 
(Enkirch et al., 2013). Thus, anti-MV immunity can be alleviated by several approaches, paving the 
way for clinical application of LVs incorporating (engineered) MV-GPs into their envelopes. 
 
3) Transduction of resting lymphocytes. 
CD4-LV selectively transduced its target cells in vitro and in vivo (Figure 37, Figure 44, Figure 45A, 
Figure 47, Figure 48A). However, a clear preference for transduction of activated or memory CD4
+
 T 
cells over naïve, resting CD4
+
 T cells was observed (Figure 38C, Figure 48B and C). In contrast to 
memory cells, naïve CD4
+
 T cells can recognize new antigens and are therefore of great importance to 
cellular immunity and of pivotal interest to gene therapy. Gene delivery into resting cells might be 
enhanced by co-transfer of the viral protein X (Vpx) derived from HIV-2 or several SIV strains. Vpx 
counteracts the HIV-1 restriction factor SAMHD1 in resting CD4
+
 T cells (Baldauf et al., 2012), 
monocytes and dendritic cells (Laguette et al., 2011), and therefore likely improves transduction 
efficiency in resting CD4
+
 T cells, as already shown by Geng et al. (Geng et al., 2014). Thus, it will be 
interesting to evaluate the effect of Vpx co-delivery by CD4-LV on transduction efficiency in resting 
CD4
+
 T cells. 
 
Taken together, despite several drawbacks, this thesis introduced two new and highly promising 
vectors candidates for immunotherapy. It will be interesting to follow further development of both 
vector types towards clinical application.  
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5. Summary 
Although pathogens are ubiquitously found in the environment, catching disease is quite scarce. This 
can be attributed to the action of immune cells, protecting the body from invading microorganisms. A 
central role in the induction and orchestration of adaptive immune responses is ascribed to antigen 
presenting cells (APCs), like dendritic cells (DCs), and CD4
+
 T lymphocytes. Due to their important 
functions, these cell types gained center stage in immunotherapy. Thereby, their specific modification 
is highly desirable for several applications, including prophylactic or therapeutic vaccination 
approaches and the fight against human immunodeficiency virus type 1 (HIV-1) infection. In recent 
years, especially viral vectors proved to be powerful tools for the modification of target cells. Among 
them, lentiviral vectors (LVs) are of particular interest as they are not only able to transduce dividing 
but also non-dividing cells. They can be retargeted to basically any receptor of choice by pseudotyping 
with (engineered) measles virus (MV) glycoproteins (GPs) hemagglutinin (H) and fusion protein (F). 
Beside transfer of genetic information, retroviral and lentiviral vectors are able to deliver heterologous 
proteins into their target cells when the cargo proteins are genetically fused to structural proteins of the 
vector particle (“protein transfer vectors”, PTVs). Taking advantage of this system, the present thesis 
aimed to employ lentiviral vectors for the specific modification of signaling lymphocyte activation 
molecule (SLAM)
+
 APCs and CD4
+
 T lymphocytes. 
 
Initially, production of PTVs was optimized to allow maximum gene and protein transfer into 
transduced cells. In order to achieve targeting of SLAM-positive APCs, PTVs were pseudotyped with 
truncated MVwt-GPs with an established tropism for SLAM. Beside SLAM, a hitherto unknown 
epithelial MV receptor was postulated, to whose identification as adherens junction protein Nectin-4 
the present thesis contributed to characterize SLAM
-
 target cell populations of MVwt-GPs. Indeed, 
upon pseudotyping of PTVs with MVwt-GPs, marker gene and GFP, Cre or ovalbumin (Ova) cargo 
protein delivery was completely restricted to SLAM- and Nectin-4-positive CHO cells and naturally 
SLAM-expressing B cell lines, whereas broad transduction was observed for VSV-G pseudotyped 
control vectors. Specific excision of the loxP-flanked cerulean open reading frame in receptor-positive 
indicator cell lines following PTV-mediated transfer of Cre recombinase exemplarily demonstrated 
cytoplasmic protein transfer and unimpaired functionality of the delivered cargo protein. Finally, 
transfer of the model antigen Ova by MVwt-GP and VSV-G pseudotyped PTVs into receptor-positive, 
murine DCs in vitro or after administration into human SLAM-transgenic and control mice in vivo was 
shown to stimulate antigen-specific T cells, and here especially CD8
+
 T lymphocytes. 
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In contrast to SLAM-targeted PTVs, which relied on MVwt-GPs, specificity of CD4-targeted LV 
(CD4-LV) was achieved by pseudotyping with engineered MV-GPs, displaying a CD4-specific 
designed ankyrin repeat domain (DARPin) as binding domain on receptor-blinded H. H-αCD4 was 
well expressed on the surface of HEK-293T packaging cells allowing its efficient incorporation into 
CD4-LV particles and giving rise to high titer vector stocks with average yields > 10
8
 transducing 
units/ml after concentration. In vitro, CD4-LV demonstrated absolute receptor specificity on cell lines 
and the naturally mixed population of primary peripheral blood mononuclear cells (PBMC), with 
transgene expression exclusively detectable in CD4
+
 but not CD4
-
 cells. Of particular note, CD4-LV 
was capable to stably transduce not only activated but also resting primary CD4
+
 lymphocytes. Beside 
transduction of CD4
+
 T lymphocytes, also gene transfer into CD4
+
 human macrophages could be 
demonstrated in vitro. In vivo, following systemic injection of CD4-LV transferring a bicistronic 
gfp/luciferase reporter gene, luciferase activity in NOD-scid IL2Rγ-/- mice reconstituted with human 
PBMC or hematopoietic stem cells was mainly detected in lymphoid organs. Flow cytometric analyses 
of GFP-expression in lymphoid organs and blood confirmed the strict receptor-dependency of 
transduction events found in vitro also to apply in vivo. Interestingly, a clear preference for 
transduction of CD4
+
 T memory cells over naïve CD4
+
 T lymphocytes was observed.  
 
Concluding, this thesis clearly demonstrated suitability of (engineered) MV-GPs pseudotyped LV for 
specific protein and gene delivery into distinct subsets of immune cells. By the successful generation 
of SLAM- and CD4-targeted LVs, which allowed specific modification of SLAM
+
 APCs and CD4
+
 T 
lymphocytes, including even resting T lymphocytes, respectively, the broad applicability of MV-GP 
based cell entry targeting approaches for diverse cell surface receptors was emphasized. Both PTVs 
and CD4-LV are promising tools for basic research and gene and immunotherapy, opening up new 
avenues for a multitude of diverse applications. 
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6. Zusammenfassung 
Obwohl wir permanent von einer Vielzahl von Pathogenen umgeben sind, werden wir nur selten krank. 
Dieses Phänomen ist auf die Gegenwart des Immunsystems zurückzuführen, das den Körper vor 
eindringenden Mikroorganismen schützt. Eine zentrale Rolle in der Induktion und Koordination 
adaptiver Immunantworten wird antigen-präsentierenden Zellen (engl. antigen presenting cells, APCs), 
wie dendritischen Zellen (engl. dendritic cells, DCs), und CD4
+
 T Lymphozyten zugeschrieben. 
Aufgrund ihrer bedeutenden Funktion sind diese Zelltypen in den Fokus der Immuntherapie gerückt. 
Ihre spezifische Modifikation ist dabei für verschiedene Anwendungen erstrebenswert, unter anderem 
für prophylaktische und therapeutische Impfung und die Bekämpfung von Infektionen durch das 
humane Immundefizienzvirus Typ 1 (HIV-1). In den vergangenen Jahren haben sich besonders virale 
Vektoren als nützliche Hilfsmittel für die genetische Modifikation von Zielzellen erwiesen. Unter 
ihnen sind vor allem lentivirale Vektoren (LVs) von großem Interesse, da sie nicht nur mitotisch 
aktive, sondern auch ruhende Zellen transduzieren können. Durch Pseudotypisierung mit den 
modifizierten Masernvirus (MV) Glykoproteinen (GPs) Hämagglutinin (H) und Fusionsprotein (F) 
kann ihnen Spezifität für nahezu jeden beliebigen Rezeptor verliehen werden. Zudem können 
retrovirale und lentivirale Vektoren neben dem Transfer von Genen auch heterologe Proteine in ihre 
Zielzellen übertragen, insofern diese genetisch mit Strukturproteinen der Vektorpartikel fusioniert 
wurden („Proteintransfervektoren“, PTVs). Basierend auf diesem System war es das Ziel der 
vorliegenden Arbeit, lentivirale Vektoren für die zielgerichtete Modifikation von SLAM
+
 (Akronym 
für engl. signaling lymphocyte activation molecule) APCs und CD4
+
 T Lymphozyten zu generieren.  
 
Initial wurde die Herstellung von PTVs optimiert, um maximalen Gen- und Proteintransfer in 
transduzierte Zellen zu ermöglichen. Um zudem zielgerichtet SLAM
+
 Zellen modifizieren zu können, 
wurden PTVs mit zytoplamatisch verkürzten MVwt-GPs pseudotypisiert, die bekanntermaßen einen 
Tropismus für SLAM aufweisen. Neben SLAM war die Existenz eines bis dato unbekannten 
epithelialen MV-Rezeptors postuliert worden, zu dessen Identifikation als Adhärenzverbindungs-
protein Nectin-4 die vorliegende Arbeit beigetragen hat, um SLAM
-
 Zielzellpopulationen von MVwt-
GPs zu charakterisieren. Tatsächlich waren Markergen- und GFP-, Cre- oder Ovalbumin- (Ova) 
Cargoproteintransfer komplett auf SLAM- und Nectin-4-positive CHO-Zellen und natürlich SLAM-
exprimierende B Zelllinien beschränkt, während VSV-G pseudotypisierte Kontrollvektoren einen 
breiten Tropismus aufwiesen. Das spezifische Ausschneiden einer loxP-flankierten cerulean-
Expressionskassette in transduzierten, rezeptorpositiven Indikatorzelllinien, das durch die in PTVs 
verpackte Rekombinase Cre katalysiert wurde, demonstrierte beispielhaft sowohl den 
zytoplasmatischen Transfer als auch die unbeeinträchtigte Funktion des übertragenen Cargoproteins. 
Schlussendlich konnte gezeigt werden, dass der PTV-vermittelte Transfer des Modellantigens Ova in 
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rezeptorpositive APCs in vitro und in für humanes SLAM transgene Mäuse oder Kontrollmäuse in 
vivo zur Stimulation antigen-spezifischer T Lymphozyten, und hier vor allem CD8
+
 T Lymphozyten, 
führt. 
 
Im Gegensatz zu SLAM-spezifischen PTVs, deren Tropismus auf MVwt-GPs basierte, wurde die 
Spezifität eines gezielt CD4
+
 Zellen transduzierenden LVs (CD4-LV) durch Pseudotypisierung mit 
modifizierten MV-GPs erreicht, wobei ein CD4-spezifisches DARPin (Akronym für engl. designed 
ankyrin repeat protein, konzipierte Proteine mit Ankyrinwiederholungseinheiten) als Bindedomäne an 
rezeptorblindes H fusioniert wurde. Die gute Oberflächenexpression von H-αCD4 in HEK-293T 
Verpackungszellen ermöglichte den effizienten Einbau in CD4-LV-Partikel und war Grundlage für die 
mit durchschnittlich > 10
8
 transduzierenden Einheiten/ ml hochtitrigen Vektorstocks nach Aufkonzen-
tration. In vitro zeigte CD4-LV absolute Spezifität für CD4
+
 Zelllinien und CD4
+
 T Lymphozyten in 
der natürlich gemischten Zellpopulation primärer PBMC (Akronym für engl. peripheral blood 
mononuclear cells, mononukleäre Zellen des peripheren Blutes), während keine Transgenexpression in 
CD4
-
 Zellen detektiert werden konnte. Dabei ist besonders hervorzuheben, dass CD4-LV nicht nur in 
der Lage war, aktivierte sondern auch ruhende, primäre CD4
+
 Lymphozyten stabil zu transduzieren. 
Zudem konnten auch CD4
+
 Makrophagen in vitro mit dem Vektor transduziert werden. Nach 
systemischer Applikation von gfp/luciferase übertragendem CD4-LV wurde Luziferaseaktivität vor 
allem in den lymphatischen Organen von mit humanen PBMC oder hämatopoetischen Stammzellen 
repopulierten NOD-scid IL2Rγ-/- Mäusen detektiert. Durchflusszytometrische Analysen der GFP-
Expression in lymphatischen Organen und Blut bestätigten die bereits in vitro beobachtete strikte 
Rezeptorabhängigkeit der Transduktion auch in vivo. Interessanterweise konnte eine bevorzugte 
Transduktion von CD4
+
 T-Gedächtniszellen gegenüber naiven CD4
+
 T Lymphozyten beobachtet 
werden.  
 
Zusammenfassend konnte in der vorliegenden Arbeit die Eignung von mit (modifizierten) MV-GPs 
pseudotypisierten LVs für den selektiven Protein- und Gentransfer in verschiedene 
Immunzellsubtypen gezeigt werden. Durch die erfolgreiche Herstellung SLAM- beziehungsweise 
CD4-spezifischer LVs, die die gezielte Modifikation von SLAM
+
 APCs oder CD4
+
 T Lymphozyten, 
einschließlich ruhender T Lymphozyten, erlaubten, wurde die breite Anwendbarkeit des auf MV-GPs 
basierenden Zelleintrittstargetings für verschiedene Zelloberflächenrezeptoren unterstrichen. Sowohl 
PTVs als auch CD4-LV stellen vielversprechende Hilfsmittel für Grundlagenforschung und Gen- und 
Immuntherapie dar und eröffnen damit neue Möglichkeiten für eine Vielzahl verschiedenster 
Anwendungen. 
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8. Abbreviations 
α  Anti 
A  Absorbance 
AIDS  Acquired immune deficiency syndrome 
Alum  Aluminium potassium sulphate 
Amp  Ampicillin 
APC  Antigen presenting cell or Allophycocyanin (dye) 
APS  Ammonium peroxydisulfate 
ATCC  American type culture collection 
AR  Ankyrin repeat 
BCR  B cell receptor 
bp  Base pairs 
BSA  Bovine serum albumin 
CA  capsid protein 
CAR  Chimeric antigen receptor 
CD  Cluster of differentiation 
CD4-LV CD4-targeted lentiviral vector 
CD8-LV CD8-targeted lentiviral vector 
cDNA   Complementary DNA  
CHO  Chinese hamster ovary 
CMV   Cytomegalovirus  
ConA  Concanavalin A 
C-terminus Carboxy-terminus 
CTL  cytotoxic T lymphocyte 
d  Day 
DAMP  Danger-associated molecular pattern 
DARPin Designed ankyrin repeat protein 
DC  Dendritic cell 
DC-SIGN Dendritic cell-specific intercellular adhesion molecule-3-grabbing non-integrin 
DMEM  Dulbecco’s modified eagle medium 
DMSO  Dimethyl sulfoxide 
DNA  Desoxyribonucleic acid 
dNTP  Deoxynucleoside triphosphate 
DTT  Dithiothreitol 
ECL  Enhanced chemiluminescence 
E. coli  Escherichia coli 
EDTA  Ethylene diamine tetraacetic acid 
ELISA  Enzyme linked immunosorbent assay 
ELISpot Enzyme linked immuno spot assay 
EM  Electron microscope 
EMEM  Eagle’s minimum essential medium 
Env  Envelope glycoprotein 
EpR  Epithelial cell receptor 
ER  Endoplasmatic reticulum 
et al.  Et alii (and others) 
F   Measles virus fusion protein 
FACS   Fluorescence activated cell sorting  
FCS  Fetal calf serum 
FDA  Food and drug administration 
FIP  Fusion inhibiting peptide 
FSC  Forward scatter 
G  Gauge (unit for the size of the outer needle diameter) 
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Gag  Group-specific antigen  
GFP  Green fluorescent protein  
GM-CSF  Granulocyte macrophage colony-stimulating factor  
GP  Glycoprotein 
GvHD   Graft versus host disease 
h  hour 
H  Measles virus hemagglutinin protein 
HEPES  4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
Her2/neu Human epithelial growth factor receptor 2 
HIV   Human immunodeficiency virus  
HRP   Horseradish peroxidase  
HSC  Hematopoietic stem cell 
IFNAR  Interferon-α/β receptor 
IFNAR
-/-
 Interferon-α/β receptor knockout mouse (IFNAR-/- N20 C57BL/6) 
IFN  Interferon 
Ig  Immunoglobulin 
i.h.  Intrahepatic 
IL  Interleukin 
IN  Integrase 
INSERM Institut nationale de la santé et de la recherche médicale 
i.p.  Intraperitoneal 
IRES  Internal ribosomal entry site 
i.s.  Intrasplenic 
IU  International unit 
i.v.  Intravenous 
IVC  Individually ventilated cage 
Ig  Immunoglobulin 
kDa  Kilodalton 
LB  Lysogeny broth (medium) 
LDL-R  Low-density lipoprotein receptor 
LSM  Laser scanning microscope 
LTR   Long terminal repeat  
Luc  Luciferase 
LV  Lentiviral vector 
MA  Matrix protein 
MACS  Magnetic cell sorting 
M-CSF  Macrophage colony-stimulating factor 
mDC  Myeloid dendritic cell 
MFI  Mean fluorescence intensity 
MHC   Major histocompatibility complex  
MLV  Murine leukemia virus 
MOI   Multiplicity of infection  
mRNA  Messenger ribonucleic acid  
MST1R Macrophage stimulating 1 receptor 
mut  Mutated 
MV  Measles virus 
MVNSe  Measles virus strain derived from vaccine strain Edmonston B 
MVvac  Measles virus vaccine strain 
MVwt  Measles virus wild-type strain 
NC  Nucleocapsid protein 
NEA  Non-essential amino acids 
NEB  New England Biolabs 
NK cells Natural killer cells 
NSG  NOD-scid IL2Rγ-/- mice 
o/n  overnight 
ORF  Open reading frame 
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Ova  Ovalbumin 
Ova257-264 MHC I (kb)-restricted immunodominant peptide epitope of ovalbumin 
Ova323-339 Immunodominant peptide epitope of ovalbumin binding to I-A(d) MHC II  
PAGE  Polyacrylamid gel electrophoresis 
PAMP  Pathogen-associated molecular pattern 
PBMC  Peripheral blood mononuclear cell 
PBS  Phosphate buffered saline 
PCR   Polymerase chain reaction 
PE  Phycoerythrin 
PEI  Polyethyleneimine  
Pol  Polymerase 
PR  Protease 
PRR  Pathogen recognition receptor 
Ψ   Psi - packaging signal of retroviral genomic RNA   
PVR   Polio virus receptor 
PTV  Protein transfer vector  
PVDF  Polyvinylidene fluoride 
RNA   Ribonucleic acid  
rpm  Revolutions per minute 
RPMI  Roswell Park Memorial Institute (Medium) 
RT  Reverse transcriptase 
SAMHD1 SAM domain and HD domain-containing protein 1 
scFv   Single chain fragment variable (single chain antibody)  
SDS   Sodium dodecyl sulfate  
SFFV   Spleen focus forming virus  
SIV  Simian immunodeficiency virus 
SLAM  Signaling lymphocyte activation molecule 
SLAM
ki
 IFNAR
-/-
 SLAM
ki
 C57BL/6 mouse (Interferon-α/β receptor knockout,                  
 SLAM knock-in) 
S.O.C  Super optimal broth with catabolite repression 
SPF  Specified pathogen-free  
SSC  Side scatter 
TAE  Tris-acetate-EDTA buffer 
TCID50  Tissue culture infective dose 50 
TCM  T cell medium 
TCM  central memory T cell  
TCR  T cell receptor  
TEM  effector memory T cell 
TEMED N,N,N',N'-Tetramethylethylendiamin 
Th1  T helper type 1 cell 
Th2  T helper type 2 cell 
Th17  T helper type 17 cell 
Tm  Melting temperature 
Treg  regulatory T cell 
Tris  tris(hydroxymethyl)aminomethane 
t.u.  Transducing unit 
U  Unit 
UV  Ultraviolet 
VLP  Virus-like particle 
Vpx  Viral protein X 
VSV   Vesicular stomatitis virus  
VSV-G  Glycoprotein of vesicular stomatitis virus 
w/o  Without 
wt  Wild-type 
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Terminology used for vectors: 
Envelope-cargo protein-kind of vector-transgene  
Examples:  
VSV-Ova-LVKatushka  = VSV-G pseudotyped lentiviral Ova protein transfer vector encoding 
                                          Katushka 
CD4-LVLuc,GFP  = CD4-targeted lentiviral vector transferring luciferase and gfp 
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